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Introduction on the pathogenesis, epidemiology and clinical management of human
immunodeficiency virus (HIV) Infections
HIV belongs to the family of retroviruses and exerts its effect through a gradual destruction of T-cell
mediated immune response of the host, leading to immunodeficiency and eventually AIDS (Acquired
Immune Deficiency Syndrome). The latter stage of the disease is characterised by the emergence of
opportunistic infections in concurrence with further deterioration of immune function1. Two subtypes of
HIV are currently recognized. The HIV-1 subtype is most common and more virulent than HIV-2, which is
predominantly found in Western Africa and is characterised by a slower and milder disease progression
with a lower mortality rate2;3. The present thesis focuses on infection by HIV-1.
HIV-1 infection in children differs from that in adults with regard to several aspects. In adults, the disease is
commonly acquired through unprotected sexual contact, sharing of needles during intravenous drug abuse, or
the use of infected blood products. In contrast, the majority of children are perinatally infected with HIV-1
during pregnancy, labor or breastfeeding by their HIV-1 infected mother4. The use of infected blood products
has in the past been a major route of infection in children. However, the incidence of these infections has
decreased since the institution of routine screening of donors and blood products. The pathogenesis of HIV-1
infection in children is also different from that in adults. This has been attributed to the fact that the virus
affects an immature immune system5. HIV-1 infection is, in most perinatally infected children, characterised
by a faster disease progression than in adults, and consequently, a very poor prognosis if untreated6.
Moreover, in children, HIV-1 infection influences several childhood specific factors related with childhood,
such as growth, neurocognitive development and sexual maturation7;8.
Without antiretroviral treatment, AIDS is associated with a high mortality6;9. Since the development of anti-
retroviral medication, the prognosis of HIV-1 infected adults and children who have access to antiretroviral
treatment has significantly improved10-12. However, at the end of 2002, globally, the pandemic had affected
an estimated number of 38.6 million adults and 3.2 million children. HIV infection most seriously threatens
the developing world, sub-Saharan Africa having both the highest numbers of patients in absolute counts,
and the highest prevalence worldwide. The estimation that more than 20 million people have died from AIDS
since the first clinical evidence HIV/AIDS in 1981 points to the need for global access to medication13.
Antiretroviral agents for treatment of HIV-1 infection
While until today, no therapy entirely eliminates the presence of HIV in infected subjects, several anti-
retroviral drugs inhibiting the activity of HIV have been developed. These agents can be divided into the
following classes, according to their modes of action:
1. Nucleoside and nucleotide reverse transcriptase inhibitors
2. Non-nucleoside reverse transcriptase analogues
3. Protease inhibitors
4. Fusion inhibitors
Nucleoside and nucleotide reverse transcriptase inhibitors
Nucleoside reverse transcriptase inhibitors are synthetic analogues of naturally occurring nucleosides and
require intracellular phosphorylation into their active, triphosphorylated moieties. These isophorms
inhibit the activity of HIV reverse transcriptase by competition with the natural nucleoside substrates
and by termination of viral DNA chain growth after their incorporation into viral DNA. Thus, replication
of HIV-1 is inhibited14. Nucleoside reverse transcriptase inhibitors are the first class of drugs approved for
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antiretroviral treatment with zidovudine as the first representative of the class. Nucleotide reverse tran-
scriptase inhibitors differ from nucleoside reverse transcriptase inhibitors in their chemical structure,
which already possesses one phosphate group. Subsequently, nucleotide reverse transcriptase inhibitors
require two, instead of three phosphorylation steps to be transformed into their active moiety15.
Non-nucleoside reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors act by non-competitive, allosteric inhibition of HIV
reverse transcriptase and do not require intracellular phosphorylation for activation16. Two non-nucleo-
side reverse transcriptase inhibitors are currenly licensed; nevirapine and efavirenz.
Protease inhibitors
HIV protease inhibitors are non-hydrolysable substrates of HIV protease. This protein is required for the
cleavage of post-translational polyproteins of the gag and gag-pol genes of HIV into functional core pro-
teins and active enzymes of HIV. Thus, by inhibiting HIV protease, the formation of mature, infectious
virions is blocked17. Since the licensing of the first protease inhibitor indinavir in 1996, several other HIV
protease inhibitors have been developed.
Fusion inhibitors
This recently developed class of drugs inhibits the infection by HIV-1 of new host cells, i.e. CD4 cells, by
blocking the fusion of HIV-1 with these target cells. The only approved fusion inhibitor, enfuvirtide,
needs subcutaneous administration18.
Antiretroviral treatment in HIV-1 infected children
During the past two decades, the development of several antiretroviral agents has considerably increased
treatment options in both HIV-1 infected adults and children. An overview of antiretroviral drugs current-
ly licensed in the United States and Europe, and the availability of pediatric dosage forms of these drugs
is provided in Table 1.
Antiretroviral treatment in HIV-1 infected children has, to a high degree, followed the situation in adult
patients. Historically, a single nucleoside reverse transcriptase inhibitor was applied for treatment of 
HIV-1 infection19. With the development of more nucleoside reverse transcriptase inhibitors and the doc-
umented higher efficacy of therapy consisting of two nucleoside reverse transcriptase inhibitors, treat-
ment consisting of two nucleoside analogues (so-called “dual nucleoside regimens”) was introduced20.
Subsequently, the drug classes of protease inhibitors and non-nucleoside analogues became available.
Combination regimens, generally consisting of 3 or more antiretroviral drugs, were shown to provide
durable suppression of HIV-1 and lower morbidity and mortality to a higher degree than dual or
monotherapy with nucleoside analogues11;21;22. These combination regimens are often referred to as
highly active antiretroviral therapy (HAART). No strict definition exists of HAART. However, HAART regi-
mens generally share the presence of a protease inhibitor and/or non-nucleoside reverse transcriptase
inhibitor combined with 2 nucleoside analogues, or the nucleoside reverse transcriptase inhibitor aba-
cavir in addition to 2 other nucleoside reverse transcriptase inhibitors. Relatively recently, regimens were
introduced in which a protease inhibitor is combined with a low dose of the protease inhibitor ritonavir.
Ritonavir has strong inhibiting properties of cytochrome P450 (CYP) of the 3A4 subtype, which is the
major metabolic pathway of most protease inhibitors23. Such ritonavir “boosted” regimens take advan-
tage of the pharmacokinetic interaction occurring due to CYP3A4 inhibition by ritonavir, which results
in decreased metabolism and consequently, increased plasma levels of the other protease inhibitor. The
use of ritonavir-boosted regimens have advantages above protease inhibitors alone, which include the
possibility of reduced dosing frequency, the capacity to overcome other pharmacokinetic interactions
and to maintain therapeutic plasma levels in case of decreased viral susceptibility, but has been little
investigated in HIV-1 infected children24.
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Current guidelines for first-line antiretroviral treatment in children recommend a regimen of one pro-
tease inhibitor or non-nucleoside analogue, combined with two nucleoside analogues. Alternatively, a
regimen consisting of three nucleoside reverse transcriptase inhibitors including abacavir may be
used25;26.
Efficacy of HAART in HIV-1 infected children
Since antiretroviral medication inhibits HIV without entirely curing this infection, only surrogate mar-
kers for efficacy can be used. Two surrogate markers are presently recommended for use in both adults
and children: the number of copies of HIV-RNA in plasma (“viral load”) and CD4+ T-cells, being the target
for HIV replication27;28. The many ways in which these surrogate markers are expressed (e.g. in absolute
counts, or as percentage decline) and the use of different methods of quantification of HIV-RNA com-
plicate a comparison of outcome between different antiretroviral regimens. Despite these difficulties,
treatment of HIV-1 in children yields a lower overall response than that observed in adults29.
This finding is likely to be related to factors, such as decreased compliance to medication in HIV-1 infec-
ted children and the more serious clinical manifestations of HIV-1 in children29;30. Also, in clinical prac-
tice, antiretroviral treatment strategies in children are often based on limited studies, or even based on
extrapolations from adult data. Thus, worse outcome of antiretroviral treatment in HIV-1 infected child-
ren may be related to a general lack of data on the clinical pharmacology of antiretroviral agents in this
patient population. If so, a further exploration of this area may contribute to improved treatment of
HIV-1 in children.
Outline of the thesis
The objective of this thesis is to enhance the knowledge on the clinical pharmacology of antiretroviral
treatment in HIV-1 infected children. For this purpose, different treatments and treatment strategies in
HIV-1 infected children were studied:
1. Optimization of nelfinavir-containing HAART
2. Dose-finding of ritonavir-boosted protease inhibitor based regimens
3. Pharmacokinetics and pharmacodynamics of nucleoside reverse transcriptase inhibitors
4. Evaluation of therapeutic drug monitoring
Chapter 1
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Abstract
Objectives: to describe the pharmacokinetics (PK) of the protease inhibitor nelfinavir and its
active metabolite M8 in children, and to evaluate the influence of patient-related factors on plas-
ma levels of nelfinavir. Methods: HIV-1 infected children treated with nelfinavir q8h were eligible
for inclusion in this retrospective study. 0-8h intensive plasma PK sampling was performed at
steady state. Nelfinavir Cmax, AUC0-8, C8 and relative apparent oral clearance (Cl*F/kg) were cal-
culated. Results: 24 children (median age: 4.5 years, median nelfinavir dose: 28 mg/kg q8h) were
included. Nelfinavir PK were highly variable. 10/24 children had an AUC0-8 below the value of
12.5 mg/L*h which has earlier been associated with increased virologic failure rate in children.
With age < 2 years and a dose of 20 mg/kg q8h, a non-significant trend was observed to more
AUC0-8 < 12.5 mg/L*h (OR (95% CI): 2.44 (0.41-14.7) and 8.7 (0.79-95), respectively). Nelfinavir
C8 correlated strongly with AUC0-8 (r=0.89, p < 0.001). C8 > 0.69 mg/L predicted an AUC0-8 >
12.5 mg/L*h with 71% sensitivity and 80% specificity. Dose of nelfinavir per body surface area
was a better predictor of AUC0-8 than dose per body weight. Conclusion: nelfinavir PK show high
interindividual variability in children. Children < 2 years old tend to be at increased risk for low
nelfinavir levels. These data show that the nelfinavir dose of 20 mg/kg q8h is inadequate in most
children. Also, these data suggest that pediatric dosing of nelfinavir based on body surface area
should be considered. Therapeutic drug monitoring can detect abnormal plasma levels and is
therefore of importance to optimize therapy with nelfinavir in HIV infected children. However,
further research is needed to more firmly establish a therapeutic range for nelfinavir in children.
Introduction
With the introduction of highly active antiretroviral therapy (HAART), HIV infection has become a
chronic disease with strongly improved survival. However, management of HIV infection is often compli-
cated by several factors, such as adverse events related to medication, complex medication schedules,
which result in non-compliance and emergence of resistant mutants of HIV. HIV protease inhibitors,
which are often part of HAART, show highly variable pharmacokinetics. Since plasma levels of protease
inhibitors have been related to virological efficacy, this may have important consequences for the suc-
cess of HIV treatment 1. Insight in the pharmacokinetics of protease inhibitors and the factors contri-
buting to variability in their pharmacokinetics is valuable, e.g. for the correct application of therapeutic
drug monitoring (TDM).
In children, additional factors, such as poor palatability of medication, the absence of pediatric dose
forms, and changes in drug disposition and elimination due to physiological maturation may complicate
an optimal response to HAART. The protease inhibitor nelfinavir is frequently prescribed for treatment of
pediatric HIV infection. It has shown effective suppression of HIV combined with good tolerability in
children > 2 years old2,3. Despite its wide use, data on pharmacokinetics of nelfinavir in children, espe-
cially in those < 2 years old, are sparse. Even less is known about the pharmacokinetics of M8, the active
metabolite of nelfinavir, in the pediatric population. The major objective of this study was to describe
the pharmacokinetics of both nelfinavir and its active metabolite M8 in HIV-1 infected children. In parti-
cular, attention was paid to the pharmacokinetics of children < 2 years old. Furthermore, the association
between patient related factors and low plasma levels of nelfinavir has been investigated.
Nelfinavir in children
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Materials and methods
Patients
HIV infected children between 0-18 years old treated with nelfinavir q8h + 2 nucleoside analogues were
eligible for inclusion in this retrospective, observational two-center study. Comedication was allowed if it
was not expected to interfere with the PK of nelfinavir. Informed consent was obtained from all patients
or care-givers prior to start of antiretroviral therapy. Nelfinavir dose was calculated as mg nelfinavir/kg
body weight. The standard adult nelfinavir dose of 750 mg q8h was not exceeded.
Pharmacokinetic sampling
In all children, intensive pharmacokinetic sampling was performed at steady state (> 1 week after start
of nelfinavir). The procedure was part of standard patient care in our clinics. Pharmacokinetic sampling
was performed at the day care unit. Medication ingestion was directly observed and with food. For
infants, medication was mixed with formula. Older children received medication with a meal. Blood sam-
ples were drawn at time points 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 h post ingestion.
Within 24 hours after collection, samples were centrifuged and plasma was stored at –20 ºC. Plasma con-
centrations of nelfinavir and M8 were determined by validated HPLC assay with UV detection (lower
limit of quantification: 0.04 mg/L)4.
Nelfinavir and M8 pharmacokinetics
Nelfinavir pharmacokinetic parameters were calculated using non-compartmental methods5. Nelfinavir
plasma peak level (Cmax) and trough level at the 8-h time point (C8) were determined. Area under the
plasma concentration-time curve 0-8h was calculated using the trapezoidal rule. Apparent oral clearance
of nelfinavir was calculated as dose (mg)/AUC0-8. Relative apparent oral clearance (Cl/kg*F) was calcu-
lated as dose (mg)/AUC0-8*body weight (kg). M8 plasma levels were also measured and Cmax, C8 and
AUC0-8 of M8 were calculated.
The association of different patient related factors with nelfinavir pharmacokinetic parameters and with
the ratio of M8 AUC0-8 / nelfinavir AUC0-8 was estimated. A nelfinavir AUC0-8 of 12.5 mg/L*h was used
as a breakpoint in data analysis, since AUC0-8s of nelfinavir below this value have been associated with
an increased virologic failure rate in children6.
To evaluate the relation between nelfinavir dose and nelfinavir AUC0-8, dose strata were formed of 20,
30 and 40 mg/kg nelfinavir q8h, respectively.
All patients were monitored as part of standard patient care. HIV-1 RNA load (copies/mL) at start and
after 6 months of nelfinavir therapy was used to measure virological efficacy. Viral load was determined
by PCR (limit of quantification 500 copies/mL, HIV-1 specific PCR (Roche Diagnostics, Brandenburg, NY,
USA). Virologic response was defined as a viral load below 500 copies/mL at 6 months after start of 
therapy.
Statistical methods
All statistical tests were performed using SPSS (SPSS, Chicago, IL, U.S.A., version 10.0). Spearman’s
rank correlation was calculated to evaluate the association between nelfinavir pharmacokinetic
parameters and patient related factors. A t test was used to test significance. Linear regression after
ln transformation of (AUC0-8, C8) was calculated. Receiver Operating Characteristic (ROC) curves
were constructed to estimate sensitivity and specificity with which C8 or nelfinavir dose (mg/m
2)
could predict an AUC0-8 > 12.5 mg/L*h. For this purpose, of patients with C8 or nelfinavir dose above
a given value, % sensitivity (% true positives) was plotted against % (1- specificity) (% false posi-
tives). Sensitivity was defined as the number of patients with an AUC0-8 > 12.5 and C8 or dose above
a given value /total number of patients with AUC0-8 > 12.5. 1-specificity was defined as % patients
with AUC0-8 < 12.5 and C8 or dose above a given value /total number of patients with AUC0-8 < 12.5.
Odds ratio calculation and Fisher’s Exact Test were performed to estimate the association of patient
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characteristics with nelfinavir AUC0-8 < 12.5 mg/L*h. For this purpose, patient characteristics and
the occurrence of nelfinavir AUC0-8 < 12.5 mg/L*h were binary scaled. The Mann-Whitney U Test and
Kruskal-Wallis test were used to compare medians. A p-value of <0.05 was considered statistically
significant.
Results
24 HIV infected children between 5 months and 18 years of age were included. Patients using comedica-
tion known to cause a pharmacokinetic interaction with nelfinavir and patients in whom intensive phar-
macokinetic sampling was incomplete were excluded. Patient characteristics are given in tables 1A and
1B. Treatment with nelfinavir q8h + 2 nucleoside analogues was initiated between November 1997 and
August 2000. Doses of nelfinavir were chosen upon the physician’s discretion. The median nelfinavir dose
was 28 mg/kg q8h (IQR: 26-31 mg/kg q8h), with a maximum absolute dose of 750 mg qh8. Patients used
nelfinavir either in tablets or in the powder formulation. 14 patients were naive to treatment with pro-
tease inhibitors, 9 were non-naive and of one patient, prior treatment was unknown. All protease
inhibitor non-naive patients had been pretreated with the protease inhibitor indinavir. They had
switched therapy to nelfinavir for several reasons (Table 1B). Two patients received the non-nucleoside
analogues nevirapine and efavirenz respectively, in addition to their nelfinavir-containing regimen. Since
earlier findings did not suggest nevirapine or efavirenz to markedly influence nelfinavir or M8 plasma 
levels, these pharmacokinetic data were not excluded from data analysis7,8. In all children, PK sampling
was performed at steady state and nelfinavir and M8 plasma concentrations were determined. Overall PK
parameters of nelfinavir and M8 are described in Table 2.
After stratification to dose groups of 20 (n=5), 30 (n=14) and 40 (n=5) mg/kg nelfinavir q8h, nelfinavir
AUC0-8 showed a less than dose proportional increase (median AUC0-8s of 8.7, 16.6 and 12.5 mg/L*h, res-
pectively). Both Cmax and C8 of nelfinavir and M8 correlated strongly with the AUC0-8 of nelfinavir or
M8, respectively (all p-values < 0.001 and r > 0.8) Figure 1 depicts the correlation of (lnC8, lnAUC0-8).
Linear regression of (Ln AUC0-8,Ln C8) showed a nelfinavir C8 of 0.67 mg/L corresponding with an AUC0-8
of 12.5 mg/L*h. A C8 > 0.69 mg/L predicted a nelfinavir AUC0-8 > 12.5 mg/L*h with optimal sensitivity
(71%) and specificity (80 %) (Figure 2).
While median nelfinavir dose was similar in children below and above 2 years of age (medians 29 and 28
mg/kg q8h, respectively), the younger group showed a tendency to lower AUC0-8, Cmax and C8 of nelfi-
navir (Table 2). Also, Cl/kg*F tended to be higher in children < 2 years old than in older children (2.8 vs.
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Table 1A Demographic characteristics overall and in age groups < and ≥ 2 years old.
age < 2 years age ≥ 2 years overall
age (years) median (IQR) 0.5 (0.5-0.58) 6.6 (3.8-8.7) 4.5 (0.71-7.1)
female (n) 3/7 6/17 9/24
body weight (kg) median (IQR) 7.0 (6.0-8.0) 17.0 (13.5-28.2) 14 (9.5-22)
BSA (m2) median (IQR) 0.37 (0.34-0.44) 0.72 (0.59-1.0) 0.63 (0.45-0.86)
ethnicity (n)
African 9 9
Caucasian 2 1 3
Asian 1 1
Hispanic 2 2
Mixed 5 4 9
*of one patient no data available
IQR: inter quartile range; n: cases; BSA: body surface area
1.9 L/h). None of these differences reached statistical significance (p values all > 0.1), except a signifi-
cantly higher absolute Cl/F of nelfinavir in older children. A non-significant trend to more lower AUC0-8s
was also observed in younger children if 12.5 mg/L*h was used as a breakpoint for AUC0-8 (Table 3). In
total, ten out of 24 children (42%) had a nelfinavir AUC0-8 < 12.5 mg/L*h, and these rates were 4/7
(57%) and 6/17 (35%), respectively, in children < 2 and ≥ 2 years old (p > 0.1). OR (95% CI) for an AUC0-8
< 12.5 mg/L*h with age < 2 years was 2.44 (0.41-14.7) (not significant).
A nelfinavir dose of 20 mg/kg q8h yielded the highest percentage of nelfinavir AUC0-8 < 12.5 mg/L*h,
although this difference was not significant (80% versus 29 and 40%, respectively, in dose groups of 30
and 40 mg/kg nelfinavir q8h p> 0.1). OR (95% CI) for AUC0-8 < 12.5 mg/L*h with a dose of 20 mg/kg
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Table 1B Clinical and pharmacological characteristics overall and in age groups < and ≥ 2 years old.
age < 2 years age ≥ 2 years overall
number of PK curves 7 17 24
dose (mg/kg) median (IQR) 29 (26-37) 28 (25-31) 28 (26-31)
HIV RNA median (IQR) at start nelfinavir 750,000 45,700 98,650 
(5,280-750,000) (12,870-389,500) (10,905-692,750)
protease inhibitor naïve (n) 5/7 9/17* 14/24*
reasons for switch 
to nelfinavir if non-naïve (n)
virological failure 2 2
nephrotoxicity 3 3
hypersensitivity 1 1
low drug levels 1 1
non-compliance 1 1
other/unknown 1 1
antiretroviral comedication (n)
AZT/3TC 3 12 15
d4T/3TC 2 2 4
d4T/ddI 3 3
other 2 2
n: cases; PK: pharmacokinetic; IQR: inter quartile range; AZT: zidovudine; 3TC: lamivudine; d4T: stavudine; 
ddI: didanosine; *: of one patient unknown
Table 2 PK parameters (median, IQR) overall and in age groups < and ≥ 2 years old.
PK parameter age < 2 years age ≥ 2 years overall
n=7 n=17 n=24 P-value
C max (mg/L) 2.2 (1.9-4.8) 3.6 (2.7-4.5) 3.5 (2.2-4.5) > 0.1
C8 (mg/L) 0.43 (0.36-0.73) 0.69 (0.50-1.44) 0.69 (0.43-1.4) > 0.1
AUC0-8 (mg/L*h) 11.2 (8.9-20.8) 15.0 (7.9-20.1) 13.1 (8.8-20.2) > 0.1
Cl/F (L/h) 15.1 (8.4-27.4) 37.4 (24.4-71.5) 32 (19.6-52.3) 0.002#
Cl/F*kg (L/h*kg) 2.8 (1.4-3.4) 1.9 (1.5-3.1) 2.1 (1.5-3.2) > 0.1
M8/nelfinavir AUC0-8 ratio 0.31 (0.21-0.43) 0.29 (0.20-0.43) 0.29 (0.20-0.44) > 0.1
# statistically significant
n: cases; Cmax: peak plasma level; C8: plasma level at the 8-h time point; AUC0-8:area under the plasma concen-
tration-time curve 0-8h; Cl/F: apparent oral clearance; Cl/F*kg: relative apparent oral clearance 
q8h compared to higher doses was 8.7 (0.79-91) (not significant). While receiving a similar median nelfi-
navir dose in mg/kg, children with a nelfinavir AUC0-8 < 12.5 mg/L*h received a statistically significant
lower median nelfinavir dose in mg/body surface area (m2), than children with a nelfinavir AUC0-8 > 12.5
mg/L*h (p=0.04) (Table 3). A nelfinavir dose > 650 mg/m2 predicted a nelfinavir AUC0-8 > 12.5 mg/L*h
with optimal sensitivity (79%) and specificity (67%). No apparent association was found between the
occurrence of nelfinavir AUC0-8 < 12.5 mg/L*h and gender.
Of the 5 children in whom the maximum adult dose of 750 mg q8h had been attained, 3 (60%) had nelfi-
navir AUC0-8s below 12.5 mg/L*h vs. 7/19 (37%) of children who had not reached the dose of 750 mg q8h
(OR (95% CI): 2.57 (0.34-19.3)).
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Figure 1 Scatter plot of ln(AUC0-8) versus ln(C8) of nelfinavir.
Figure 2 Receiver Operating Characteristic curve describing sensitivity versus 1-specificity for C8 of nelfinavir to
predict AUC0-8  > 12.5 mg/L*h.
The M8/nelfinavir ratio ranged between 0.1 and 0.8, (not shown in Table 2), except for two patients, in
whom plasma levels of M8 were below the limit of quantification. No relation was found between
M8/NFV ratio and dose of nelfinavir, age, gender, ethnicity or pre-treatment (p values all > 0.1).
Twenty-two of twenty-four children completed 6 months of nelfinavir containing therapy. The two
remaining children had switched on their parents’ request to q12h regimens containing abacavir and
lopinavir/ritonavir, respectively. Of the 22 children who completed 6 months of treatment with nelfi-
navir, sixteen (73%) showed virologic response (viral load < 500 copies/mL). Virologic response rates at 6
months in nelfinavir dose categories of 20, 30 and 40 mg/kg q8h were 50, 71 and 100%, respectively
(p>0.1). In children with a nelfinavir AUC0-8 < 12.5 mg/L*h, the virologic response rate at 6 months was
80%, while in children with nelfinavir AUC0-8 > 12.5 mg/L*h, a percentage of 71% was found (p > 0.1)
(Table 3). In none of the patients, serious adverse events were reported.
Discussion
This study provides a description of the PK of nelfinavir in a relatively large number of children in whom
intensive PK sampling was performed. In adults, plasma levels of nelfinavir have been associated with
virological efficacy9-11. In children, a target value of 10 mg/L*h has been used for nelfinavir AUC0-8, but
studies correlating nelfinavir levels with efficacy are limited3;12. In the present study, a nelfinavir AUC0-8
of 12.5 mg/L*h was used as a threshold in data analysis. This was at the time of the study the only
reported PK cut-off value for virologic response to nelfinavir in pediatric patients6. However, this 
value was derived from a naive population of HIV-infected children and has not yet been validated in
pretreated patients.
Risk factors for low nelfinavir levels
Age < 2 years and a dose of 20 mg/kg q8h both showed a trend to lower plasma concentrations of nelfi-
navir, and higher rate of AUC0-8s below 12.5 mg/L*h. Also, children in whom the maximal (adult) dose of
nelfinavir was reached tended to have higher rates of AUC0-8s below 12.5 mg/L*h. Although none of
these differences was statistically significant, these findings are relevant for clinical practice.
Age below 2 years has previously been associated with an increased risk for lower than average, possibly
subtherapeutic nelfinavir plasma levels6,12-14. In infants < 4 months old, even nelfinavir doses up to 40
Chapter 2.1
26
Table 3 Patient characteristics of children with nelfinavir AUC0-8 < vs. > 12.5 mg/L*h.
nelfinavir AUC0-8 nelfinavir AUC0-8
< 12.5 mg/L*h > 12.5 mg/L*h
n=10 n=14 P-value
age (yr.) median (IQR) 2.9 4.8 > 0.1
female (n) 4/10 5/14 > 0.1
dose (mg/kg) median (IQR) 28 (17-39) 30 (28-37) > 0.1
dose (mg/m2) median (IQR) 551(391-835) 727 (628-809) 0.04#
body weight (kg) median (IQR) 12 (6-40) 14 (9-23) > 0.1
BSA (m2) median (IQR) 0.56 (0.38-1.25) 0.63 (0.42-0.89) > 0.1
HIV RNA median baseline (IQR) 77,350 (13,920-750,000) 106,150 (6955-578,250) > 0.1
protease inhibitor naïve (n) 8/10 6/14* > 0.1
Virologic response week 48 8/10 (80) 10/14 (71) > 0.1
(HIV-RNA < 500 copies/mL) 
(n (%))
* of one patient, no data available, # statistically significant, n: cases; IQR: inter quartile range; BSA: body surface area
mg/kg q8h have resulted in plasma levels far below adult values14. This may be explained by factors such
as higher metabolic clearance in young children, impaired absorption, and lower amount of alpha-acid
glycoprotein15.
The very high rate of nelfinavir AUC0-8s < 12.5 mg/L*h in the dose category of 20 mg/kg q8h nelfinavir
when compared to doses of 30 and 40 mg/kg q8h suggests, that the nelfinavir dose of 20 mg/kg q8h is
insufficient and should not be applied in children. The considerable rate of nelfinavir AUC0-8s < 12.5
mg/L*h (60%) in children who had reached the adult nelfinavir dose indicates that in some children, 
the adult nelfinavir dose needs to be exceeded in order to normalize plasma levels of nelfinavir. At the
time of enrolment in this study, the adult nelfinavir dose was recommended in children with body
weight > 23 kg. Currently, guidelines recommend the adult nelfinavir dose in children > 13 years old,
which corresponds with a higher body weight16. Nevertheless, in the present study, 2/3 children using
750 mg q8h nelfinavir and showing low nelfinavir AUC0-8s were below 13 years old, suggesting that an
actual age limit probably should be below 13 years.
Interestingly, a significantly lower nelfinavir dose/body surface area was found in children with AUC0-8
< 12.5 mg/L*h when compared to children with AUC0-8 > 12.5 mg/L*h, while both groups were receiving
the same median dose per body weight. This suggests, that when nelfinavir dose is calculated per body
weight, (younger) children with a relatively high body surface area are at increased risk for lower plasma
levels. Body surface area has been described as a more accurate measure of metabolic activity, and might
therefore be more appropriate in children15. Our data indicate that a nelfinavir dose > 650 mg/m2 q8h
would be needed to obtain an AUC0-8 > 12.5 mg/L*h. No association was found between gender and low
nelfinavir plasma levels, which is in accordance with previous data17. Assuming, that gender-related dif-
ferences in PK of protease inhibitors are related to hormonal differences between males and females,
they would mainly be expected after sexual maturation. These differences were difficult to distinguish 
in this relatively young pediatric population (median age: 4.5 years)15.
PK of nelfinavir and M8
A strong correlation was found for both nelfinavir and M8 between Cmax, or C8 and AUC0-8. This correla-
tion could largely simplify TDM by using one time point from a PK curve (e.g. C8) as a predictor of total
exposure. Ln-linear regression showed a C8 of 0.67 mg/L corresponding with a nelfinavir AUC0-8 of 12.5.
Similarly, a C8 > 0.69 mg/L predicted nelfinavir AUC0-8 > 12.5 mg/L*h with optimal sensitivity and speci-
ficity. Both values are in accordance with efficacy thresholds for twice daily nelfinavir in adults9-11.
Earlier data found a strong correlation between the 2-h plasma concentration and AUC0-8 of nelfinavir
18.
However, these findings warrant further investigation.
While previous studies in pediatric and adult patients assumed a dose-proportional increase of nelfinavir
AUC0-8, in the present study, AUC0-8 showed a less than dose proportional increase. The effect of a
dosage increase can efficiently be monitored using TDM. However, these findings suggest that some
patients with low plasma levels of nelfinavir might not benefit from a dosage increase, i.e. would not
experience sufficiently higher plasma levels after a dosage adjustment.
In adults, the ratio between M8 and nelfinavir plasma levels is relatively constant at a nelfinavir dose of
1250 mg q12h and a M8/NFV ratio of 0.3 is in accordance with findings in adult patients19;20. In child-
ren, also lower M8/nelfinavir ratios have been reported, which we could not confirm13.
Factors contributing to variability in nelfinavir PK
Nelfinavir absorption strongly improves when nelfinavir is taken with food21. In the present study,
infants took their medication with formula, while older children received a standard meal. However, dif-
ficulties with ingestion of medication are common in children. For example, very young children, who
take medication with formula, may be unable to take in the total medication dose at once, which may
alter the time to peak level. While special attention was paid to complete medication ingestion in the
presence of a substantial amount of food, interindividual variability of PK due to food effects and diffi-
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culties with medication ingestion could not totally be ruled out in this pediatric population. Nelfinavir is
principally metabolised by cytochrome enzymes (CYP) 3A4 and 2C19. CYP-inducing comedication is
known to decrease nelfinavir plasma levels, but in this study, except for the two patients who used nevi-
rapine or efavirenz, no other CYP-modifying comedication was used21. While NVP and EFV are known to
affect CYP3A4, the effect on metabolism of nelfinavir appears absent for nevirapine, and very slight for
efavirenz. EFV, but not NVP has shown to slightly decrease M8 concentrations7;8. Of interest, the child
who used EFV showed a high AUC0-8 of nelfinavir (38 mg/L*h) and a M8/NFV AUC ratio of 0.14, while
the child who used NVP showed a low AUC0-8 of nelfinavir (9 mg/L*h) and a M8/NFV ratio of 0.3. The
relevance of these individual cases remains uncertain. Genetic polymorphism of CYP2C19 might have
caused additional variability of nelfinavir and M8 PK. CYP2C19 polymorphism is especially found in Asians
and Caucasians, with 18-22 and 2-6% of slow metabolizers, respectively17. However, the effect of CYP2C19
polymorphism was not likely, since most children were of African or mixed African origin and Asians and
Caucasians were poorly represented (Table 1). It should also be remarked, that CYP2C19 is not a unique
pathway of nelfinavir metabolism and impact of CYP2C19 polymorphism on nelfinavir plasma levels may
be moderate. Furthermore, polymorphism in P-glycoprotein expression, of which nelfinavir is a substrate
and possibly an inductor, may have influenced the PK of nelfinavir22-24. These factors were not examined,
but might also explain part of the observed variability of nelfinavir PK.
Virologic outcome
An overall virologic response of 73% was measured after 6 months of nelfinavir containing HAART. Both
similar and considerably lower success rates have been reported in children using protease inhibitor con-
taining treatment2;3;25-30. The difference between virologic responses in the dose group of 20 vs. 30 and
40 mg/kg nelfinavir q8h would be in accordance with the high rates of AUC0-8 < 12.5 mg/L*h in the lo-
west dose category. Meanwhile, in this study, no significant relationship was found between plasma lev-
els of nelfinavir and virologic efficacy, and response rate was not significantly different between chiIdren
with an AUC0-8 < 12.5 mg/L*h and children with an AUC0-8 > 12.5 mg/L*h. However, it should be noted
that children naive and non-naive for protease inhibitors were not equally distributed between these
groups, since most children with a nelfinavir AUC0-8 < 12.5 mg/L*h (8/10) were naive, while this was
the case in only 6/14 (43%) of children with a AUC0-8 > 12.5 mg/L*h. Taking into account, that naive
patients tend to better respond to antiretroviral therapy than pretreated patients, this may have biased
our findings. Finally, as stated before, the cut-off value of 12.5 mg/L*h for AUC0-8 of nelfinavir has been
proposed for naive children, while a different cut-off value may be needed for non-naive children,
depending on e.g. the presence of viral resistance and differences in clinical condition in these patients.
Conclusion
PK of nelfinavir in children showed high interindividual variability in this population heterogeneous with
regard to pre-treatment, age and dose. Children < 2 years old tend to be at higher risk for low plasma
levels of nelfinavir. A nelfinavir dose of 20 mg/kg q8h yielded a low plasma levels in most of the children.
Although this findings were not statistically significant, they suggest that children using nelfinavir
should be closely monitored by TDM. Also, the dose of 20 mg/kg q8h nelfinavir is insufficient and should
not be used. The strong correlation between C8 and nelfinavir AUC0-8 could simplify PK sampling. The
maximum dose of 750 mg q8h is frequently suboptimal and needs to be exceeded in children. Nelfinavir
dose based on body surface area, rather than body weight should be considered in children. While low
plasma levels of nelfinavir have been related with virologic outcome in adults, we were not able to find
such an association in this highly heterogeneous pediatric study population. Meanwhile, in children,
TDM of nelfinavir is expected to be of similar importance as in adults, e.g. since it can detect abnormal
plasma levels and allows handling in order to prevent toxicity or virologic failure. However, further
research is strongly needed to more firmly establish a therapeutic range for nelfinavir in children.
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Abstract
Objective:
To describe a case of successful protease inhibitor based Highly Active Antiretroviral Therapy
(HAART) concomitant with rifampin.
Case Summary:
In a 7-month-old infant with tuberculosis and HIV-1 infection, tuberculosis therapy including
rifampin and HAART containing the protease inhibitor nelfinavir 40 mg/kg q8h was started.
Intensive steady state 0-8h pharmacokinetic sampling revealed very low plasma levels, (area
under the plasma level-time curve (AUC0-24) of nelfinavir < 10% of adult population values for
750 mg q8h), and non-quantifiable levels of nelfinavir’s principal metabolite (M8). Nelfinavir 40
mg/kg q8h was then substituted for nelfinavir 30 mg/kg q12h + ritonavir 400 mg/m2 q12h.
Intensive steady-state (0-12h) pharmacokinetic sampling was repeated. Levels of nelfinavir had
improved, but remained low when compared to adult population values of 1250 mg q12h: AUC0-24
was 21.9 vs. 47.6 mg/L*h (46%), 12-h trough level (C12) was 0.25 vs. 0.85 mg/L (29%). However,
levels of M8 considerably exceeded population values: AUC0-24 57.5 vs. 13.6 mg/L*h (443%), C12
1.35 vs. 0.28 mg/L (482%). Since levels of M8 were highly elevated, pharmacokinetic parameters
for (nelfinavir+M8) were used, instead of for nelfinavir alone. Thus, AUC0-24 (nelfinavir+M8) and
C12(nelfinavir+M8) comprised 130 and 142% respectively the adult population values. This, in
addition to good clinical response and good tolerability, favored continuation of the regimen.
Discussion/conclusion:
In one patient, nelfinavir-containing HAART was successfully used together with rifampin, after
addition of ritonavir. Ritonavir resolved the pharmacokinetic interaction between rifampin and
nelfinavir, by boosting nelfinavir and especially M8 levels. More research is needed to confirm
these results.
Introduction
Development of Highly Active Antiretroviral Therapy (HAART) has changed HIV-infection to a relatively
manageable chronic disease. Nevertheless, treatment of pediatric HIV-infection often remains challenging
due to additional problems, such as highly variable pharmacokinetics in children and the lack of ade-
quate pharmacokinetic data in the pediatric population1. Furthermore, the need for treatment of co-
infections, such as tuberculosis, may complicate HAART. Rifampin, which is often part of tuberculosis
therapy, is a potent inducer of hepatic cytochrome P450 (CYP) enzymes. It is known to very strongly
decrease plasma levels of protease inhibitors, making their combination not preferable2;3.
Here is presented the case of an HIV-infected infant with tuberculosis. In this patient, HAART containing
the protease inhibitor nelfinavir was successfully continued together with rifampin, after the addition of
ritonavir as a booster of nelfinavir.
Case report
A seven month-old sick male infant was hospitalized after he had been diagnosed with miliary tuberculo-
sis. Tuberculosis therapy containing rifampin 10 mg/kg q24h, isoniazid 10 mg/kg q24h, ethambutol 25
mg/kg q24h and pyrazinamide 25 mg/kg q24h was started. However, clinical symptoms also suggested
the presence of an HIV-infection, which was indeed confirmed by positive HIV ELISA, Western Blot and
PCR (HIV-1 RNA: 5.5 log10 copies/mL, Roche monitor assay, version 1.5). CD4
+ count was 490*106/L,
which is below the reference value of 1750*106/L for children below 1 year old. Subsequently, although
Nelfinavir and ritonavir combined with rifampin
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Table 1 pharmacokinetic parameters of nelfinavir and M8 in a patient on rifampin, compared to adult popula-
tion parameters for nelfinavir without rifampin 7;9
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in contrast to literature data concerning HAART in the presence of rifampin, nelfinavir 40 mg/kg q8h,
zidovudine 100 mg/m2 q8h and lamivudine 4 mg/kg q12h were started2;4. Other medication consisted of
cotrimoxazole suspension, prednisone, miconazole for topical use and a vitamin A/D suspension.
Intensive pharmacokinetic plasma sampling of nelfinavir and its principal oxidative metabolite nelfinavir-
hydroxy-t-butylamide (M8), which has shown in vitro activity equal to nelfinavir, was performed at
steady state5. Blood samples were drawn at time points 0 (pre-dose), 1, 2, 3, 4, 5 and 6h post ingestion.
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Figure 2a Plasma concentrations of nelfinavir and M8; nelfinavir 40 mg/kg q8h with rifampin.
Figure 1 HIV-1 viral load vs. time and outline of events.
Medication ingestion was observed and took place with food. Plasma concentrations of nelfinavir and M8
were simultaneously measured by validated HPLC assay (limit of quantification was 0.04 mg/L for both
nelfinavir and M8. Inter-day variability was 3.2 - 5.4% for nelfinavir, and 2.0 - 3.0% for M8)6;7.
Pharmacokinetic analysis of nelfinavir and M8 was performed using non-compartmental methods 8. AUCs
of nelfinavir and M8 were expressed as AUC0-24 (AUC0-24 = 3* AUC0-8). Pharmacokinetic parameters were
compared with population values of nelfinavir 750 mg q8h in adults without rifampin9. AUC0-24, 8-h
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Figure 2b Plasma concentrations of nelfinavir and M8; nelfinavir 30 mg/kg q12h with ritonavir 400 mg/m2 q12h
and rifampin.
Figure 3 Plasma concentrations of (nelfinavir + M8); nelfinavir q8h vs. q12h + ritonavir regimen with rifampin.
trough level (C8 ) and peak level (Cmax) of nelfinavir were far below adult population data (Figure 2A,
Table 1) and plasma levels of M8 were below the lower limit of quantification. Meanwhile, apparent oral
clearance (Cl/F*kg) of nelfinavir was approximately 60 times the estimated adult population value 
(Table 1). Since these results were attributed to accelerated metabolism of nelfinavir due to rifampin, it
was decided to add ritonavir as a pharmacokinetic enhancer of plasma levels of nelfinavir. Therefore, nel-
finavir 40 mg/kg q8h was substituted for nelfinavir 30 mg/kg q12h + ritonavir 400 mg/m2 q12h, with
the doses of nucleoside analogues unchanged.
To evaluate the effect of the nelfinavir/ritonavir regimen on the plasma levels of nelfinavir and M8 in
the presence of rifampin, intensive pharmacokinetic plasma sampling was repeated at steady state. Blood
samples were drawn at time points 0 (pre-dose), 0.25, 0.75, 1.25, 1.75, 2.25, 2.75, 3.75, 4.75, 5.75, 6.75,
7.75 and 12h post ingestion. Medication ingestion was observed and took place with food.
Pharmacokinetic parameters were calculated as for the first pharmacokinetic sampling; AUCs were
expressed as AUC0-24 (AUC0-24= 2 * AUC0-12). AUC0-24, Cmax and C12 of nelfinavir and M8 were compared
with population data for 1250 mg nelfinavir q12h in adults without rifampin. For nelfinavir, AUC0-24, C12
and Cmax had improved when compared to the prior regimen, but remained low at 46, 29 and 53%,
respectively, of population values. An 18-fold decrease was observed for Cl/F*kg of nelfinavir. Meanwhile,
AUC0-24, C12 and Cmax of M8 had highly increased to 4.2, 4.8 and 2.4 times the adult population values,
respectively (Figure 2B, Table 1). M8/nelfinavir AUC0-24 ratio had increased from 0 to 2.6.
Ritonavir plasma levels were measured with the same HPLC method as was used for the measurement 
of nelfinavir and M8 plasma levels. Cmax and C12 were 10.34 mg/L and 2.8 mg/L, respectively, which 
corresponds with adult population values for the standard dose of ritonavir 600 mg q12h10.
Given the increase of plasma concentrations of active metabolite M8 in this patient when using nelfi-
navir combined with ritonavir, AUC0-24 and C12 for (nelfinavir + M8), instead of nelfinavir alone were
used. AUC0-24 (nelfinavir+M8) and C12 (nelfinavir+M8) comprised 130 and 142%, respectively, the popu-
lation values of (nelfinavir + M8) for 1250 mg q12h in adults (Figure 3, Table 1).
HIV-RNA levels showed a decline to 68 copies/mL, and CD4+ cell count gradually increased to
1220*106/L, which is above the reference value of 1000*106/L for children aged 1-2 years (Figure 1).
Except for a temporary dermal hypersensitivity reaction, which was resolved by the use of clemastine,
the regimen was well tolerated and no adverse events were observed. Monthly-performed liver function
tests showed ALT, AST and gamma-GT levels within their normal ranges. Also, serum glucose, cholesterol
and triglycerides remained normal.
Taking into account these favorable pharmacokinetic and clinical data, twice-daily HAART was continued.
Discussion
Pharmacokinetics of nelfinavir / M8
Nelfinavir is extensively metabolized by cytochrome enzymes, mainly CYP2C19 and CYP3A45. Other pro-
tease inhibitors are mainly substrates of CYP3A411. Nelfinavir’s major metabolite M8 shows in vitro anti-
retroviral activity equal to nelfinavir5. Formation of M8 is almost exclusively mediated by CYP2C19, while
M8 is further metabolized to inactive compounds, the major route being via CYP3A45;12. It can be
assumed that M8, given its antiretroviral activity in vitro, also contributes equally to the activity of nel-
finavir in vivo. However, it should be taken into account that the use of plasma levels of these two com-
ponents together as a measure of clinical efficacy has yet to be validated in clinical practice.
In this case, pharmacokinetic parameters were compared with adult data. It should be noted that the
comparison of pediatric pharmacokinetic data with adult population data confers limitations related to
different pharmacokinetics in adults and children. In adults, pharmacokinetics of both nelfinavir and M8
have been well described. In infants and children though, only relatively sparse and highly variable data
exist, which also limits the application of pediatric population data13-16.
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Pharmacokinetic interactions with rifampin
Rifampin is a potent inducer of CYP2C19 and 3A4, which results in lowered plasma levels of nelfinavir,
and of other protease inhibitors17. In adult patients, rifampin decreased AUC and Cmax of nelfinavir by 82
and 76% respectively, which makes this combination not preferable4;9.
In our case, the extent to which plasma levels of nelfinavir decreased in the presence of rifampin (with-
out ritonavir) is in accordance with literature data. However, apart from an enzyme inducing effect by
rifampin, other factors, such as lower absorption or increased metabolism of nelfinavir in infants may
contribute to low plasma levels of nelfinavir13;16;18.
To overcome these complex drug interactions between HAART and rifampin, often HAART is delayed
until tuberculosis treatment has been completed19. As an alternative for rifampin, rifabutin, which has
weaker enzyme inducing properties than rifampin, can be administered. Nevertheless, with HAART, still,
interactions remain present: plasma levels of protease inhibitors are lowered by rifabutin, although to a
lesser extent than with rifampin. Co-administration of ritonavir with rifabutin is not recommended
because of high elevation of rifabutin levels4;17.
Ritonavir as a booster of protease inhibitors
Ritonavir is both a substrate and potent inhibitor of CYP3A4. Thus, ritonavir is able to increase (boost)
plasma levels of other PIs by inhibiting their metabolism11. The use of ritonavir as a booster of saquinavir
combined with a rifampin-containing regimen has been reported in two adult HIV+ patients. In these
patients, ritonavir-boosted plasma levels of saquinavir equaled those of saquinavir without rifampin20.
Effect of ritonavir on nelfinavir and M8
In general, pharmacokinetics of nelfinavir without ritonavir are characterized by a ratio of M8/nelfinavir
which remains constant during the dosing interval at a value of approximately 0.305;7;21. Although rito-
navir only slightly affects plasma levels of nelfinavir, it has been shown to strongly elevate plasma levels
of active metabolite M822;23. Therefore, in our case, it was assumed that the effect of ritonavir would be
sufficient also to overcome an interaction between nelfinavir and rifampin. It has been shown that in
children plasma levels of nelfinavir 30 mg/kg q12h with ritonavir are similar to nelfinavir 30 mg/kg q8h
without ritonavir18. Furthermore, in children exposure to nelfinavir 50-55 mg/kg q12h with nevirapine
was similar to nelfinavir 30 mg/kg with ritonavir 400 mg/m2 q12h15. Our dose calculations were based
on these pediatric data of the pharmacokinetics of nelfinavir with ritonavir. The high M8/nelfinavir AUC
ratio of 2.6 in our patient, after the addition of ritonavir, exceeds M8/nelfinavir AUC ratios observed
with nelfinavir and ritonavir without rifampin, which vary between 0.6 and 1.022;23. This observation
may be explained by CYP3A4 inhibition, combined with CYP2C19 induction by rifampin and possibly also
ritonavir10. Since CYP3A4 and 2C19 are involved in metabolism and formation of M8 respectively, an
increased M8/nelfinavir AUC ratio would be the combined result of inhibition of M8 elimination by
ritonavir and enhanced M8 formation by rifampin. In the presented case, after the addition of ritonavir,
Cl/F*kg of nelfinavir strongly decreased from approximately 60 to 2.8 times the estimated Cl/F*kg in
adults using nelfinavir without ritonavir or rifampin (Table 2). When compared to infants using nelfinavir
q8h and data from 8 children using nelfinavir and ritonavir without rifampin (not shown in Table 2), the
patient’s Cl/F*kg were approximately 14 and 2 times higher, respectively with the q8h and q12h regi-
men14;15. This strong decline of Cl/F*kg of nelfinavir, when compared to both the adult and pediatric
population, clearly illustrates the inhibiting effect of ritonavir on rifampin induced apparent oral clear-
ance of nelfinavir.
Clinical response and tolerability
In this patient, both virologic and immunologic responses were satisfactory and tolerability of the regi-
men was good. A slight increase in viral load, which eventually decreased to nadir, occurred by week 23
of HAART (Figure 1). Subtherapeutic drug plasma levels previous to nelfinavir with ritonavir containing
Chapter 2.2
40
HAART may have had contributed to this virologic ‘blip’. Nevertheless, while the importance of regular
medication intake was discussed with the infant’s caregiver, poor compliance most probably caused the
temporary viral rebound.
Moreover, in view of the good clinical response it should be remarked that the standard (full) dose of
ritonavir was used, i.e. not ‘low-dose’. Consequently, the virologic response could also have been due to
substantial antiretroviral activity of ritonavir.
Influence of HAART on rifampin levels
Plasma levels of rifampin have not been measured in this case. Therefore, it was not possible to deter-
mine if pharmacokinetics of rifampin were affected by nelfinavir or ritonavir. Meanwhile, this was not
very likely, since no typical rifampin related adverse events (e.g. gastrointestinal problems, abnormal
liver function) were seen.
Summary
In one patient, HAART containing nelfinavir was successfully continued in combination with rifampin
treatment, after the addition of ritonavir. Ritonavir boosted nelfinavir plasma levels and highly elevated
plasma levels of nelfinavir active metabolite M8. Good immunologic and virologic responses were favor-
able to continuation of the regimen. More research is needed to confirm these data in the pediatric pop-
ulation, and especially to establish the role of nelfinavir and M8 together as a measure of antiretroviral
activity in clinical practice.
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Abstract
Introduction:
Several studies in HIV-1-infected adults have demonstrated that suboptimal plasma concentra-
tions of the HIV protease inhibitor nelfinavir are related to virological failure. These relationships
are not yet well-defined in HIV-1-infected children.
Methods:
A pharmacokinetic substudy was conducted in previously untreated children participating in the
PENTA 5 trial. All children received nelfinavir plus two nucleoside reverse transcriptase inhibitors.
Nelfinavir was dosed 25-30 mg/kg q8h or 45-55 mg/kg q12h. A morning nelfinavir trough concen-
tration was determined between weeks 20 and 80 after starting treatment. Virological failure
was defined as an HIV-1 RNA viral load above 50 copies/mL at week 24 or week 48. Differences in
virological response were compared in children with a nelfinavir trough concentration either
below or above the consensus minimum effective concentration of 0.8 mg/L.
Results:
Forty-four children participated in this pharmacokinetic substudy. Data from 12 were not evalu-
able, leaving 32 (22 boys, 10 girls) children. Median (range) pretreatment viral load was 5.1 (4.1-
6.6) log10 copies/mL, and median age at pharmacokinetic sampling was 6.7 (0.8-17.3) years.
Seven (22%) children had a subtherapeutic nelfinavir plasma concentration; virological response
was observed in 43 and 29% of these children at week 24 and week 48, respectively. Conversely,
in 25 children with a nelfinavir trough concentration above 0.8 mg/L: 72 and 80% had HIV RNA
<50 copies/mL at week 24 (p=0.20) and week 48 (p=0.02), respectively.
Conclusion:
As in adults, suboptimal pharmacokinetics of nelfinavir are related to virological failure in HIV-1-
infected children. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves
treatment outcome in these children.
Introduction
Several studies have demonstrated that suboptimal pharmacokinetics of the HIV-1 protease inhibitor nel-
finavir are related to the risk of virological failure in HIV-1 infected adults1-4. Subsequently, a randomized
controlled clinical trial of therapeutic drug monitoring of nelfinavir in treatment-naive HIV-1 infected
adults has shown that routine measurement of plasma nelfinavir concentrations improves the virological
outcome of nelfinavir-based triple drug therapy5.
For HIV-1 infected children, there is less evidence concerning the importance of maintaining plasma con-
centrations of nelfinavir above a certain threshold to optimize treatment. Several groups have indicated
that there is a large interpatient variability in the plasma concentrations of nelfinavir when given to
HIV-1 infected children6-11. We could find only one study, presented as an abstract, that found a relation-
ship between exposure to nelfinavir (determined as the area under the plasma concentration vs. time
curve (AUC)) and virological response in the pediatric population8. A recent study from Italy, in contrast,
was not able to confirm these findings12. Therefore, there is a need for more data on the potential rela-
tionship between plasma concentrations of nelfinavir and the virological response in HIV-1 infected 
children. If such a relationship is firmly established, there is a rationale for considering therapeutic 
drug monitoring of nelfinavir on a routine basis in this patient population.
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Methods
Patients
This pharmacokinetic study was conducted as a substudy of the Pediatric European Network for
Treatment of AIDS (PENTA) 5 trial. Details on PENTA 5 are provided elsewhere13. Briefly, PENTA 5 was a
multicentre, randomised controlled trial of dual nucleoside-analogue reverse transcriptase inhibitor regi-
mens with or without nelfinavir in treatment-naive HIV-1 infected children. During this substudy, nelfi-
navir was dosed 25-30 mg/kg q8h or 45-55 mg/kg q12h with food. The main trial protocol and this sub-
study were approved by the ethics committee of each participating centre. All primary caregivers, and
where appropriate the children themselves, gave written approval for the main trial and this substudy.
Nelfinavir plasma concentrations
A nelfinavir trough concentration was measured between week 20 and week 80 in the morning just
before the next intake of medication. The time between the last intake and the blood sample was recor-
ded. Plasma was analyzed for nelfinavir by LC-MS by Virco. A nelfinavir trough concentration below 0.8
mg/L was considered subtherapeutic, based on a recent consensus document for target trough concen-
trations to be used in therapeutic drug monitoring services14. Children with a nelfinavir plasma concen-
tration below the limit of quantification were considered non-adherent and were excluded from further
analyses. As the aim of this substudy was to determine the association between nelfinavir trough levels
and virological response, the only effect of including such children would be to confound an effect of
trough concentration itself.
Viral load response
HIV-1 RNA concentrations were measured at two central laboratories with the Roche UltraSensitive assay
version 1.5 (lower limit of detection of 50 copies/mL). Virological response was defined as an unde-
tectable viral load at week 24 or week 48.
Statistical analysis
Differences in virological response between children with either subtherapeutic or therapeutic plasma
concentrations of nelfinavir were compared at weeks 24 and 48 using Fisher’s Exact Test for nominal and
Mann-Whitney test for numerical parameters. A p value less than 0.05 was considered statistically signi-
ficant.
Results
A total of 44 children participated in this substudy providing fasting plasma samples. There were no dif-
ferences in baseline characteristics between these children and the entire sample of children receiving
nelfinavir in PENTA 5. One child did not have enough plasma collected to measure nelfinavir. Another
child was reported to take nelfinavir only once-daily. Six children had inadvertently already taken the
morning nelfinavir dose before the fasting blood sample was drawn and were also excluded since no true
trough nelfinavir concentration could be determined in these children. Finally, four children were exclu-
ded from this analysis as the nelfinavir plasma concentration was below the limit of quantification, sug-
gesting non-adherence to the regimen. As a result, data from 32 children were evaluable (Table 1).
The average nelfinavir trough concentration in these 32 children was 2.1 mg/L for the q12h regimen (n =
18; coefficient of variation: 65.8%) and 1.7 mg/L for the q8h regimen (n = 14; coefficient of variation
90.0%). A total of 7 children (22%) had a concentration below 0.8 mg/L, the consensus target trough
concentration for nelfinavir14, ranging from 0.10 to 0.57 mg/L. The remaining 25 children all had a nelfi-
navir trough concentration above 0.8 mg/L, with 5.3 mg/L as the highest observed value.
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At weeks 24 and 48, 21 (66%) and 22 (69%) of the 32 evaluated children, respectively, had a viral load
below 50 copies/mL. However, this proportion differed at both time points between children who had 
a plasma nelfinavir trough concentration below or above 0.8 mg/L (figure 1). This difference reached 
statistical significance (p=0.02) at week 48 but not at week 24 (p=0.20). Of note, the two children
with a subtherapeutic nelfinavir trough concentration and an undetectable viral load at week 48, were
those with a low baseline viral load (4.1 and 4.5 Log10 copies/mL, respectively). Genotypic resistance
test results were available from 2 out of the 5 children with a nelfinavir trough below 0.8 mg/L and 
virological failure at week 48. One sample contained the primary mutation L90M, the other contained
only secondary mutations (K20R, M36I, M46L).
Discussion
This pharmacokinetic substudy of PENTA 5 in HIV-infected children confirms previous observations of a
positive association between nelfinavir plasma levels and virological response in HIV-infected adults1-4.
Children who had a nelfinavir trough concentration above 0.8 mg/L had a better virological response
than children with a value below this threshold. This difference was already visible as a trend at week 24
but increased after prolonged follow-up and reached statistical significance at week 48 (figure 1). These
data indicate that the advised target concentration of 0.8 mg/L for a nelfinavir trough concentration as
derived from treatment-naive adult patients, and published in a recent consensus document14, is also
valid for treatment-naïve children.
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Table 1 Patient characteristics at baseline and at time of sampling. Values are medians (ranges) or numbers
(n). * = significant
All patients Patients with Patients with P value
(n = 32) nelfinavir trough nelfinavir trough 
> 0.8 mg/L (n = 25) < 0.8 mg/L (n = 7)
At baseline
Gender (n) 0.86
Males 22 17 5
Females 10 8 2
HIV-1 RNA 5.1 5.1 5.4 0.45
(Log10 copies/mL) (4.1-6.6) (4.3-6.4) (4.1-6.6)
At time of sampling
Age (years) 6.7 (0.8-17.3) 8.3 (3.2-17.3) 3.8 (0.8-4.6) 0.001*
Weight (kg) 23.2 (9.7-86) 25.8 (15.5-86) 13.8 (9.7-16.6) <0.001*
Daily nelfinavir dose 94 96 91 0.96
(mg/kg) (26-119) (26-119) (72-109)
Nelfinavir dose 
frequency (n) 0.96
q8h 14 11 3
q12h 18 14 4
Time between intake 12.4 (8.5-17.0) 12.1 (8.5-17.0) 14.0 (9.0-16.5) 0.20
and sampling (h).
As far as we know there have been two other reports dealing with potential relationships between nelfi-
navir pharmacokinetics and virological response in HIV-infected children. The first study8 has only been
presented as an abstract. Hsyu et al. found a significant relation between nelfinavir AUC and virological
response in protease inhibitor-naïve children participating in clinical trials with nelfinavir q8h. The opti-
mal AUC0-8h of nelfinavir was defined as 12.5 mg/L.h or higher. In clinical practice, however, it may be
unpractical to obtain a full AUC in every child, and sparse sampling (for instance, a trough sample) is
much more convenient. Furthermore, the majority of children is using nelfinavir q12h these days, and it
is unknown whether these data can be extrapolated from q8h to q12h regimens.
In contrast to our observations and those from Hsyu et al., a recent study by Gatti et al.12 was not able
to detect a relationship between nelfinavir trough plasma concentrations and virological response in 25
children. There may be several explanations for this discrepancy. First, the large majority of the children
in that study had been pretreated with nucleoside reverse transcriptase inhibitors. Thus, the effect of
the new nelfinavir-containing regimen was possibly partly disturbed by cross-resistance developed
against the nucleoside analogues that were added to nelfinavir in these patients. This makes an analysis
of nelfinavir’s pharmacokinetic-pharmacodynamic effects more complex. Second, in that study, virological
response was evaluated at week 24, while in this substudy of PENTA 5 both week 24 and week 48
responses were evaluated (and the difference became statistically significant only at week 48). HIV-1
infected children may have very high viral loads at baseline, and week 24 may be too early to expect
complete plasma viral suppression. Indeed, here 4 children (13%) still had detectable viral load at week
24, but were undetectable at week 48. There were 3 further children (9%) who were undetectable at
week 24 but relapsed between weeks 24 and 48. Thus, the potency of this nelfinavir-containing regimen
was better evaluated (and reached statistical significance only) at week 48 than at week 24. Finally,
Gatti et al. used a different threshold for the nelfinavir trough concentration (1.0 mg/L), a different 
outcome parameter for virological response (decline in viral load between baseline and week 24), and 
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Figure 1 Proportion of children with an undetectable viral load at week 24 and week 48. The difference
between the subgroups with a nelfinavir trough concentration above or below 0.8 mg/L is statistically
significant at week 48 (p=0.02).
did not exclude patients with undetectable nelfinavir plasma concentrations; this all may have influenced
their results.
One aspect that all pediatric studies with nelfinavir have in common is the huge interpatient variability
in the plasma concentrations of this drug. In this study, the coefficient of variation in the morning nelfi-
navir trough concentration was 65.8% and 90.0% for the q8h and q12h dosing regimens, respectively.
This variability may have several causes including variation in food-dependent absorption, hepatic
metabolism and elimination through membrane transporters such as P-glycoprotein. Previous research
indicated that especially younger children were at risk for having subtherapeutic nelfinavir plasma 
concentrations11. This is confirmed by our data, as there was a significant difference in age (and body
weight) between children with subtherapeutic vs. therapeutic plasma concentrations (table 1); for exam-
ple, 7 out of the 13 children younger than 5 years had a subtherapeutic nelfinavir trough concentration
vs. none of the 19 children of 5 years of age or older.
Although a strong relationship between nelfinavir trough concentrations and virological response was
observed in this study, it is clear that other factors may also play a role. First, and most important, is
adherence to a regimen. As we included only one sample after unobserved intake in this analysis, it 
may well be true that some children had a therapeutic nelfinavir plasma concentration at the time 
of sampling, but became virological failures due to nonadherence at other times. Repeated sampling 
at different days may increase the likelihood of detecting nonadherence15. A full AUC is even more
informative than a single (trough) sample after unobserved intake of a drug since it precludes children
who are either nonadherent or have inadvertently taken the morning dose before sampling8. A random
or trough sample is, of course, more practical and less inconvenient for the child. A randomized, con-
trolled clinical trial of therapeutic drug monitoring of antiretroviral agents, including nelfinavir, address-
ing this issue, is currently in preparation (PENTA 14).
In conclusion, we have demonstrated that, as in adults, suboptimal pharmacokinetics of nelfinavir are
related to virological failure in HIV-infected children. Maintaining the nelfinavir trough concentration
above 0.8 mg/L significantly improves virological response in treatment-naïve children 48 weeks after
treatment initiation.
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Abstract
A protease inhibitor (PI) or non-nucleoside analogue (NNRTI) with nucleoside analogues (NRTIs)
are common as Highly Active Antiretroviral Therapy (HAART). Alternatively, a PI with an NNRTI
may offer perspectives. However, the NNRTIs nevirapine and efavirenz lower plasma levels of PIs,
which necessitates a 33% dose increase of the PI lopinavir in adults. In children, a 30% increased
lopinavir dose is recommended with nevirapine, but this has not been evaluated with efavirenz.
Aim: to investigate the pharmacokinetics of increased dose (300/75 mg/m2 q12h) lopinavir with
normal dose (14 mg/kg q24h) efavirenz in children.
Methods: HIV-1 infected children using lopinavir with efavirenz were eligible for inclusion.
Pharmacokinetics were evaluated at steady state.
Results: Fifteen children of median age (range) 11.8 (5.7-16.3) years were included. Area under
the plasma concentration-time curve (AUC0-12), peak level (Cmax) and trough level (Cmin) of
lopinavir were similar to historical data in adults and children: medians (interquartile range) 
were 92.3 (43.5-138.5) mg/L*h, 12.5 (6.9-16.7) mg/L and 5.7 (1.3-8.0) mg/L, respectively.
Pharmacokinetics of efavirenz approximated historical data in adults and children.
Conclusion: pharmacokinetics of 300/75 mg/m2 q12h lopinavir with 14 mg/kg q24h efavirenz were
generally similar to historical data, suggesting correctness of the evaluated doses in children.
Introduction
The introduction of HAART (highly-active antiretroviral therapy) has considerably improved efficacy of
treatment of HIV infection. HAART including either an HIV protease inhibitor or non-nucleoside analogue
combined with 2 nucleoside analogues has shown high potential with regard to virological suppression
and immune restoration and is generally recommended in both adults and children1;2. In addition, regi-
mens consisting of protease inhibitors with a non-nucleoside analogue may offer perspectives, particular-
ly as a treatment option for patients in whom viral resistance to nucleoside analogues has developed or
who experience intolerance to this class of drugs3-6. Lopinavir is a potent HIV protease inhibitor, which
is produced in co-formulation with low dose of ritonavir. In this combination, ritonavir acts as a pharma-
cokinetic booster of lopinavir by increasing its plasma levels. When combined with the non-nucleoside
analogues nevirapine or efavirenz, lopinavir has displayed good antiretroviral efficacy in both naive and
pretreated patients7. Importantly, pharmacokinetic data on these latter regimens have indicated, that
both efavirenz and nevirapine lower plasma levels of lopinavir, while pharmacokinetics of nevirapine and
efavirenz remain unaffected by lopinavir. In adults, a 33% increased dose of lopinavir (533/133 mg q12h)
used with nevirapine or efavirenz, resulted in plasma levels equal to lopinavir alone8;9. In children using
nevirapine, a 30% increased lopinavir dose was needed to obtain plasma levels of this drug similar to levels
without nevirapine10;11. An interaction between lopinavir and efavirenz, analogous to the interaction
with nevirapine is very likely to occur also in children. However, it has not yet been investigated if the
recommended 30% increased dose of lopinavir is also sufficient for the combination of lopinavir with
efavirenz in children.
Objective: to investigate the pharmacokinetics of the combination of a 30% increased dose (300/75
mg/m2 q12h) of lopinavir with normal dose (14 mg/kg q24h) efavirenz in HIV-1 infected children.
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Methods
Patients
Pharmacokinetic data were included from HIV-1 infected children between 3 months and 18 years old
treated with lopinavir and efavirenz. Children were recruited from two medical centers. Part of the 
children were enrolled in RODU-01, a study which investigated the pharmacokinetics, pharmacodynamics,
safety and tolerability of lopinavir with efavirenz in HIV-infected children who were pretreated exten-
sively with single or dual nucleoside analogues. The other patients were treated with the combination 
as part of a treatment protocol in one of the centers and had been pretreated with HAART including a
(ritonavir boosted) protease inhibitor or non-nucleoside analogue in addition to nucleoside analogues.
Informed consent was obtained from all patients or care-givers prior to enrollment into the study or
prior to start of antiretroviral treatment, respectively.
Medication
Lopinavir was prescribed in capsules of 133/33 mg lopinavir/ritonavir each and/or oral liquid containing
80 mg lopinavir and 20 mg ritonavir per mL. Efavirenz was prescribed in capsules of 50, 100 or 200 mg
and/or oral liquid containing 30 mg efavirenz per mL. Comedication was allowed if it was not expected
to interfere with the pharmacokinetics of either of the antiretroviral drugs. Selected doses were 300/75
mg/m2 lopinavir/ritonavir twice daily (q12h) and 14 mg/kg efavirenz once daily (q24h), respectively.
The selected dose of lopinavir was 30% higher with regard to the regular pediatric dose (230/58 mg/m2
lopinavir/ritonavir q12h) and similar to the recommended dose when used with nevirapine in children12.
Since pharmacokinetic data in adults did not show any effect of lopinavir on efavirenz plasma levels,
lopinavir was neither expected to interfere with efavirenz plasma levels in children. Therefore, the normal
pediatric dose of 14 mg/kg q24h efavirenz was selected for our study.
Patients and/or caretakers were instructed to take/administer efavirenz in the evening to reduce the 
risk of central nervous system related adverse experiences.
Also, it was emphasized to patients and/or caretakers to take medication at regular time intervals as 
prescribed for both drugs, and to take medication with food in order to enhance absorption of lopinavir.
Pharmacokinetic sampling
In all children, intensive pharmacokinetic sampling was performed at steady state (> 2 weeks after start
of medication). In the morning of the day of pharmacokinetic sampling, children were admitted to the
day care unit of the hospital. The ingestion of the morning dose of lopinavir was directly observed.
Medication was taken with a regular, bread-containing breakfast. Blood samples were drawn at time
points 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10 and 12 h post ingestion of lopinavir. Time of
ingestion of the last dose of efavirenz was recorded. Within 24 hours after collection, samples were 
centrifuged and plasma was stored at –20 ºC. Plasma concentrations of lopinavir and efavirenz were
determined by validated HPLC assays with UV detection (lower limits of quantification: 0.10 mg/L for
both compounds)13;14.
Pharmacokinetics of lopinavir and efavirenz
Pharmacokinetic parameters of lopinavir were calculated using non-compartmental methods15. The plasma
peak level (Cmax) and trough level at the 12-h time point (Cmin) were determined. Area under the plasma
concentration-time curve 0-12h (AUC0-12) was calculated using the trapezoidal rule. Relative apparent
oral clearance (Cl/m2*F) was calculated as dose (mg)/ AUC0-12*body surface area (m
2). Time to Cmax
(Tmax) was determined visually from the pharmacokinetic curve. To determine the terminal half-life
(t1/2), the elimination coefficient (Kel) was calculated as (slope of the terminal phase of the log-trans-
formed plasma concentration-time curve of lopinavir) /ln10. Slope was determined by linear regression 
of at least 3 time points of the log-transformed plasma concentration-time curve. T1/2 was derived by
dividing ln2/Kel.
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Since patients took efavirenz in the evening and plasma sampling was performed during daytime, plasma
concentrations of efavirenz were obtained only from the second half of the dosing interval. These plasma
concentrations allowed to calculate the average plasma concentration (Cavg), i.e., for a q24h regimen,
the plasma concentration at the 12-h time point15. Cavg of efavirenz was derived directly from the plasma
concentration-time curve, or calculated by inter- or extrapolation. From Cavg, the area under the plasma
concentration-time curve 0-24h (AUC0-24) for efavirenz was estimated by the following equation: Cavg =
D*F/Cl*τ = AUC0-24/τ, in which D is efavirenz dose in mg; F = oral bioavailability; τ is the dose interval
(24h for efavirenz) and Cl = apparent oral clearance (L/h). In patients in whom the curve exhibited a 
terminal elimination phase, Kel was calculated similarly as for lopinavir and the 24-h trough concentration
(C24) was determined.
Pharmacokinetic parameters of lopinavir were compared with historical data of lopinavir alone and of
increased dose of lopinavir with nevirapine in children, and with data of lopinavir with efavirenz in
adults11;12;16. Efavirenz data were compared to historical data in children (only AUC0-24 and C24) and
adults14;17;18.
Statistical methods
All statistical tests were performed using SPSS (SPSS, Chicago, IL, U.S.A., version 10.0). Spearman’s rank
correlation was calculated to evaluate the in between association of pharmacokinetic parameters and
association of pharmacokinetic parameters with patient related factors (age, body weight, body surface
area). A t test was used to test significance. The Fisher’s Exact Test was performed to estimate the asso-
ciation of nominally scaled patient characteristics with pharmacokinetic parameters. The Mann-Whitney
U Test was used to compare medians of continuously scaled variables. A p-value of <0.05 was considered
statistically significant.
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Table 1 Patient baseline characteristics N=15
Age (median, range) 11.8 (5.7-16.3)
Gender (female/male) 9/6
Body weight (kg) (median (IQR)) 32.5 (26.0-36.5)
Body surface area (m2) (median (IQR)) 1.1 (1.0-1.2)
Ethnicity (N=15), (numbers (%))
Asian 2 (13)
African 9 (60)
Caucasian 1 (7)
Hispanic 1 (7)
Other 2 (13)
Previous antiretroviral treatment (N=15), (numbers (%))
Protease inhibitor + 2 nucleoside analogues 7 (47)
Nevirapine + 2 nucleoside analogues 1 (7)
Mono- or dual nucleoside analogues 7 (47)
Number of different previous antiretroviral regimens per patient (median (range)) 1 (1-3)
Lopinavir dose (mg/m2 q12h) (median (IQR)) 300 (290-341)
Efavirenz dose (mg/kg q24h) (median (IQR)) 12.9 (12.1-13.9)
IQR: interquartile range
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Table 2 Pharmacokinetic parameters of lopinavir in children using lopinavir with efavirenz (N=15), compared to
historical data of children using lopinavir alone or increased dose lopinavir with nevirapine and histori-
cal data of adults using lopinavir alone or increased dose lopinavir with efavirenz.
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Results
Baseline patient characteristics
A number of 16 HIV-1 infected children were enrolled in the study between October 2001 and April 2003.
Pharmacokinetic data from one patient were excluded due to strong suspicion of non-compliance, based
on several unquantifiable plasma levels of lopinavir and efavirenz in samples taken at regular patient vis-
its and an unquantifiable pre-dose level at intensive pharmacokinetic sampling. Patient demographic
characteristics of the remaining 15 patients are listed in Table 1. Median age (range) of these patients (9
girls, 6 boys) was 11.8 (5.7-16.3) years. All 15 evaluable patients had received prior antiretroviral treat-
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Figure 1 (A) AUC0-12, (B) Cmax and (C) Cmin of lopinavir in children using lopinavir 300/75 mg/m
2 q12h with 
14 mg/kg efavirenz (N=15).
Figure 2 Individual pharmacokinetic curves of lopinavir in children using 300/75 mg/m
2
q12h lopinavir with 
14 mg/kg q24h efavirenz.
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ment; either a protease inhibitor with 2 nucleoside analogues (47%), a solely nucleoside based regimen
consisting of one or two nucleoside analogues (47%), or a non-nucleoside analogue with 2 nucleoside
analogues (7%). All 15 patients had multiple genotypic resistance to nucleoside analogues at baseline.
Intensive pharmacokinetic sampling was performed 2-8 weeks (median 4 weeks) after start of the regi-
men.
Pharmacokinetics
Lopinavir AUC0-12, Cmax and Cmin were similar to average values of lopinavir alone, increased dose
lopinavir with nevirapine in children, and increased dose of lopinavir with efavirenz in adults11;12;16
(Table 2). Tmax and Cl/m
2*F (median, interquartile range) were 3.2 (1.6-5.2) h and 3.1 (2.5-7.0) L/h*m2,
respectively. AUC0-12, Cmax and C12 of lopinavir showed 11, 9 and 34-fold interindividual variation, 
respectively. Both AUC0-12 and Cmax of lopinavir correlated well with C12 (R
2= 0.80 and 0.77 respectively,
p values both < 0.001). None of the pharmacokinetic parameters (AUC0-12, Cmax, Cmin, Cl/m
2*F, Tmax or
t1/2) of lopinavir was related with gender, age or weight (p values all > 0.1).
Remarkably, five of the 15 children showed clearly lower plasma levels of lopinavir with regard to both
the other evaluated patients and historical references. In these 5 children, AUC0-12, Cmax and Cmin of
lopinavir were significantly lower than in the 10 remaining children (medians for each group were 37.7
vs. 105.4 mg/L*h; 6.5 vs. 15.2 mg/L; 0.58 vs. 7.1 mg/L, respectively) (p values all 0.002, Figures 1 and 2,
Table 2). Also, the absolute difference between median Cmax and Cmin of lopinavir was smaller in the
children with low plasma levels (p=0.04). In 3/5 children with low plasma levels of lopinavir, C12 of
lopinavir was below the value of 1.0 mg/L. This plasma level approximates 15 times the 50% inhibitory
concentration (IC50) of lopinavir for wild type virus in a serum containing medium, and is considered 
as a lower limit for Cmin in naive patients
19;20. Also, t1/2 of lopinavir was significantly lower and Cl/m
2*F
significantly higher in the 5 children with lower plasma levels (p values both 0.002).
The 5 patients with lower plasma levels of lopinavir were not significantly different from the 10 patients
with higher plasma levels with regard to median age (10.5 vs. 11.9 years), body weight (33.4 vs. 31.7 kg),
gender (2/5 vs. 4/10 males), lopinavir dose (306 vs. 296 mg/m2 q12h), efavirenz dose (12.1 vs. 12.9
mg/kg q24h) or Cavg or AUC0-24 of efavirenz (p values all > 0.1). The only difference in patient characte-
ristics which could be found between these groups of children, was ethnicity. While 5/5 children with
lower lopinavir levels were of African origin, ethnicity of the children with higher plasma levels was as
follows: 2/10 Asian, 4/10 African, 1/10 Caucasian, 1/10 Hispanic and 2/10 other.
Analysis of plasma levels of efavirenz showed a Cavg (median (interquartile range)) of 3.9 (3.0-5.9) mg/L
in the whole group of children, which tended to be higher than has been reported in adults14;18. In 11/15
patients, the pharmacokinetic curve of efavirenz showed a terminal elimination phase. In these patients,
t1/2 and C24 were calculated, resulting in t1/2 and C24 of median (interquartile range) 25.5 (12.3-64.9)
hour and 2.1 (1.5-3.1) mg/L, respectively, which was in accordance with historical data in adults and
children14;17;18. Estimated AUC0-24 of efavirenz (median (interquartile range)) was 93.9 (73.8-130.2)
mg/L*h, which tended to be higher than these historical data.
Discussion
In 15 HIV-1 infected children, the increased dose of 300/75 mg/m2 q12h lopinavir combined with 14
mg/kg q24h efavirenz resulted in median AUC0-12, Cmax and Cmin of lopinavir which were similar to his-
torical data of either lopinavir alone and increased dose lopinavir with nevirapine (children) or efavirenz
(adults), suggesting that the investigated doses are correct in children. Meanwhile, plasma levels of
lopinavir showed high interindividual variability. Efavirenz levels, measured only during the second half
of the dose interval, resulted in t1/2 and C24 approximately similar to historical data in children and
adults, but Cavg and estimated AUC0-24 tended to be higher than historical data
14;17;18.
While treatment options for HIV-1 positive children have increased during the past decade, several fac-
tors may still impose limitations. Viral resistance is frequently encountered, especially after long-term
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treatment. All children in this study had received prior antiretroviral treatment containing at least one
nucleoside analogue and had developed (multiple) resistance against this class of drugs. A regimen con-
taining a (ritonavir-boosted) protease inhibitor with a non-nucleoside analogue is especially interesting
in this patient population, for whom nucleoside analogues do not offer a treatment option anymore. A
combination of lopinavir with efavirenz is attractive in these children, firstly, because of its documented
efficacy in adults21;22. Secondly, the regimen may be more convenient when compared to other regimens,
because of its relatively limited pill burden and availability of liquid formulations of both drugs, enabling
their use by children who cannot swallow capsules.
The decrease of plasma levels of lopinavir occurring when this drug is coadministered with nevirapine or
efavirenz is also seen when other protease inhibitors are combined with these drugs. This pharmacoki-
netic interaction is attributed to an induction by nevirapine and efavirenz of cytochrome (CYP) 3A4, 
the major enzyme involved in metabolism of most protease inhibitors17;23.
In our study, in the majority of the children, lopinavir pharmacokinetic parameters were similar to his-
torical controls. Although in most children the explored lopinavir dose was adequate, interestingly, in
5/15 patients, AUC0-12, Cmax and Cmin of lopinavir were significantly lower than in the other children.
This finding may reflect the presence of a subpopulation of patients with lower plasma levels of
lopinavir. In 3 out of these 5 patients, Cmin fell below 1.0 mg/L, a value equaling 15 times the IC50 of
lopinavir for wild-type virus as determined in the presence of 50% human serum and 10% fetal calf
serum, i.e. an inhibitory quotient (IQ) of 15. An IQ above 15 for lopinavir has been associated with signi-
ficantly improved antiviral response16;20. Especially in protease inhibitor pretreated patients, virus may
have become less susceptible to lopinavir, and in that case, the IQ of 15 is only reached at plasma levels
above 1.0 mg/L. Consequently, the children with Cmin below 1.0 mg/L in our study possibly had subthe-
rapeutic plasma levels of lopinavir.
In the 5 patients with lower plasma levels, t1/2 of lopinavir was significantly shorter when compared to
the 10 remaining children, reflecting a higher elimination rate in the children with lower plasma levels.
This finding could result from an increased enzyme inducing effect of efavirenz. Induction of hepatic
CYP3A4 has been correlated with plasma levels of efavirenz24. However, in the present study, this could
not be confirmed, since in the children with lower levels of lopinavir, levels of efavirenz were not signifi-
cantly higher. Also, in these children, Cl/m2*F was significantly increased, which could reflect both
decreased absorption and increased elimination. The findings that not only Cmin, but also Cmax was 
lowered and that the absolute difference between Cmax and Cmin was smaller in these children, suggest
also decreased intestinal absorption of lopinavir. Consequently, in this study, lower plasma levels of
lopinavir were most likely caused by decreased absorption combined with an increased hepatic clearance
of lopinavir. Absorption of lopinavir is increased with food and therefore, ingestion of the drug is recom-
mended with a meal. While all patients ingested medication with a standardized breakfast on the day of
pharmacokinetic sampling, it cannot entirely be excluded that patients with lower plasma levels ingested
medication with a smaller amount of food. An explanation for increased elimination, and possibly also
for decreased absorption of lopinavir, could be lower plasma levels of its pharmacokinetic booster rito-
navir, which is both a substrate and an inhibitor of CYP3A4, and, at least in vitro, inhibits activity of
the membrane efflux protein P-glycoprotein (PgP)25-28. The boosting effect by ritonavir on plasma levels
of lopinavir and other protease inhibitors has been found to depend on plasma levels of ritonavir29.
Remarkably, the only difference between the children with higher and lower plasma levels of lopinavir
was ethnicity, African children being more strongly represented in the group of children with lower plas-
ma levels than in the group of children with higher plasma levels of lopinavir. Genetic polymorphism of
CYP3A4, the major enzyme involved in metabolism of lopinavir and ritonavir, has been found more fre-
quently in Africans than in other ethnic groups, but does not seem to be of remarkable influence on
CYP3A4 related metabolism30;31. Also, polymorphism of the gene (MDR1) coding for PgP has been found
significantly more frequent in Africans than in other races32;33. Genetic polymorphism may influence
metabolism of PgP substrates, but its effects in vivo still remain to be elucidated34. In addition, activity
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of CYP or PgP is known to be influenced by several external factors, such as concomitant medication and
nutritional patterns. While no relevant co-medication was registered during the study, the regular use of
food containing modifiers of CYP or PgP may have influenced plasma levels of lopinavir or efavirenz.
However, the impact of genotypic parameters and plasma levels of ritonavir on the pharmacokinetics of
lopinavir could not be evaluated in the present study, since none of these factors were determined.
Finally, the pharmacokinetics of efavirenz were approximately similar to historical data in adults and
children, except for the estimated AUC0-24 and Cavg, which tended to be higher than these data
14;17;18.
The relevance of this latter finding may be low, especially for AUC0-24, since by measuring plasma levels
of efavirenz during the second part of the pharmacokinetic curve, only a rough estimate of AUC0-24
could be made. Furthermore, earlier data in adults did not shown any influence of lopinavir on plasma
levels of efavirenz9.
In conclusion, these data indicate, that the investigated doses of 300/75 mg/m2 q12h lopinavir with 
14 mg/kg q24h efavirenz in the majority of children result in pharmacokinetic parameters similar to 
historical data of lopinavir alone in adults and children, and of increased dose lopinavir with nevirapine
or efavirenz in children and adults, respectively. Plasma levels of efavirenz were approximately similar to
historical data, enabling the use of the pediatric standard dose of efavirenz (14 mg/kg q24h). These
results suggest that the evaluated doses of lopinavir and efavirenz are correct in most children. However,
regarding the high interindividual variability in plasma levels of in particular lopinavir, therapeutic drug
monitoring should be applied to detect individual patients who display abnormal plasma levels.
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Abstract
Background: The HIV-protease inhibitor indinavir has been successfully used in Highly Active
Antiretroviral Treatment (HAART). The addition of ritonavir combines a favorably increased indi-
navir trough level (Cmin) with the convenience of q12h dosing. However, no pediatric doses for
indinavir with ritonavir have been defined yet. This study evaluated the pharmacokinetics of 
400 mg/m2 indinavir with 125 mg/m2 q12h ritonavir in HIV-1 infected children.
Methods:
Children starting indinavir with ritonavir and 2 nucleoside analogues were enrolled into this
prospective, non-randomized open label study. 0-12h pharmacokinetic plasma sampling was per-
formed at steady-state. Estimated area under the curve (AUC0-24), peak level (Cmax) and trough
level (Cmin) of indinavir were compared with historical data.
Results:
14 children (6 males) of median age (range) 8.5 (2.4-16.2) years were included. Compared to chil-
dren and adults using indinavir q8h, significantly higher AUC0-24 (geometric mean ratios (GMR),
(90% confidence interval (CI)) 1.8 (1.5-2.3) and 1.8 (1.4-2.2), respectively), significantly higher
Cmin (GMRs (90%CI) 8.4 (5.3-13.4) and 4.9 (3.1-7.9), respectively), and non-significantly increased
Cmax (GMRs (90%CI) 1.1 (0.97-1.4) and 1.2 (0.99-1.4), respectively), were observed. AUC0-24 and
Cmin of indinavir were similar to data of indinavir/ritonavir 800/100 mg q12h in adults, while
Cmax was slightly decreased (GMRs (90%CI)): 1.1 (0.87-1.3), 0.96 (0.60-1.5) and 0.80 (0.68-
0.94), respectively. Tolerability was generally good.
Conclusion: In children, 400 mg/m2 indinavir with 125 mg/m2 q12h ritonavir showed generally
good short-term tolerability and resulted in significantly higher AUC0-24 and Cmin than seen with
indinavir q8h. Pharmacokinetics of indinavir approached those of indinavir with low-dose rito-
navir in adults.
Introduction
The HIV-protease inhibitor indinavir has been licensed since 1996 for the treatment of HIV-1 infection in
adults and children of 4 years and older. In HIV-infected adults, the efficacy of indinavir as a component
of Highly-Active Antiretroviral Therapy (HAART) has been established7-10. Indinavir, if used as a sole pro-
tease inhibitor, should be administered three times daily (q8h), preferably on an empty stomach or with
a low-caloric meal (Anonymous. Product monograph Crixivan®, Merck & Co. Inc., West Point, PA, USA,
1996). The addition of the HIV protease inhibitor ritonavir to indinavir containing therapy is known to
increase plasma levels of indinavir, especially the 12-h trough level (Cmin)
2;11. The increased Cmin of indi-
navir, when combined with ritonavir, can potentially improve antiretroviral efficacy of the regimen1.
Data on the use of indinavir as a component of HAART in HIV-infected children are relatively limited and
often based on small sample size4;6;14-18;22-24. Children show generally lower 8-h trough levels (Cmin) of
indinavir than adults and may therefore be at higher risk of virologic failure4,6 In HIV-infected children,
the combination of indinavir with ritonavir is promising, in view of its higher Cmin, and the possibility
of twice daily (q12h) administration. However, this combination has been very little explored in children.
Consequently, no pediatric doses for the regimen have been established. This study aimed to investigate
the pharmacokinetics and short-term tolerability in HIV-infected children of a regimen of indinavir boos-
ted with low-dose ritonavir.
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Materials and Methods
Study Subjects
HIV-1 infected children between 2 and 18 years of age, naive or non-naive for prior antiretroviral therapy
were eligible for enrollment. Children needed to have a confirmed HIV infection on 2 consecutive tes-
tings. Patients with any acute infection requiring treatment, active malignancy requiring chemotherapy,
or Grade 3-4 clinical or laboratory toxicity as defined by the National Institute of Health/Division of AIDS
(NIH/AIDS) at screening were excluded. Patients were not allowed to use non-nucleoside analogue
reverse transcriptase inhibitors (NNRTIs) from two weeks prior to start and during the study. Nor were
patients allowed to use other concomitant medications known to interfere with the pharmacokinetics of
indinavir and/or ritonavir, other investigational agents, immunomodulators, HIV-1 vaccines or systemic
glucocorticoids. In female patients of childbearing potential, a urine pregnancy test was performed with-
in 72 hours before start of study medication to exclude pregnancy. Patients with any condition or history
of any illness which might confound the results of the study, or pose additional risk in administering the
study drugs to the patient were excluded from enrollment into the study. Children had to be able to
swallow capsules. Patients or caregivers had to be able to give written informed consent.
Study outline
This was a prospective, one-armed, one period, open label study. After enrollment, patients started study
medication consisting of indinavir 400 mg/m2 q12h with 125 mg/m2 ritonavir q12h on Study Day 1.
Medication consisted of indinavir capsules of 100, 200, 333 or 400 mg strength and ritonavir in capsules
of 100 mg strength, or oral liquid containing 80 mg/mL ritonavir. In each patient, doses of indinavir and
ritonavir were chosen as close as possible to 400 and 125 mg/m2 q12h, respectively, depending on avai-
lable strength of capsules and/or oral liquid. Selection of doses of indinavir and ritonavir was based on
the following considerations.
Previous data on 4 children treated with 500 mg/m2 q12h indinavir with 100 mg/m2 q12h ritonavir
showed a promising increase in Cmin when compared with indinavir q8h, but also an increased AUC0-24
and possibly plasma level related, toxicity21. Therefore, the investigational doses of indinavir with riton-
avir in this study should preferably result in no increase in AUC0-24 and preferably a decreased Cmax, but
still an increased Cmin when compared to data of indinavir without ritonavir. In order to obtain the
desired AUC0-24 of indinavir, the selected dose of indinavir was lower than 500 mg/m
2 q12h. A slightly
increased ritonavir dose (125 mg/m2 q12h) was selected to inhibit indinavir metabolism more strongly, in
order to result in an adequate Cmin despite the dose reduction of indinavir. Based on these considera-
tions, the selected doses of indinavir and ritonavir were 400 and 125 mg/m2 q12h, respectively.
In addition to indinavir and ritonavir, two nucleoside reverse transcriptase analogues (NRTIs) according
to the pediatricians’ choice were used. On the pharmacokinetic sampling day (PK day), a 12-h pharmaco-
kinetic curve to obtain plasma levels of indinavir and ritonavir was recorded. The PK day was planned 2-4
weeks after Study Day 1 (start of study medication) to ascertain that steady state was reached, and
preferably at the day of a regular patient visit to minimize interference with the child’s daily activities.
Compliance was extensively discussed with the patient/caretaker. Patients in whom the pre-dose trough
level on the PK day was below the lower limit of quantification (LLOQ), while the 12-h level after
observed dosing was normal, suggesting non-compliance and lack of steady-state, were excluded from
further data analysis. Follow-up after the duration of the study consisted of regular patient care. Here
are described the pharmacokinetics and short-term safety and efficacy of the study regimen between
Study Day 1 and the PK day.
Pharmacokinetics
In the morning of the PK day, intensive 0-12h pharmacokinetic sampling was performed. For this pur-
pose, patients were admitted to the day care unit of the hospital. Drug intake was directly observed and
children took their medication with a light breakfast, mostly consisting of bread with fruit juice. Blood
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samples were drawn at time points 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours after
drug intake. Within 24 hours, blood samples were centrifuged to plasma and stored at –20 ºC. Plasma con-
centrations of indinavir and ritonavir were determined by a validated assay of high-performance liquid
chromatography using a reversed-phase C18 column and quantification with UV at a wavelength of 215
nm13. Linearity of the method was validated between concentrations of 0.04 and 30 mg/L for both indi-
navir and ritonavir. Intra-assay variance was between 2.6 and 7.5% for indinavir and between 2.0 and
8.1% for ritonavir. Inter-assay variance was between 0.43 and 3.5% for both indinavir and ritonavir.
Pharmacokinetic parameters of indinavir and ritonavir were calculated using non-compartmental methods.
Peak plasma level (Cmax) and Cmin were determined. Time to peak plasma concentration (Tmax) was deter-
mined visually from the pharmacokinetic curve. The area under the plasma concentration-time curve 
0-12h (AUC0-12) was calculated using the trapezoidal rule. For comparison with historical data of indina-
vir q8h, the estimated AUC over the 24h time interval (AUC0-24) was calculated by multiplying AUC0-12
by 2. AUC0-24 and Cmin of indinavir were compared with historical data of indinavir q8h in adults (Merck
study protocol 021), indinavir q8h in children (combined data from Merck study protocol 068 and
Pediatric AIDS Clinical Trial Group (PACTG) 395) (Merck & Co. Inc., West Point, PA, U.S.A., data on file),
and with historical data of indinavir with ritonavir q12h in adults2.
Safety and efficacy assessment
Safety was assessed at baseline (before start of study medication) and on the PK day. Laboratory assess-
ments of safety consisted of hematology, blood chemistry and urinalysis. Clinical assessments of safety
consisted of physical examination and monitoring of adverse experiences by questioning child and/or
caretaker. HIV RNA load was determined at baseline and during visits for follow-up using Roche Amplicor
test (Roche, Branchburg, NJ, USA) with lower limit of quantification 500 copies/mL. CD4+ counts were
expressed both as absolute counts (cells/mm3) and as % of age-specific median values (neonatal: 1900, 1
week - 2 months old: 3500, 2-5 months old: 2500, 5-9 months old: 2800, 9-15 months old: 2300, 15-24
months old: 2200, age 2-5 years old: 1300, age 5-10 years old: 1000, age 10-16 years old: 800, > 16 years
old: 700).
Statistics
All statistical tests were performed using SPSS (SPSS, Chicago, IL, U.S.A., version 10.0). Geometric
means with 90% confidence intervals were calculated for AUC0-24, Cmax, and Cmin of indinavir and 
ritonavir. Medians were calculated for Tmax of indinavir and ritonavir. Geometric mean ratios with 90%
confidence intervals of pharmacokinetic parameters of indinavir versus historical controls were calculated.
Statistical significance was concluded if the 90% confidence interval of a geometric mean ratio did not
include 1.
Two hypotheses were stated for estimated AUC0-24 and Cmin of indinavir:
1. The 90% confidence interval of the geometric mean ratio of estimated indinavir plasma AUC0-24 vs.
historical controls of indinavir q8h would fall entirely within the range (0.8-1.8), assuming a geometric
mean ratio of 1.2
3. The lower bound of the 90% CI for the geometric mean ratio of indinavir Cmin vs. historical controls
of Cmin for indinavir q8h would be greater than 1.
A sample size of 15 was estimated sufficient to obtain 80% power.
Results
Fourteen HIV-infected children between 2.4 and 16.2 years old were enrolled in the study between
September 2000 and October 2002. Most of the children (71%) had received prior antiretroviral treat-
ment. Of the children who were antiretroviral treatment experienced, most had been pretreated with a
regimen containing indinavir without ritonavir.
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Baseline patient characteristics are given in Table 1. Written informed consent was obtained of all
patients and/or caregivers. In all 14 patients, 12-h intensive pharmacokinetic sampling was performed
between 15 and 28 days after start of study medication. All patients had used study medication without
interruption for at least 2 weeks before pharmacokinetic sampling. Two patients were eventually not able
to swallow intact capsules of indinavir and had to open the capsules. All enrolled patients completed the
duration of the study.
Of all 14 enrolled patients, pharmacokinetic data were included in data analysis, indicating that none of
the patients was suspected of non-compliance and lack of steady state. Pharmacokinetic parameters of
indinavir and ritonavir for the total of 14 patients are summarized in Table 2. Tmax of indinavir in the 2
patients who opened capsules of indinavir were 3 and 3.3 hours, respectively, which is slightly longer
than the median Tmax in the other enrolled children. Pharmacokinetic parameters in these children were
not highly different from geometric means in the group as a whole, suggesting no clear influence of
opened capsules on pharmacokinetics of indinavir (data not shown in table). Therefore, both patients
remained included in further data analysis. Overall, the regimen of indinavir/ritonavir 400/125 mg/m2
q12h resulted in significantly higher AUC0-24 of indinavir than reference data of indinavir q8h in both
adults and children. This increase in AUC0-24 was reflected in significantly higher geometric mean Cmin,
while Cmax was only marginally and non-significantly increased (Table 2). The geometric mean ratio of
AUC0-24 vs. historical controls of indinavir q8h exceeded the hypothesized value of 1.2, and the upper
limit of the 90% CI exceeded 1.8 (defined as upper limit in hypothesis 1). Consequently, hypothesis 1,
which stated that estimated AUC0-24 of indinavir would be approximately equal to the AUC0-24 of indi-
navir q8h was not met. Meanwhile, the significantly higher geometric mean of Cmin for indinavir con-
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Table 1 Baseline characteristics of 14 enrolled patients.
Gender (n (%)) Male 6/14 (43%)
Age (years) (median (range)) 8.5 (2.4-16.2)
Race (n (%))
White 2 (14)
Black 9 (64)
Asian 1 (7)
Other 2 (14)
Dose indinavir in mg/m2 q12h (median (range)) 393 (345-483)
Dose ritonavir in mg/m2 q12h (median (range)) 126 (100-132)
Patients with one or more prior antiretroviral therapies (%) 10/14 (71)
Antiretroviral prior treatment (n=10)
Indinavir q8h 8/10 (80)
Indinavir/ritonavir q12h 1/10 (10)
Nelfinavir 1/10 (10)
Zidovudine + Lamivudine 10/10 (100)
CD4+ cell count
Cells/mm3 (median (range)) 650 (200-2100)
% of age specific median cell counts (median (range)) 65 (20-162)
Plasma HIV RNA viral load (Log10 copies/mL), (median (range)) 3.13 (2.70-5.45)
Concomitant treatment (n)
Zidovudine/lamivudine 12
Didanosine/stavudine 2
Fluconazole 1
Terbinafine 1
Co-trimoxazole 2
Indinavir with low dose ritonavir
Table 2 Pharmacokinetic parameters of indinavir and ritonavir (Geometric Means (90% confidence interval)) of
14 children using indinavir with low-dose ritonavir and compared to historical controls (Geometric
Mean Ratios).
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firmed hypothesis 2, stating that Cmin of indinavir would be significantly higher than with indinavir
q8h. In none of the patients, Cmin of indinavir was below the value of 0.1 mg/L, which has been associ-
ated with increased virologic failure rate3.
Compared to the pharmacokinetic data of 800 mg indinavir with 100 mg ritonavir q12h in adults, geo-
metric means of AUC0-24 and Cmin of indinavir were not significantly different, while geometric mean
Cmax was modestly, but significantly decreased.
Ritonavir AUC0-12, Cmax, and Cmin were significantly higher than historical references of 100 mg ritonavir
q12h combined with indinavir in adults (Table 2).
Finally, pharmacokinetic data of 3 additional children (1/3 male) below 2 years old (range 0.5 –1.1) using
the study regimen, but not meeting the inclusion criteria with regard to age, were evaluated as protocol
violators after informed consent was obtained. Pharmacokinetic results of these patients were considered
worth reporting because of the lack of data on use of (boosted) indinavir in very young children. All 3
children used opened capsules of indinavir. When compared to the group of 14 children, geometric means
of AUC0-24 and Cmax of indinavir in the 3 children below 2 years old differed slightly (AUC0-24 was 24%
lower and Cmax was 14% higher). However, Cmin of indinavir was considerably lower (-70%) in younger
children, resulting in Cmin below 0.1 mg/L in one child (Table 3, Figures 1 A, B and C). Similarly, for
ritonavir, relatively moderate differences were seen in AUC0-24 and Cmax of ritonavir (-41 and -18%), while
Cmin of ritonavir was more strongly decreased (-63%) when compared to older children (Table 3). Also,
absorption rates of indinavir and ritonavir were higher in the 3 children below 2 years old, as compared
to the 14 older patients.
Short-term safety and tolerability
Of the 14 children enrolled, 8 (57%) suffered from a clinical or laboratory adverse experience between
Study Days 1 and 2. In total, 22 adverse experiences were listed (Table 4). These 22 events include 2
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Table 3 Pharmacokinetic parameters of indinavir and ritonavir of 3 children < 2 years old who did not meet
inclusion criteria of age using indinavir with low-dose ritonavir.
AUC0-24 Cmax Cmin Tmax 
(mg/L*h) (mg/L) (mg/L) (hour, medians)
Indinavir (geometric means) (N=3) 70.5 9.8 0.19 0.5
Ritonavir (geometric means) (N=3) 45.3 4.9 0.41 0.5
Table 4 Description of adverse experiences (cases (% of the total of 22 adverse experiences))
Adverse experience Frequency (%)
Gastrointestinal disorders 3 (14%)
Ear, nose and throat infections 1 (5%)
Skin disorders 2 (9%)
Urinary tract disorders 2 (9%)
(nephrolithiasis and leucocyturia)
Jaundice/hepatomegaly 2 (9%)
Abnormal liver function tests 4 (18%)
Abnormal blood cell counts 1 (5%)
Increased cholesterol/triglyceride levels 5 (23%)
Increased amylase levels 1 (5%)
Decreased platelet count 1 (5%)
Total of all adverse events 22 (100%)
severe adverse experiences (jaundice and vomiting) and 1 case of suspected nephrolithiasis, which led to
a four-days’ interruption of study medication. In none of the other patients, study medication was inter-
rupted. Besides this single case of nephrolithiasis, no other clinically distinct cases of nephrolithiasis
were observed.
Of the 3 patients below 2 years old who did not meet the inclusion criteria of age, one patient experi-
enced mild adverse events consisting of increased amylase and direct bilirubin (not listed in Table 4).
These adverse events were considered mild in nature and were considered possibly and probably related
to study drugs, respectively.
Discussion
The investigated regimen of 400 mg/m2 indinavir with 125 mg/m2 ritonavir in children resulted in high-
er AUC0-24 and Cmin of indinavir, when compared to data on indinavir without ritonavir in adult and
pediatric populations. AUC0-24 and Cmin were not different from plasma levels observed in adults using
800/100 mg q12h indinavir/ritonavir. Also, a slight, but significant decrease in Cmax was observed with
regard to these data.
Published data in HIV-infected children have indicated that a pediatric dose of indinavir q8h should be in
the order of 500–600 mg/m2 q8h4;17. The pharmacokinetics of indinavir as a sole protease inhibitor in
children are characterized by a higher Cmax than in adults, followed by relatively high drug clearance,
often resulting in lower Cmin than in adults
4-6;15. In substantial numbers of children, Cmin of indinavir is
below the concentration of 0.1 mg/L, which has been associated with virologic efficacy and approxi-
mates the in vitro 95% inhibitory concentration (IC95) of indinavir for wild type virus1,3. While doses of
indinavir above 500-600 mg/m2 q8h result in higher Cmin and possibly better clinical response, toxicity
of indinavir seems to be dose limiting in children4;20. Meanwhile, the relatively strong increasing effect
of ritonavir on Cmin of indinavir, with only moderate influence on Cmax may offer perspectives for the
treatment with indinavir in children. In contrast to adults, in children, no doses for the combination of
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Figure 1A AUC0-24 of indinavir in 14 patients > 2 years old and 3 patients < 2 years old.
Figure 1B Cmax of indinavir in 14 patients > 2 years old and 3 patients < 2 years old.
Figure 1C Cmin of indinavir in 14 patients > 2 years old and 3 patients < 2 years old.
indinavir with ritonavir have been established yet. For the current study, it was hypothesized, that to
join optimal antiviral efficacy with limited risk of toxicity, the selected doses of indinavir with ritonavir
should preferably result in an increased Cmin, but a comparable AUC0-24 and if possible, decreased Cmax
of indinavir when compared to data of indinavir without ritonavir.
In the 14 HIV-1 infected children described here, the regimen of 400 mg/m2 indinavir q12h with 125
mg/m2 ritonavir q12h resulted in higher than expected AUC0-24 and Cmin compared to pharmacokinetic
data of indinavir q8h in both adults and children. Consequently, the hypothesis concerning increased
Cmin was met, while expectations concerning AUC0-24 were not. The explored dose combination resulted
in AUC0-24 and Cmin of indinavir approximately similar to the pharmacokinetic data of indinavir with
low-dose ritonavir in adults2.
For further evaluation, it is interesting to compare our results with the sparse other pharmacokinetic
data on indinavir with ritonavir in children.
When compared to published data from a case series on 4 children between 0.8 and 10 years old treated
with 500/100 mg/m2 q12h indinavir with ritonavir, AUC0-24 and Cmax of indinavir were dose-proportio-
nally lower in our study21. In contrast, Cmin of indinavir was approximately 40% higher, and not lower, 
as might have been expected, than found in the case series. An explanation for this increase in Cmin
could be that inhibition of indinavir metabolism by ritonavir is stronger with increased ritonavir dose,
which seems even to outweigh the decreased dose of indinavir. A stronger boosting effect of increasing
ritonavir doses on Cmin of fixed doses of indinavir has been reported earlier in healthy volunteers
11;12.
In comparison with preliminary pharmacokinetic data from a pediatric study in 11 patients between 
3 and 11 years old who used 350 mg/m2 q12h indinavir with 125 mg/m2 ritonavir, in our study, AUC0-24
and Cmin of indinavir were 59% and 50% higher, respectively, while Cmax was 16% higher (E. G.
Chadwick, J. H. Rodman, P. Samson, T. Fenton, E. J. Abrams, B. Nowak, S. I. Pelton, S. Lavoie, K. Knapp,
M. Bambji, R. Yogev, 10th Conference on Retroviruses and Opportunistic Infections, abstract 875, 2003).
Especially the differences in AUC0-24 and Cmin were remarkable, since the 2 regimens were only distin-
guished from each other by a slight difference (14%) in indinavir dose (the indinavir dose was 400
mg/m2 q12h in the present study, vs. 350 mg/m2 q12h in the study by Chadwick et al.). This finding
confirms data in healthy volunteers suggesting that altered indinavir doses with constant ritonavir dose
result in a more than dose-proportional impact on AUC0-24 and Cmin, but not Cmax of indinavir
11. In addi-
tion, plasma levels of ritonavir were higher in our study compared to levels observed by Chadwick et al.
Earlier data have indicated that indinavir increases plasma levels of ritonavir19. While it remains unclear
if this effect is dependent on indinavir dose, increased plasma levels of ritonavir could have stronger
inhibited indinavir metabolism, contributing to the higher plasma levels of indinavir in the present
study. Considering our data with respect to the other data on pharmacokinetics of indinavir with rito-
navir in children, it should be taken into account that differences in outcome may be partly due to high
interindividual variability and limited sample size of these studies. Nevertheless, based on these data, 
a dose modification to obtain more decreased exposure to indinavir, as was initially aimed to, seems puzz-
ling. A decrease in indinavir dose tends to decrease Cmin to an undesirable extent. While an increased
dose of ritonavir with further decreased indinavir dose might be of interest, the very poor palatability of
ritonavir oral solution makes the exploration of increased doses of ritonavir less attractive in children.
Finally, the 3 children below 2 years old showed moderately decreased plasma levels of indinavir and
ritonavir when compared to the 14 older children in our study using the same drug combination. This
decrease in plasma levels was most obvious for Cmin of both agents, resulting in sub optimal Cmin in one
of the 3 children. The finding of lower plasma levels is not uncommon in younger children, and may
result from lower absorption, possibly combined with increased elimination of drugs in children25.
Moreover, in our study, the 3 children below 2 years old showed faster absorption and slightly increased
Cmax of indinavir and ritonavir. It might be speculated that the increased Tmax was due to ingestion of
opened capsules of indinavir, but, in contrast, Tmax in the 2 older children who opened capsules did not
suggest a major influence of opening capsules on absorption rate of indinavir. The higher absorption rate
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of ritonavir could also be explained by a different absorption rate of the liquid formulation of ritonavir,
which was used by the 3 children, when compared to capsules, which were used by older children.
However, differences in absorption rates have not been described for the two formulations of ritonavir
(Anonymous. Product monograph Norvir®, Abbott, Chicago, IL, USA). The slightly higher Cmax in younger
children might have been due to less food intake with ingestion of medication in younger children. In
adults, intake of the combination of indinavir and ritonavir with food has shown to reduce the Cmax of
indinavir, when compared to ingestion without food, while no influence of food was observed on the
exposure to indinavir in the same regimen (R. Aarnoutse, J. Wasmuth, G. Fätkenheuer, K. Schneider, P.
Reiss, D. Burger, J. Rockstroh, XIV International AIDS Conference, abstr. TuPeB4570, 2002).
In conclusion, the investigated doses of indinavir with ritonavir resulted in higher than expected AUC0-24,
combined with a favorably increased Cmin of indinavir, resulting in values of Cmin > 0.1 mg/L in all child-
ren above 2 years old. While the short-term tolerability of study medication was generally good, data on
long-term safety and efficacy of this regimen in children are needed for a better evaluation. Also, phar-
macokinetics, safety, tolerability and efficacy in children below 2 years old need additional investigation.
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Abstract
This study evaluates the plasma pharmacokinetics of zidovudine in 6 HIV-1 infected children
(median age (range) 7.8 (2.5 – 13.4) years) who switched zidovudine from q8h to q12h. In these
children, geometric mean ratios of AUC0-24 and Cmax for zidovudine q12h vs. q8h were not signi-
ficantly different from 1.0, suggesting bioequivalence.
Introduction
Zidovudine was the first drug licensed for treatment of HIV-1 infection. It is recommended as part of
highly-active antiretroviral treatment (HAART) and for prophylaxis of perinatal transmission of HIV-11;2.
Current guidelines indicate a pediatric dose of 90-180 mg/m2 q6h or q8h. Meanwhile, zidovudine is
increasingly used q12h. However, with the exception of neonates and infants, there are no published
data on the pharmacokinetics of zidovudine q8h or q12h in children3-5. We here report the plasma phar-
macokinetics of zidovudine q8h and q12h in six HIV-1 infected children.
Methods
This was a retrospective pharmacokinetic study in HIV-1 infected children between 1 and 18 years old,
who were included in an ongoing study on the simplification of HAART conducted in our center (inclu-
sion August 2000 - January 2003). Briefly, children were offered the possibility of changing HAART from
q8h to q12h. Antiretroviral medication prior to switch consisted of 4 mg/kg q12h lamivudine combined
with zidovudine 120 mg/m2 q8h and indinavir 400-600 mg/m2 q8h or nelfinavir 30 mg/kg q8h. After
switch, children received lamivudine 4 mg/kg q12h combined with zidovudine 180 mg/m2 q12h and
either indinavir/ritonavir 500/125, or 400/125 mg/m2 q12h, or abacavir 8 mg/kg q12h. Written informed
consent was obtained from patients or caregivers prior to enrollment. Intensive pharmacokinetic sam-
pling of all antiretroviral drugs was performed at steady state, prior to and > 2 weeks after switch to the
q12h regimen. We here describe the pharmacokinetics of zidovudine.
Plasma concentrations of zidovudine were determined by validated HPLC assay with UV detection (lower
limit of quantification: 0.017 mg/L (accuracy 99-101%, intra- and interday coefficients of variation 1.5-
2.0% and 1.5-2.2%, respectively. Data were included from patients with both a q8h and q12h curve of at
least 5 evaluable time points available and absolute total daily zidovudine doses q12h and q8h differing
less than 25%. Pharmacokinetic samplings had to be less than six months apart.
Estimated area under the plasma concentration-time curve 0-24h (AUC0-24), peak level (Cmax), trough
level (Cmin), relative apparent oral clearance (Cl/F*m
2) and terminal plasma half-life (t1/2) of zidovudine
were calculated using non-compartmental methods6. To compare regimens, within-patient ratios of phar-
macokinetic parameters for zidovudine q12h versus q8h were calculated. From these ratios, geometric
means (GMRs) with 90% confidence intervals (CI) were obtained. A 90% CI of GMR containing 1.0 was
considered as reflecting similarity of both regimens.
Results
Initially, 17 children were enrolled, of whom 6 had evaluable data (7 children were excluded since time
between pharmacokinetic samplings exceeded 6 months, 4 children because of insufficient number of
evaluable time points in one or both pharmacokinetic curves). Thus, six patients (5 girls, 1 boy) of medi-
an age 7.8 years (range 2.5–13.4) were included. All children were taking a q8h regimen of zidovudine
with indinavir and lamivudine (lamivudine q12h) and switched to the q12h regimen of zidovudine, indi-
navir/ritonavir and lamivudine. The median number of samples per curve was 7 for q8h regimens and 7.5
for q12h regimens. GMRs of pharmacokinetic parameters of zidovudine q12h versus q8h did not show sig-
nificant differences between both regimens, but were characterized by a wide CI. Except for Cmax of the
q12h regimen, zidovudine levels were slightly higher than previously reported in adults (Table 1, Figure
1)7;8. Zidovudine q12h did not result in a higher Cmax than q8h. No significant correlation was found of
zidovudine AUC0-24, Cmax and Cl/F*m
2 with age, body weight or body surface area (p-values all > 0.05).
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Table 1 Pharmacokinetics of zidovudine q12h and q8h in HIV-1 infected children and historical data of zidovu-
dine in adults.
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However, zidovudine t1/2 inversely correlated with age for both the q12h and q8h regimen (r2 -0.78 and
–0.69, p values 0.019 and 0.042, respectively).
Discussion
This study presents the first pharmacokinetic data of zidovudine q12h compared to q8h in children above
the infant age. Pharmacokinetic parameters q12h compared to q8h did not reveal significant differences,
suggesting pharmacokinetic equivalence of both regimens. The slightly higher plasma levels in our study
versus adults could be due to the higher pediatric zidovudine dose per body weight: 360 mg/m2/day =
12.9 mg/kg/day in a child with 1 m2 body surface area weighing 28 kg, versus 600 mg/day = 8.6
mg/kg/day in an adult weighing 70 kg. Zidovudine q12h did not result, as expected with lower dose fre-
quency of the same daily dose, in a higher Cmax than q8h
7;8. Pharmacokinetic parameters were highly
variable, probably as a result of small sample size and should therefore be confirmed in a larger number
of patients. Zidovudine pharmacokinetic parameters were independent of age, body weight or body sur-
face area. This is in accordance with literature data, indicating that zidovudine Cl/F*m2 most strongly
increases during first weeks of life, reaching adult levels after 2 years, while all children in our study
were above this age5;9-11. In contrast, the significantly decrease of t1/2 of zidovudine with age would
suggest further maturation of its metabolism during childhood. Remarkably, higher elimination rate was
not reflected in lower AUC0-24 or Cmax and higher Cl/F*m
2 in older children, possibly indicating a
decrease in the volume of distribution of zidovudine in older children. While this finding should be con-
sidered cautiously because of the small number of patients in our study, an explanation mentioned earli-
er for premature infants could be a decreased zidovudine absorption or increased first-pass metabolism in
younger children, resulting in no net difference of AUC0-24, Cmax and Cl/F*m
2 between younger and
older children5.
Importantly, unlike other antiretroviral agents, nucleoside reverse transcriptase inhibitors require intra-
cellular phosphorylation for activation. Plasma concentrations of parent drugs are only weakly correlated
with triphosphate concentrations, possibly explaining the lack of a clear relationship between their plas-
ma pharmacokinetics and efficacy12. While not ideal, plasma pharmacokinetic sampling is often per-
formed as an alternative for the highly complex intracellular pharmacokinetic sampling of these drugs.
In conclusion, in six HIV-1 infected children, pharmacokinetics of zidovudine q12h were not significantly
Zidovudine twice compared to three times daily
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Figure 1 (A) AUC0-24 and (B) Cmax of zidovudine q12h (squares) vs. q8h (circles) in 6 children who switched 
zidovudine q8h to q12h.
different from q8h, suggesting bioequivalence. These findings need confirmation in studies of larger sam-
ple size, including intracellular pharmacokinetics. Finally, efficacy of both regimens in children should be
evaluated in a comparative study.
Acknowledgements
Technicians of the Department of Clinical Pharmacy, University Medical Center, Nijmegen, are kindly
acknowledged for processing and analysis of the plasma samples. Study nurses of the Department of
Pediatrics, Erasmus MC/Sophia, Rotterdam, are kindly acknowledged for blood drawings.
References
1. Anonymous. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
www.aidsinfo.nih.gov/guidelines/adult . Last visited November 25, 2003
2. Anonymous. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. www.aidsin-
fo.nih.gov/guidelines/pediatric . Last visited November 25, 2003
3. Mirochnick M, Capparelli E, Dankner W, Sperling RS, Van Dyke R, Spector SA. Zidovudine pharmacoki-
netics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother
1998; 42:808-12.
4. Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH et al. Pharmacokinetics of zidovu-
dine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin
Pharmacol 2001; 41:732-41.
5. Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD et al.
Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142:47-52.
6. Gibaldi M. Compartmental and noncompartmental pharmacokinetics. Biopharmaceutics and clinical
pharmacokinetics. Philadelphia, London: Lea & Febiger; 1991. p. 14-23.
7. Vanhove GF, Kastrissios H, Gries JM, Verotta D, Park K, Collier AC et al. Pharmacokinetics of
saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997;
41:2428-32.
8. Crémieux AC, Katlama C, Gillotin C, Demarles D, Yuen GJ, Raffi F. A comparison of the steady-state
pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet
and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Pharmacotherapy 2001; 21:424-30.
9. Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analy-
sis across studies. Clin Pharmacol Ther 1999; 66:16-24.
10. Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P et al. Population pharma-
cokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol
2003; 43:133-40.
11. King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the paediatric
population: a review. Clin Pharmacokinet 2002; 41:1115-33.
12. Stein DS, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.
Pharmacotherapy 2001; 21:11-34.
Chapter 4.1
90
Zidovudine twice compared to three times daily
91

Chapter 4.2
Plasma pharmacokinetics of once versus twice
daily lamivudine and abacavir- simplification of
combination treatment in HIV-1
infected children (Penta-13)
Manuscript in preparation
Alina S. Bergshoeff1,2
David M. Burger1,2
Corrien Verweij1,2
Laura Farrelly3
Jacquie Flynn4
Marthe LeProvost5
Sarah Walker3
Vas Novelli4
Hermione Lyall5
Di Gibb3
on behalf of the PENTA-13 Study Group
1 University Medical Centre Nijmegen, the Netherlands
2 Nijmegen University Center for Infectious Diseases (NUCI), the Netherlands
3 MRC Clinical Trials Unit, London, United Kingdom
4 Infectious Diseases Unit, ABC Family Clinic, Great Ormond Street Hospital for Sick Children,
London, United Kingdom
5 Infectious Diseases Unit, Family Clinic, St. Mary’s Hospital, London, United Kingdom
Chapter 4.2
94
Abstract
Background: Little is known on once daily use of nucleoside analogues in HIV+ children. This
study compared the plasma pharmacokinetics (PK) of q24h with twice daily (q12h) lamivudine
(3TC) (8 mg/kg q24h vs. 4 mg/kg q12h) and abacavir (ABC) (16 mg/kg q24h vs. 8 mg/kg q12h) 
in HIV+ children.
Methods: HIV+ children ≥ 2 - <13 years old receiving combination treatment containing 3TC
and/or ABC q12h were included in this one arm, open label cross-over study. Intensive plasma 
PK sampling was performed at steady state, after which children switched to taking their 3TC
and/or ABC q24hrly. PK sampling was repeated at steady state. Daily area under the curve 
(AUC0-24) and peak level (Cmax) of q24h and q12h regimens were compared by geometric mean
ratios (GMR) with 90% confidence intervals (CI).
Results: 24 children were enrolled, of whom 20 (median age (range) 5.6 (2.1-12.8) years) had
evaluable PK data of 3TC (N=19) and/or ABC (N=14). AUC0-24 and Cmax (GM (90% CI)) of 3TC
were 8.88 (7.67-10.28) mg/L*h and 1.11 (0.96-1.29) mg/L for q12h, and 9.80 (8.64-11.12) mg/L*h
and 2.09 (1.80-2.42) mg/L for q24h, respectively. Cmin of 3TC (median) was 0.067 and 0.050
mg/L, respectively, for q12h and q24h regimens. AUC0-24 and Cmax of ABC (GM (90% CI)) were
9.91 (8.26-11.89) mg/L*h and 2.14 (1.79-2.56) mg/L, for q12h, and 13.37 (11.80-15.16) mg/L*h
and 4.80 (4.04-5.71) mg/L for q24h, respectively. Cmin of ABC (median) was 0.025 and < 0.015
mg/L, respectively, for q12h and q24h regimens. GMRs of 3TC and ABC AUC0-24 and Cmax q24h 
vs. q12h significantly exceeded 1.0. GMRs were not significantly different between children aged
≥ 2-6 and >6- <13 years (p values all >0.08).
Conclusion: in HIV+ children, AUC0-24 and Cmax of both 3TC and ABC q24h were not inferior to
q12h regimens. In view of their relatively good tolerance and promising data on once daily use of
3TC and ABC in adults, these results suggest feasibility of once daily use of these agents in HIV+
children. Therapeutic equivalence should be further evaluated in a comparative clinical trial.
Introduction
Treatment of HIV-1 infection in children is often complicated by several factors. One challenge is the dif-
ficulty to obtain compliance to medication in children. Compliance is related to different factors, such 
as pill burden encountered in highly active antiretroviral (HAART) regimens, palatability of medication,
but also complexity of medication schedules, interfering with a child’s daily activities. Less moments of
medication intake per day offer more convenience and are likely to enhance compliance in HIV-1 infected
children. The nucleoside analogues lamivudine and abacavir are very common as part of HAART in child-
ren. While in adults, pharmacokinetics and efficacy of these drugs applied once daily (q24h) have shown
promising results, to the knowledge of the authors, no published results exist on their q24h use in HIV-1
infected children. Taking into account the advantages of q24h HAART, data on the q24h application of
these agents in HIV-1 infected children are of high importance.
The first aim of this study was to compare the plasma pharmacokinetics of q24h with q12h lamivudine
and abacavir in HIV-1 infected children ≥2 - <13 years old. Secondly, this study aimed to evaluate if age-
related differences in the pharmacokinetics of lamivudine and abacavir are present between younger 
(≥2 - 6 years of age) and older children (>6 - <13 years of age).
Once versus twice daily lamivudine and abacavir
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Materials and Methods
This was a single-sequence, two-period, cross-over, open label pharmacokinetic study conducted in two
centers. HIV-1 infected children between 2 and 13 years of age who used q12h lamivudine and/or abacavir
as part of their HAART regimen were eligible for inclusion. In a subpopulation of patients, also analysis
of intracellular levels of lamivudine and abacavir was performed, the results of which will be described
separately.
Inclusion criteria
In all children, HIV-1 infection had to be confirmed by the results of HIV-1 antibody testing. Children had
to be receiving HAART containing lamivudine and/or abacavir, be in a clinically stable condition for more
than 6 months and expected to stay on their current regimen for at least 3 further months. Patients were
considered clinically stable if HIV-1-RNA load was either below the lower limit of quantification (< 400
copies/ mL), or non-suppressed, but low (between 400 and 20,000 copies/mL). If non-suppressed, viral
load had to be stable prior to study entry (last two measurements of HIV-1 RNA load both < 1000 copies/
mL, or not more than 0.7 log different and measured not less than 3 months apart). Absolute CD4+ cell
count had to be stable or rising prior to study entry and not be expected to fall within the next 6 months.
For doses of lamivudine and abacavir, a difference of less than 25% between the q12h and q24h dose was
accepted. Children and/or parents had to be able and willing to give informed consent at screening.
Exclusion criteria
Children where excluded if they had intercurrent illness, or used concomitant therapy with the exception
of Pneumocystis Carinii pneumonia prophylaxis. Moreover, abnormal renal or liver function of grade 3 or
higher (NIH classification) was considered an exclusion criterium.
Medication
Study medication of the q12h regimen consisted of lamivudine 4 mg/kg q12h and/or abacavir 8 mg/kg
q12h and was crossed over to lamivudine 8 mg/kg q24h and/or abacavir 16 mg/kg q24h, i.e. maintaining
the same daily doses. Daily adult doses of both drugs were not exceeded. Lamivudine was prescribed in
tablets of 150 or 300 mg lamivudine, or oral liquid formulation containing 10 mg lamivudine per mL.
Abacavir was prescribed in tablets of 300 mg or oral liquid formulation containing 20 mg abacavir per
mL. Medication was obtained from the community pharmacy by the child’s parents or caretakers.
Pharmacokinetic sampling
From all children, serial blood samples to obtain pharmacokinetic profiles of lamivudine and/or zidovu-
dine of q12h and q24h regimens were taken on two occasions. First sampling was performed at steady
state, 4 weeks after enrollment. Subsequently, children crossed over from lamivudine and/or abacavir
q12h to q24h. Pharmacokinetic sampling was repeated at week 8. The procedure of pharmacokinetic sam-
pling was as follows: in the morning, children were admitted to the day care unit of their hospital.
Ingestion of medication was directly observed by the study nurse. Children were allowed to take medica-
tion with or without food. Blood samples of 2 mL were drawn at time points 0 (pre-dose), 1, 2, 3, 4, 6, 8
and 12 h post ingestion of medication for q12h regimens and at time points 0 (pre-dose), 1, 2, 3, 4, 6, 8
and 24 h for q24h regimens. Within 24 hours after collection, blood samples were centrifuged and plasma
was stored at –20 ºC. Plasma concentrations of lamivudine and abacavir were determined by a validated
high performance liquid chromatography assay with UV detection at a wavelength of 260 nm (unpub-
lished data). In brief, a sample volume of 500 µl was pretreated by solid phase extraction on a Waters
Oasis MAX® extraction cartridge (Waters Instruments Inc., Minneapolis, Minnesota, USA). Eluate was
evaporated under nitrogen at 37ºC, dissolved in 0.2 mL of a mixture of 95:5 water (HPLC Analyzed
Baker): acetonitrile (super gradient), and injected on a 150 x 4.6 mm Symmetry Shield RP18 3.5 µm ana-
lytical column with a 3.9 x 20 mm Symmetry Shield RP18 3.5 µm guard column (Waters Instruments Inc.,
Minneapolis, Minnesota, USA). Mobile phase consisted of acetonitrile/acetate buffer of pH 4.6. Elution
Chapter 4.2
96
was performed using a gradient. Lower limits of quantification were 0.050 mg/L for lamivudine and
0.015 mg/L for abacavir. Accuracy was 92-98% for lamivudine and 97-100% for abacavir. Within-day vari-
ability was 1.4-2.3% for lamivudine and 1.1-1.9% for abacavir. Between-day variability was 0.66-2.2% for
lamivudine and 0.16-2.3% for abacavir.
Pharmacokinetics of lamivudine and abacavir
Pharmacokinetic parameters of lamivudine and abacavir were calculated using non-compartmental 
methods using Microsoft Excel 2000®1. The peak level (Cmax) and trough level at the 12-h time point
(Cmin) were determined visually from the plasma pharmacokinetic curve. Area under the plasma concen-
tration-time curve 0-12h (AUC0-12) was calculated using the trapezoidal rule. To compare q12h with q24h
regimens, estimates of daily AUC (AUC0-24) were made (AUC0-24 = 2* AUC0-12). Relative apparent oral
clearance (Cl/kg*F) was calculated as dose (mg)/ AUC0-12* body weight (kg).
Statistics
Statistical calculations were performed using SPSS, Version 10.0 (SPSS, Illinois, USA). To enable the eva-
luation of bioequivalence between the q12h and q24h regimens, a number of 16 pharmacokinetic sets of
q12h and q24h results was anticipated for both lamivudine and abacavir. Sample size calculation was
based on an estimated intra-patient standard deviation of AUC of lamivudine in adults of 10%. In case 
of no difference in AUC0-24 between the q12h and q24h regimens, a number of 16 pharmacokinetic data
sets would result in an estimated 90% confidence interval (CI) of geometric mean ratio (GMR) of AUC0-24
within 0.95-1.05. Since it was assumed that a number of 8 children would be using both lamivudine 
and abacavir concomitantly (providing pharmacokinetic data for both drugs at once), a total number
of 32 – 8 = 24 children was scheduled for enrollment. To compare pharmacokinetic parameters between
younger and older children, enrolment was performed 1:1 in age-strata of ≥ 2 – 6 years and > 6 - < 13
years old. Geometric means of all pharmacokinetic parameters were calculated. For comparison of q12h
with q24h regimens, of each patient, ratios of AUC0-24 and Cmax and Cl/F*kg q24h versus q12h were 
calculated. GMR with 90% CI were calculated after log-transformation of within-patient ratios. A GMR
with 90% CI including 1.0 and falling entirely within 0.80-1.25 was considered as bioequivalence.
Data were compared with published historical controls on steady-state pharmacokinetics, as far as 
available. For lamivudine, historical controls were from adults using 150 mg q12h or 300 mg q24h
lamivudine2;3. Pharmacokinetic data of abacavir were compared with historical controls of adults using
300 mg q12h abacavir and children using 4 or 8 mg/kg abacavir4;5. Pharmacokinetic parameters and 
geometric mean ratios of pharmacokinetic parameters for q24h versus q12h regimens were compared
between children of ≥ 2 –6 years versus > 6 - < 13 years old using a t-test for independent samples on
log-transformed values. The Fisher’s Exact test was used to compare the number of cases of Cmin below
the lower limit of quantification in younger versus older children. A two-sided P-value < 0.05 was 
considered statistically significant.
Results
Twenty-four HIV-1 infected children underwent both occasions of pharmacokinetic sampling. Of these
children, 4 were excluded from data analysis: one child using lamivudine and abacavir, because her phar-
macokinetic profiles suggested that the morning dose had already been administered prior to start of
pharmacokinetic sampling on the first sampling day. Two children using lamivudine were excluded
because their q12h and q24h doses differed > 25%. Similarly, in one child using lamivudine and abacavir,
data of abacavir were excluded because q12h and q24h doses differed > 25%. One child using lamivudine
was excluded because an incorrect q12h lamivudine dose had inadvertently been administered. Baseline
patient characteristics of the remaining 20 included children overall and per group of children in whom
pharmacokinetics of lamivudine and abacavir were evaluated are given in Table 1.
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Table 1 Baseline patient characteristics overall and in patients using lamivudine or abacavir.
Overall Patients using 3TC Patients using ABC 
(N=20) (N=19) (N=14)
Age (years) 5.6 (2.1-12.8) 5.8 (2.1-12.8) 5.1 (2.1-12.8)
(median (range)) 
Gender 10/10 9/10 6/8
(N males/ N females)
Body weight (kg) 22.5 (12.5-60.5) 21.3 (12.5-60.5) 19.3 (13.7-60.5)
(median (range)
Other comedication (N) Amoxicillin/ Amoxicillin/ None
clavulanic acid (1) clavulanic acid (1)
** one patient using 3TC/ABC with non-evaluable ABC data.
3TC=lamivudine; ABC=abacavir; AZT=zidovudine; D4T= stavudine; EFV=efavirenz; LPV/r= lopinavir; NFV=nelfinavir;
NVP=nevirapine; TDF= tenofovir
Antiretroviral therapy
used (N of patients)
AZT, 3TC, ABC, NVP (6)
AZT, 3TC, NVP (2)
AZT, 3TC, ABC (2)**
TDF, EFV, 3TC, (1)
EFV, 3TC, ABC (5)
NVP, 3TC, D4T (1)
3TC, AZT, NFV (1) 
AZT, ABC, EFV (1)
3TC, ABC, LPV/r (1)
AZT, 3TC, ABC, NVP (6)
AZT, 3TC, NVP (2)
AZT, 3TC, ABC (2)
TDF, EFV, 3TC, (1)
EFV, 3TC, ABC (5)
NVP, 3TC, D4T (1)
3TC, AZT, NFV (1) 
3TC, ABC, LPV/r (1)
AZT, 3TC, ABC, NVP (6)
AZT, 3TC, ABC (1)
EFV, 3TC, ABC (5)
AZT, ABC, EFV (1)
3TC, ABC, LPV/r (1)
Table 2 Pharmacokinetic parameters of lamivudine dosed q12h and q24h; comparison between both regimens
and with regard to historical controls in adults and children.
Current study Historical controls in adults
AUC0-24 8.88 9.80 1.12 17.09 ± 6.46 16.64 ± 4.15
(mg/L*h) (7.67-10.28) (8.64-11.12) (1.03-1.21)
Cmax 1.11 2.09 1.90 2.08 ± 0.82 3.46 ± 0.85
(mg/L) (0.96-1.29) (1.80-2.42) (1.67-2.16)
Cmin (mg/L) 0.067 0.050 N.A. 0.33 ± 0.22 0.15 ± 0.087
(median (range) (<0.050-0.153) (<0.050-0.076)
Cl/F*kg (L/h*kg) 0.90 0.80 0.89 N.A. N.A.
(0.78-1.04) (0.70-0.92) (0.82-0.96)
N.A.: not applicable; GM: geometric mean; GMR: geometric mean ratio; SD: standard deviation
Pharmacokine-
tic parameter
4 mg/kg q12h
(GM (90% CI))
(N=19)
8 mg/kg q24h
(GM (90% CI))
(N=19)
Within-patient
comparison
lamivudine q24h
versus q12h
(GMR (90% CI))
(N=19)
Lamivudine 
150 mg q12h2
(N=12)
(mean ± SD)
Lamivudine 
300 mg q24h2
(N=12)
(mean ± SD)
Once versus twice daily lamivudine and abacavir
Table 3 Lamivudine pharmacokinetic parameters in children ≥2-6 years compared to >6-<13 years old
(Geometric means (GM) (90% confidence interval) and p-values for differences between GM.
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Table 4 Pharmacokinetic parameters of abacavir dosed q12h and q24h; comparison between both regimens
and with regard to historical controls in adults and children.
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Table 5 Abacavir pharmacokinetic parameters in children ≥ 2-6 years compared to >6-<13 years old: Geometric
means (90% confidence interval) and p-values for differences between GM.
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Lamivudine
In 19 children, pharmacokinetics of lamivudine were evaluated. Median doses (interquartile range) of
lamivudine were 4.1 (4.0-4.3) mg/kg q12h and 8.2 (7.8-8.4) mg/kg q24h. The only comedication repor-
ted during the study was amoxicillin/clavulanic acid used by one child on both occasions of pharmacoki-
netic sampling.
Pharmacokinetic parameters of lamivudine per dosing regimen and with regard to historical controls in
adults and children are given in Table 2. The q24h regimen resulted in a higher geometric mean AUC0-24,
and an approximately two times higher geometric mean Cmax for q24h than for lamivudine q12h; both
differences were statistically significant. GMR of AUC0-24 differed significantly from 1.0, which precluded
bioequivalence between the q24h and q12h regimen. Cl/F*kg was significantly lower for q24h versus
q12h lamivudine.
In the children who were ≥2 - 6 years old (N=10), plasma levels of lamivudine were lower than in the
children >6 – <13 years old (N=9) (Table 3). For the q24h regimen, these differences reached statistical
significance for Cmax, but neither for AUC0-24 nor Cl/F*kg. For the q12h regimen, these differences
reached significance for Cmax, while AUC0-24 showed borderline significance (p=0.05). Cl/F*kg was not
significantly different between younger and older children using lamivudine q12h (Table 3). Cmin was not
different between children ≥2 - 6 and >6 - <13 years old. For lamivudine q24h, Cmin was < 0.050 mg/L in
5 out of 10 younger children versus 3 out of 9 older children (p=0.650). Using lamivudine q12h, in 2 out
of 10 younger children versus 1 out of 9 older children, Cmin was < 0.050 mg/L (p=1.00). Meanwhile,
geometric mean ratios for the q24h regimen versus the q12h regimen of lamivudine were not significant-
ly different between younger and older children: GMRs in younger and older children were 1.17 and 1.06
for AUC0-24, 1.84 versus 1.96 for Cmax and 0.85 versus 0.93 for Cl/F*kg, respectively (p values all >0.30).
Abacavir
Pharmacokinetic data of abacavir were evaluable in 14 children. Median doses (interquartile range) of
q12h abacavir were 8.1 (7.8-8.5) mg/kg q12h and 16.4 (15.4-16.8) mg/kg q24h. Pharmacokinetic parame-
ters of abacavir are given in Table 4.
GMR of AUC0-24 slightly, but significantly exceeded 1.0, precluding bioequivalence between the q24h and
q12h regimen. Cmax of abacavir q24h was more than 2 times, and significantly higher than Cmax of aba-
cavir q12h. Similar to lamivudine, significantly higher AUC0-24 and Cmax for abacavir q24h were reflected
by a significantly decreased Cl/F*kg for this regimen.
AUC0-24, Cmax and Cl/F*kg in children ≥ 2 - 6 years old (N=9) were not significantly different of children
>6 - <13 years old (N=5) (p values > 0.12 and > 0.50 for q24h and q12h regimens, respectively).
However, Cmin of abacavir q24h tended to be lower in younger children, since all 9 children of the
younger age group had a Cmin of abacavir of < 0.015 mg/L, while this was the case in 2 out of the 5
older children (p=0.03). For the q12h regimen, this difference was not present: 1/9 younger children ver-
sus 1/5 older children had a Cmin < 0.015 mg/L (p=0.60).
Geometric mean ratios of AUC0-24, Cmax and Cl/F*kg for the q24h regimen versus the q12h regimen of
abacavir were not significantly different between younger and older children; GMRs in younger and older
children were 1.46 and 1.17 for AUC0-24, 2.61 versus 1.72 for Cmax and 0.67 versus 0.85 for Cl/F*kg (p val-
ues all >0.08).
Discussion
For both lamivudine and abacavir, GMR of AUC0-24 of q24h versus q12h regimens were significantly high-
er than 1.0. While, consequently, the q24h and q12h regimens were not bioequivalent, these data sug-
gest non-inferiority of the q24h regimens of lamivudine and abacavir with regard to the corresponding
q12h regimens. This finding was independent of age in children within the two evaluated age strata of 
≥ 2 – 6 years and >6 - <13 years. Meanwhile, for both the q12h and q24h regimen of lamivudine,
younger children tended to have lower plasma levels than older children.
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The q24h application of antiretroviral drugs confers a simplification of medication schedules and may
therefore be desirable for HIV-1 infected adults and children. Although attractive, the feasibility of many
q24h antiretroviral regimens remains yet to be explored, especially in children. Nucleoside analogues are
characterized by a relatively short plasma half-life, which would normally limit their options for q24h
application as plasma levels are bound to fall below their IC50 within one dosing interval. However, anti-
retroviral activity of nucleoside analogues is exerted only after intracellular phosphorylation. For both
lamivudine and abacavir, the active, tri-phosphorylated moieties have a longer in vivo intracellular half-
life than their non-phosphorylated forms in plasma, which supports the q24h use of these drugs6-8.
Currently, the quantification of intracellular levels of nucleoside analogues requires a more complicated
sample handling than is needed for the determination of plasma levels of these drugs. In addition, a larg-
er sample volume is needed, which may be difficult to obtain from certain patients, e.g. young children.
Several data in limited numbers of subjects exist, though, on the intracellular pharmacokinetics of
lamivudine and abacavir. For lamivudine, intracellular triphosphate concentrations, but not plasma levels
have been correlated with virologic outcome, the latter possibly due to the lack of a linear relationship
between plasma and intracellular triphosphate levels of lamivudine9;10. In healthy volunteers, regimens
of 150 mg q12h and 300 mg q24h lamivudine have been found equivalent, not only in terms of plasma
levels, but also intracellular triphosphate levels, which has been explained by the apparently saturable,
rate-limiting conversion from lamivudine diphosphate to the active triphosphate2;7;10. This mechanism
would result in intracellular accumulation of lamivudine diphosphate and the possibility of continued
formation of triphosphate after lamivudine has been eliminated from the plasma compartment10.
Efficacy of q24h lamivudine in HIV-1 infected adult patients has been evaluated in non-comparative stu-
dies, which showed favorable results11;12. In addition, two comparative (of which one ongoing) studies
in HIV-1 infected adults have shown no difference between the efficacy of the q24h versus q12h regi-
men13;14. In contrast to lamivudine, for abacavir, significant correlations (although mostly weak) were
found between abacavir plasma AUC, Cmax and Cmin and HIV-1 viral load decline in adult patients
4;15.
Moreover, after both a 150 mg and 600 mg abacavir dose, in HIV-1 infected adults, the triphosforylated
anabolite of abacavir (carbovir) has been shown to persist intracellularly for at least 24 hours at levels
above the in vitro inhibitory constant for antiretroviral activity of carbovir6;8. Apart from an in vitro
simulation, which suggested the feasibility of q24h dosing in adults, interim results of an ongoing 
comparative study of abacavir q24h and q12h in HIV-1 infected adults have shown no difference between
efficacy of the q24 versus q12h regimen13;16.
Altogether, these factors served as a rationale for evaluation of q24h plasma pharmacokinetics of lami-
vudine and abacavir compared to the regular, q12h dosing schemes of these drugs in HIV-1 infected child-
ren. This study primarily focused on the plasma pharmacokinetics, as plasma sampling and analysis can
be relatively easy performed in HIV-1 infected children, while data on intracellular levels in a subpopula-
tion of patients will be described elsewhere.
Apart from the promising results, which suggest non-inferiority of q24h versus q12h plasma pharmaco-
kinetics of lamivudine and abacavir, several other findings deserve special attention. For lamivudine, in
children within the evaluated age group, remarkably, lamivudine plasma levels were lower than seen in 
a comparative pharmacokinetic study of lamivudine q24h versus q12h in adults2. However, the data
showed similarity with other historical controls of lamivudine q12h in adults (data not shown)3;17. In
view of this discrepancy among historical steady-state pharmacokinetic data in adults using lamivudine,
it is difficult to determine the relevance of this finding2;3;17. Of interest, the currently recommended
dose of 4 mg/kg q12h lamivudine in children approximates twice the licensed adult dose of 150 mg q12h
(~2 mg/kg body weight) and was selected to compensate for the approximately 50% lower plasma levels
in children < 12 years old, than in adults using 150 mg q12h lamivudine3. However, the hypothesis that 
4 mg/kg q12h lamivudine would result in plasma levels in children below 12 years old similar to adults
using lamivudine 150 mg q12h has, to the knowledge of the authors, not been earlier confirmed in pub-
lished data.
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Amoxicillin/clavulanic acid was used by two different patients as concomitant medication. However,
amoxicillin is not expected to cause a pharmacokinetic interaction with lamivudine and did not cause
abnormal plasma levels of the drug during this study (data not shown).
Pharmacokinetics of lamivudine and abacavir may be different in younger and older children. Indeed, in
our study, a trend for lower plasma levels of lamivudine was found in children of ≥2 - 6 years old com-
pared to children of >6 - <13 years old. Lower levels of lamivudine have been reported in children below
12 years old, (as mentioned before, resulting in a higher recommended dose in children below the age 
of 12 years, than in adults), but no differences have been reported between children of ≥2 - 6 versus 
>6 - <13 years old3. Our data, however, suggest that such age-related differences may exist. An explana-
tion for these findings could be a higher volume of distribution in younger children. While according to
our data, children in the age group of ≥2 - 6 years old possibly need higher doses of lamivudine to reach
plasma levels similar to adults, intracellular levels of lamivudine in these younger children should be con-
sidered to enable a more proper evaluation of the clinical relevance of this finding.
The pharmacokinetics of abacavir were similar to steady-state data in adults and children using abacavir
q12h and AUC0-24, Cmax and Cl/F*kg were not significantly different between younger and older children.
Although this confirms earlier data suggesting the absence of age-related differences in the pharmacoki-
netics of abacavir q12h in children, in our data, a Cmin of abacavir below the lower limit of quantifica-
tion occurred at a higher rate in younger children using the q24h regimen than in older children18. Based
on the long half-life of carbovir in adults, this finding seems of little clinical relevance, but this should
yet be confirmed by intracellular pharmacokinetic data of these doses6;8.
It should be noted, that our study did not include children below 2 years of age, which may be a chal-
lenging patient population, e.g. due to fluctuating gastrointestinal absorption rate and slower renal
clearance, (the latter being the principal route of elimination for both lamivudine, and abacavir metabo-
lites) in very young children3;19;20. Therefore, the findings presented here cannot simply be extrapolated
to children < 2 years old and need additional investigation.
The slight increase (albeit significant) which was found between AUC0-24 of q24h and q12h regimens of
lamivudine, in addition to the approximately twice higher Cmax for the q24h regimen suggest dose-pro-
portionality of lamivudine pharmacokinetics within the investigated dose range. This is in accordance
with earlier findings in adults and children3;21;22. In the present study, pharmacokinetics of abacavir
tended to be more than dose-proportional for AUC0-24 and Cmax. In both adults and children, more that
dose-proportional pharmacokinetics have been reported with escalating single doses of abacavir, but not
in studies of steady-state pharmacokinetics4;5;15;18;23. The most likely explanation for more than dose-
proportional pharmacokinetics of abacavir seems saturation of first-pass metabolism of abacavir, since
the more than dose-proportional increases were observed for Cmax and AUC0-24, but not Cmin
4.
In conclusion, we suggest that in HIV-1 infected children ≥ 2- <13 years old, both lamivudine and aba-
cavir given in a q24h regimen are non-inferior to the corresponding q12h regimens. Based on these plas-
ma pharmacokinetic data, the q24h regimens of abacavir and lamivudine should be further explored in
comparative efficacy studies versus q12h regimens in HIV-1 infected children of ≥ 2 - <13 years old. The
tendency for lower plasma levels of lamivudine in children ≥ 2 – 6 years old compared to older children
pose the question, if higher doses of lamivudine should be applied in younger children. Data on the
intracellular pharmacokinetics of these regimens in HIV-1 infected children should be included in the
evaluation of the clinical relevance of this latter finding.
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Abstract
Objective:
To assess the antiviral efficacy, safety and pharmacokinetic parameters of the replacement of pro-
tease inhibitors (PIs) for the nucleoside reverse transcriptase inhibitor (NRTI) abacavir in pediatric
patients with HIV-1 RNA levels < 500 copies/ml.
Methods:
Pediatric patients receiving 2 NRTIS and at least one PI with HIV-1 RNA levels < 500 copies/ml
were offered a medication change to abacavir containing HAART in an open label study. Clinical
assessment included plasma RNA levels, lymphocyte counts, chemistry, hematology, and adverse
events monitoring. In addition, intensive plasma pharmacokinetic sampling of abacavir was per-
formed.
Results:
In intention to treat analysis considering switch as failure, 10/11 enrolled patients had HIV-1 RNA
levels < 50 copies/ml after 48 weeks of treatment. In one child, medication was changed because
of viral failure at week 12. This child was one of 4 enrolled patients who had received mono
and/or dual NRTI treatment prior to HAART. Plasma pharmacokinetic parameters of abacavir were
similar to historical controls in HIV-1 infected children.
The abacavir containing combination treatment was well tolerated and most side effects were
mild. A significant reduction in cholesterol plasma levels, but not triglycerides, was observed
after initiation of abacavir.
Conclusion:
Replacement of PIs by abacavir in HIV-1 infected children with HIV-1 RNA levels < 500 copies/ml
provides continued viral suppression and improvement of lipid abnormalities.
Introduction
After the introduction of highly-active antiretroviral therapy (HAART), an impressive reduction in the
rate of disease progression to AIDS and HIV-1 related deaths has been observed in adults, adolescents and
children1;2. Still, institution of optimal treatment poses a major challenge. Large interindividual differ-
ences in the pharmacokinetics of antiretroviral drugs, different viral dynamics in children, a developing
immature immune system and difficulties in adherence to the medication regimen complicate therapy3-5.
In 1997, we initiated a Dutch multicenter study on the treatment of HIV-1 infected children using pro-
tease inhibitor (PI) based HAART. Our study had favourable results in children using either indinavir or
nelfinavir with viral response rates of 69% HIV-1 RNA levels < 500 copies /ml and 50% < 50 copies/ml
after 96 weeks6. Despite these good results, the PI based medication regimens that were used have dis-
advantages. These include frequent dosing, sometimes during sleeping time and school hours, poor
palatability of medication, food restrictions during intake of medication, and a high pill burden.
We sought to simplify the medication regimen in children to ensure a maximal degree of adherence
without jeopardising antiretroviral efficacy. The nucleoside reverse transcriptase inhibitor (NRTI) abacavir
has been proposed as a new component of HAART allowing for such simplification of therapy7. It is
administered twice daily, has a low pill burden and has acceptable palatability. Abacavir as part of a triple
NRTI regimen may not be the first choice of medication in children, since it has reduced efficacy with
high viral loads, which are characteristic for pediatric HIV infection8;9. However, after the viral load has
been reduced by initial PI based treatment, abacavir can possibly replace the PI. In addition, changing a
PI based regimen to an abacavir based regimen may lower abnormal serum lipids and possibly decrease
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the risk for abnormal distribution of fat tissue associated with PI use10;11.
Studies in adults showed that in patients previously on well controlled PI based HAART, replacement 
of the PI for abacavir was generally well tolerated and effective, reducing the chance for therapy discon-
tinuation7;11;12. In addition a significant decrease was observed in cholesterol and triglyceride levels.
We here report on a study in children with undetectable HIV-1 RNA levels while on a PI based regimen,
in whom the PI was replaced for abacavir.
Materials and methods
Patients
This was an open label study, in which HIV-1 infected children aged between 1 and 18 years using HAART
containing the PIs indinavir or nelfinavir and 2 NRTIs with viral load < 500 HIV-1 RNA copies at least 4
weeks before baseline could be enrolled. Prior treatment with NRTI before HAART was allowed. The study
protocol was approved by the center’s medical ethical committee. Written and informed consent was
obtained from patients and/or parents (if required). Physical examinations and laboratory measurements
were performed within 4 weeks before start of the abacavir containing medication regimen (baseline)
and after 4, 8, 12, 24, 36 and 48 weeks of treatment. Plasma HIV-1 RNA levels were measured by an in
vitro nucleic acid amplification test (Amplicor 1.5 HIV-1 Monitor test (Roche Diagnostic Systems,
Branchburg, US)) with a lower limit of quantification of 50 copies/ml. On baseline, week 12, 24, 36 and
48, lymphocyte subsets were analyzed with the FACSCount System (Bencton Dickinson
Immunocytometry Systems, San Jose, CA, USA).
Medication and pharmacokinetics
Medication was prescribed in the following doses: abacavir 8 mg/kg q12h (max 300 mg q12h), zidovu-
dine: 180 mg/m2 q12h (max 300 mg q12h), lamivudine 4 mg/kg q12h (max 150 mg q12h), didanosine
120 mg/m2 q12h (max 200 mg q12h) and stavudine 1 mg/kg q12h (if body weight <60 kg, not exceeding
30 mg q12h; if bodyweight > 60 kg, not exceeding 40 mg q12h). No food restrictions were given, except
for didanosine. Abacavir was administered as oral solution containing 20 mg/ml abacavir, tablets of 
300 mg or customised pharmacy prepared capsules. The dose of 8 mg per kg could deviate if the maxi-
mum dosage was attained or if necessary to enable the use of a whole tablet formulation (patient or
pharmacy request).
All patients were admitted to the hospital to determine steady state 12h pharmacokinetics of abacavir.
Blood samples were obtained 0, 30, 60, 90, 120, 150, 180, 240, 300, 360, 420 and 480 minutes after
ingestion of the medication. Plasma was separated by centrifugation (10 min at 3000 x g) and samples
were stored at -20 °C until analysis. Abacavir concentrations were determined in plasma by validated
method of HPLC (unpublished data). The lower limit of quantification was 0.015 mg/L with accuracy of
97-100%. Within-day and between-day variability was 1.1-1.9% and 0.16-2.3%, respectively.
Pharmacokinetic parameters were calculated in Microsoft Excel© 97 using non-compartmental methods13.
The abacavir peak plasma level (Cmax), the trough level at the 12-h time point (Cmin) and the time to
peak plasma concentration (Tmax) were determined visually from the plasma concentration-time curve.
Area under the plasma concentration-time curve 0-12h (AUC0-12) was calculated using the trapezoidal
rule. Apparent oral clearance (Cl/F) of abacavir was calculated as dose (mg)/AUC0-12. Relative apparent
oral clearance (Cl/F*kg) was calculated as dose (mg)/AUC0-12 * body weight (kg).
Adverse events
During the whole study period, adverse events were scored. They were defined as any clinical sign or
symptom, or meaningful laboratory test abnormality, possibly or probably related to the study medica-
tion, excluding HIV-related disorders. Severity, relation to medication and hospitalization were scored.
When possible, grading of severity of adverse events was performed conform to the NIH division of AIDS
toxicity table for grading severity of pediatric adverse experiences. During visits, patients and their par-
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ents or caretakers were asked to report on the patient’s well-being, activity and appetite. Blood samples
for serum triglycerides and total cholesterol were obtained at baseline, when using PI based HAART and
week 4 after therapy change. Hereafter, the patients’ lipid levels were analysed once every 6 months
according to the center’s treatment protocol. For analysis of late term effects of abacavir on cholesterol
and triglycerides, the last sample obtained after a minimal duration of abacavir therapy of 1 year was
used. Samples for cholesterol and triglyceride levels and were taken after a fasting period of at least
three hours.
Statistics
For statistical analysis of the data, SPSS© version 10.0 (SPSS, IL, U.S.) and Microsoft Excel© 97 software
were used. All statistical analyses were based on non-parametric tests. Comparison of paired data from
patients at different times of follow-up was performed with the Wilcoxon signed rank test. Viral response
was defined as the percentage of patients with HIV-1 RNA levels below 500 or 50 copies/ml. For analysis
of efficacy, intention to treat (ITT) analysis was used. ITT analysis was applied in two different ways: all
exposed patients included (regardless of therapy switch) or as switch equaling failure (in which change
of medication was considered as viral failure). Because absolute CD4+ T-cell and CD8+ T-cell counts are
age-dependent, relative CD4+ and CD8+ T-cell counts were calculated. Hereto, at the different time-
points, age-specific reference values were calculated by dividing the patient’s individual value by the
median age-related reference value14. The Friedman test was used for differences in CD4+ and CD8+ per-
centages of normal measurements in time. All p-values are two tailed and p-values below 0.05 were con-
sidered statistically significant.
Results
Patient characteristics
A total of 11 children were included in the study between November 2000 and January 2003. The base-
line characteristics of the 11 enrolled patients are shown in Table 1. Although some children had experi-
enced progressive disease and significant immunosuppression in the past, none of the patients showed
signs or symptoms of AIDS-defining illness at baseline. Five children had been pre-treated with indinavir
containing HAART, 5 had received both indinavir and nelfinavir and one child was pre-treated with nelfi-
navir alone. Four children had received monotherapy with zidovudine prior to the start of HAART. One
patient had received subsequently monotherapy or dual therapy with zidovudine, stavudine and lamivu-
dine prior to the start of HAART. The median duration on HAART was 4.5 (range 1.9-4.75) years. At base-
line, all 11 patients had HIV-1 RNA levels below 500 copies/ml and 10 of the 11 children had HIV-1 RNA
levels < 50 copies/ml.
Pharmacokinetics of abacavir
In all 11 children included in the study, intensive plasma pharmacokinetic analysis was performed for aba-
cavir (Figure 1). The median dose of abacavir was 7.9 mg/kg (range: 5.1-9.8). Pharmacokinetic parameters
are listed in Table 2. Pharmacokinetic parameters were in accordance with historical controls of children
using abacavir15.
Clinical observations
No changes were observed in the patient’s overall well being, activity and appetite as reported by the
children and the caregivers. None of the patients showed disease progression. No AIDS defining signs or
symptoms were observed. All children were still on study after 48 weeks of treatment.
HIV-1 virological and immunological response
In ITT analysis of all exposed patients included, at 48 weeks after the switch to abacavir, all 11 children
had HIV-1 RNA levels below 500 and 50 copies/ml. When using the switch equals failure analysis, 10 of
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the 11 children (91%) had successful treatment outcome at 48 weeks.
In one child, HIV-1 RNA levels increased from < 50 copies/ml at baseline to 236 copies/ml at week 8 and
554 at week 12. On patient request, medication was changed to lopinavir/r and efavirenz at week 12,
which resulted in a viral load decrease to below 50 HIV-1 RNA copies/ml at week 24. This patient had
received extensive monotherapy with zidovudine, stavudine and lamivudine before initiation of HAART.
The 3 other patients who had received mono NRTI treatment prior to HAART responded well to the aba-
cavir containing regimen with viral loads below 50 copies/ml 48 weeks after initiation of abacavir con-
taining treatment.
In another child, which was enrolled into the study with a viral load above 50, but below 500 copies/ml,
viral load was suppressed to below 50 copies/ml at week 4 after therapy switch to abacavir containing
HAART.
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Table 1 Baseline patient characteristics.
Number of patients 11
Age in years (median (range)) 8.9 (3.1-17.8)
Route of infection (number of cases)
Vertical 8
Blood products 1
Unknown 2
Clinical stage (CDC-classification) N2: 1
A2: 3
B2: 3
B3: 1
C2: 1
C3: 2
Prior treatment with mono NRTI (number of cases):
None 7
Monotherapy AZT 3
Monotherapy AZT, d4T, 3TC 1
Prior HAART
IDV/AZT/3TC/(RTV) 5
IDV/AZT/3TC/(RTV), AZT/3TC/NFV 4
NFV/d4T/ddI 1
IDV/AZT/3TC, NFV/d4T/ddI 1
HIV-1 RNA levels at baseline
HIV-1 RNA < 500 copies/ml 11
HIV-1 RNA < 50 copies/ml 10
CD4+ T-cells Median (IQR)
Absolute counts (106 cells/ml) 880 (530-1656)
% of age specific reference value 88 (66-165)
CD8+ T-cells Median (IQR)
Absolute counts (106 cells/ml) 1070 (810-1656)
% of age specific reference value 165 (158-208)
Abbreviations : NRTI : nucleoside reverse transcriptase inhibitor; 3TC: lamivudine ; AZT: zidovudine;
d4T: stavudine; ddI: didanosine; IDV: indinavir; NFV: nelfinavir; RTV: ritonavir.
Median CD4+ and CD8+ T-cell counts as percentage of normal fluctuated throughout the study period
(Table 1; Figure 2). At baseline, median CD4+ percentage of age specific reference values was 88
(interquartile range (IQR): 66-165) At week 48, median CD4+ percentage of age specific reference values
was 79 (IQR: 56-136). Changes in the CD4+ and CD8+ T-cell counts as percentage of age specific reference
values in time were not statistically significant (p-value for CD4+ percentages = 0.243 and p-value for
CD8+ percentages = 0.544).
Adverse events
Abacavir containing combination treatment was well tolerated by all children. The adverse events were
mild and all transient in nature. None of the patients changed medication due to adverse events.
Therapy related side effects included diarrhoea (2 cases), abdominal pain (2 cases), abdominal and flank
pain (1 case), malaise (1 case), fever (1 case), eczema/dry skin (1 case) and a skin rash (1 case). This rash
was transient and was reported upon the study visit at the time it had already resolved. Medication was
not discontinued. In one child, thrombocytes decreased to 24,000 109/l (NIH toxicity grade 4), but
restored on a subsequent measurement. The cause for this transient thrombocytopenia remained
unknown. One child had a transient grade 3 elevation of serum amylase. No other grade 3 or 4 events
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Table 2 Steady-state pharmacokinetic parameters of 11 children using abacavir in combination with 2 NRTI.
AUC0-12 (mg/L*h) 9.3 (7.1-11.5) 9.8 (47)
Cmax (mg/L) 5.0 (4.1-6.7) 3.71 (37)
Tmax (h) (median) 0.58 (0.50-0.88) N.A.
Cmin (mg/L) 0.04 (0.04-0.07) N.A.
Cl/F (L/h) 21.4 (18.0-29.4) 19 (62)
Cl/F*kg (L/h*kg) 0.85 (0.67-1.12) N.A.
t1/2 (h) 2.3 (2.1-3.6) 1.28 (33)
N.A. not available
Pharmacokinetic parameter
(median (interquartile range))
Current study (N=11) Historical data of abacavir in
children (mean (coefficient of 
variation)) (N=45)15
Table 3 Virological response in 11 children who switched PI based HAART to abacavir in combination with 2
NRTI. Intention to treat analysis on all exposed patients and using switch equals failure.
0 11/11 (100%) 10/11 (91%) 11/11 (100%) 10/11 (91%)
4 11/11 (100%) 11/11 (100%) 11/11 (100%) 11/11 (100%)
8 11/11 (100%) 10/11 (91%) 11/11 (100%) 10/11 (91%)
12 10/11 (91%) 10/11 (91%) 10/11 (91%) 10/11 (91%)
24 11/11 (100%) 11/11 (100%) 10/11 (91%) 10/11 (91%)
36 11/11 (100%) 11/11 (100%) 10/11 (91%) 10/11 (91%)
48 11/11 (100%) 11/11 (100%) 10/11 (91%) 10/11 (91%)
Weeks on 
treatment
All exposed
patients.
HIV-1 RNA 
< 500 copies/ml 
(% of total)
All exposed
patients.
HIV-1 RNA 
< 50 copies/ml 
(% of total)
Switch equals 
failure: HIV-1 RNA 
< 500 copies/ml 
(% of total)
Switch equals 
failure: HIV-1 RNA 
< 50 copies/ml 
(% of total)
were documented. Grade 1 and 2 laboratory adverse events included anaemia (2 cases), low erythrocyte
count (8 cases), raised potassium level (2 cases), raised amylase levels (4 cases) raised calcium levels (1
case) and abnormal liver function: ALT raised (2 cases), AST raised (3 cases) and γ-GT raised (7 cases).
Four children had increased levels of LDH. Creatinine was increased in one child (48 µmol/L) and urea in
two children (7.0 and 7.5 µmol/L, respectively).
Of nine children, plasma cholesterol levels could be analysed in follow up. Two children were excluded
from the analysis. One child was excluded since insufficient amounts of blood could be obtained. Also,
the patient who had changed medication to a PI based regimen was excluded from this analysis. The
median time between start of abacavir and the last obtained lipid plasma level was 60 (IQR: 49-106)
weeks. Median total cholesterol plasma levels decreased from 5.2 mmol/l (IQR: 3.7-5.45) to 4.1 (IQR: 3.3-
4.95) at week 4 and 3.8 (3.15-4.5) in the last sample, after a follow-up of at least 48 weeks (p-value of
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Figure 1 Individual pharmacokinetic profiles of abacavir in 11 children.
Figure 2 CD4+ and CD8+ T-cells (median (interquartile range)) as percentage of age-specific reference values.
baseline vs. 48 weeks follow-up was 0.011). Median (IQR) plasma triglycerides decreased from 0.88
mmol/l (0.74-1.28) to 0.66 (0.43-1.08) at week 4, but increased again to 0.74 (0.55-1.11) in the last sam-
ple, after a follow-up of at least 48 weeks (p-value of baseline vs. week 48 was 0.138). One child was sus-
pected for lipoatrophy on baseline, which did not change based on visual inspection. No other cases of
lipodystrophy of lipoatrophy were reported while on abacavir.
Discussion
Children living with HIV/AIDS face the challenge of life-long complex antiretroviral therapy regimens.
Watson et al. showed in children with HIV-1 that non-adherence is common and might be the major
impediment to successful treatment5. Simplification of antiviral therapy in HIV-1 infected children with
viral suppression on PI based HAART may increase adherence or prevent possible future non-adherence.
In our study population of 11 HIV-1 infected children, the abacavir based regimen had potent antiviral
activity. In ITT of all exposed patients included, after one year of treatment 100% of the children had a
sustained viral response. When using the switch equals failure ITT analysis, this percentage was 91%.
In one child, HIV-1 RNA levels could be fully suppressed to below 50 copies/ml after start of the abacavir
based regimen. In one child, the regimen failed. This was the patient who had received extensive therapy
with mono NRTIs prior to HAART became available. Viral resistance tests of this child during mono NRTI
treatment were not available and could not be retrospectively performed since no samples were available.
In later samples of this patient, after initiation of HAART, viral resistance tests were not feasible since
HIV-1 RNA was no longer detectable. In adult patients also, suboptimal treatment in the past resulted in
therapy failure of abacavir based regimens11;12. Our observations and data observed in adults show that
an abacavir based regimen is potent in HIV-1 infected children with viral load suppression. The finding
that 3 out of 4 children responded well to the abacavir containing regimen despite pre-treatment with
mono NRTI therapy prior to HAART is encouraging. Nevertheless, this regimen should be applied with
caution in patients who have received prior suboptimal NRTI treatment and in whom no data on earlier
acquired viral resistance are available.
The regimen was well tolerated and no serious side effects were seen, especially hypersensitivity syn-
drome was not observed. Interestingly plasma cholesterol decreased sharply immediately after the medi-
cation change. This indicates that the PI used at baseline had a direct effect on lipid metabolism that
was quickly and with sustained effect reversed after its removal. Similar observations have been made in
adults in whom medication was changed from a PI based regimen to abacavir7;11;12. For triglycerids, in
our study, no such a decrease at 48 weeks was observed, despite an initial decrease after change of
medication. An explanation for this observation could be the small sample size of this study.
The plasma exposure to abacavir in our group was somewhat higher than the exposure reported in adults
but data were in accordance with previously reported pediatric data15-17. Most children used zidovudine
as part of their abacavir combination treatment. In adults, the co-administration of zidovudine with aba-
cavir produced a small and inconsistent effect on the pharmacokinetic parameters of abacavir16. While
this phenomenon is of unclear significance, it may have increased the interindividual variability in our
pharmacokinetic data.
Clearly, our study was performed in a selected population. All children had viral load levels below 500
copies/ml, which suggests that adherence was good. In this population, our study showed that a diffi-
cult to use PI based regimen can be changed to the more easy to use abacavir based regimen. Whether
viral load suppression of this regimen is similar to a PI based regimen needs to be further investigated in
a larger scale, comparative study.
In conclusion, replacement of PI by abacavir in a HAART regimen in HIV-1 infected children with sup-
pressed viral load provides continued viral suppression and improvement of lipid abnormalities. The regi-
men should be applied with caution in patients who have been extensively pretreated with mono NRTIs,
in whom resistance to NRTI is likely to be present.
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Abstract
Introduction:
Adherence to highly active antiretroviral therapy (HAART) is required to obtain an optimal long-
term virological response rate of HIV-1 infected children. Plasma concentrations of protease
inhibitors (PIs) outside the limits of the reference values indicate non-adherence to antiretroviral
therapy in adults. We studied during a two-year follow-up period routinely taken plasma protease
inhibitor concentrations to assess adherence to antiretroviral therapy in HIV-1 infected children.
Methods:
In 40 children (age: 3 months to 18 years) blood samples were taken at regular outpatient visits
every 12 weeks after the start of HAART and analyzed for plasma concentrations of indinavir or
nelfinavir by HPLC and for plasma HIV-1 RNA load. The percentage of samples fulfilling the crite-
ria for adherence was assessed for each child using three methods. For each sample a concentra-
tion ratio was calculated by dividing the concentration in that sample by the time adjusted
population value. According to method 1 concentration ratios below or above concentration 
ratio limits (CORALs) of population data obtained in adults, were highly indicative of non-adher-
ence. Since many children have high PI levels method 2 evaluated plasma samples of PIs using
only the lower CORAL. According to method 3 only children with plasma samples below the limit
of quantification (0.04 mg/L) were considered non-compliant. Differences in adherence rate
between virological responders and virological non-responders and between adherence rates and
the two protease inhibitors were analysed. The cumulative incidence of HIV-1 RNA levels >500
(copies/ml) in children was calculated.
Results:
Thirty-one children started treatment with indinavir and nine children with nelfinavir. The medi-
an adherence rates (interquartile range (IQR)) for indinavir as determined by methods 1, 2, and 3
were 54 (25-69)%, 67 (50-92)% and 80 (63-100)% respectively. For nelfinavir median (IQR) adhe-
rence rates of 60 (39-75)%, 100 (67-100)% and 100 (100-100)% were observed. Adherence rates
calculated with method 2 were significantly higher in virological responders (p=0.04). Adherence
rates calculated with methods 2 and 3 were significantly lower in children using indinavir com-
pared with those using nelfinavir (p=0.02 and p=0.02, respectively).
Conclusion:
Calculation of adherence rates using the lower limit of CORALs of indinavir or nelfinavir in child-
ren (PI plasma levels below the lower CORAL are highly indicative of non-adherence) may be a
useful measurement for the assessment of non-adherence to antiretroviral therapy in children.
Introduction
The institution of highly active antiretroviral therapy (HAART) in HIV-1 infected adults and children has
led to increasingly complex drug regimens. Adherence is required to obtain optimal suppression of the
virus, which is necessary for an optimal long-term virological response1-3. Poor adherence is associated
with several factors including: age (with adolescents being less compliant), the number of medications,
the number of doses of the medication, the extent to which the regimen interferes with the patient’s
life, the occurrence of side-effects in asymptomatic patients and longer duration of the disease4-10. All
factors that are associated with poor adherence are also present in HIV infected children. Therefore opti-
malization of the use of HAART in children poses an enormous challenge for physicians involved in the
treatment of children with HIV/AIDS.
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Overall adherence rates in adults are 75% versus only 58% in children11-14. The high percentage of children
who do not adhere to antiretroviral therapy and the subsequent risk for virological failure and long-term
clinical failure underscores the importance of the development of methods to predict poor adherence.
This may subsequently contribute to early intervention and optimization of the antiretroviral regimen.
The analysis of the level of adherence is complicated by the limitations of the current methods. Self-
reported measures, electronic monitoring systems (Medication Event Monitoring System (MEMS)), pill
counts, blood concentrations of protease inhibitors and refill history have been used11-16. However, all of
them have their limitations. Recently Hugen et al.17 reported that plasma concentrations of protease
inhibitors in adults outside the limits of a reference population strongly suggest non-adherence. This
method is objective, easy to perform and can be an attractive way to assess non-adherence in combina-
tion with other objective measures. This method has not yet been applied in children and is potentially
complicated by the large interindividual differences in the pharmacokinetics of protease inhibitors in
children18,19. We report the results of a study to assess adherence to antiretroviral therapy in HIV-1
infected children by means of therapeutic drug monitoring of nelfinavir and indinavir and the associa-
tion between plasma concentrations and the virologic response rate.
Methods
Inclusion and exclusion criteria
Children between the ages of 3 months and 18 years were eligible for enrollment in five participating
centers between April 1997 and May 2000. HIV-1 infected children with an HIV-1 viral load of more than
5000 copies/ml and/or a CD4+ cell count below the age-specific reference values were included20.
Methods
The study was approved by the medical ethical committees of the participating centers. Written
informed consent was obtained from parents or legal guardians. Blood samples were taken after a median
(interquartile range (IQR)) time of 3.8 hours after the ingestion of the protease inhibitor, at regular out-
patient visits every 12 weeks after the start of HAART and stored at -20 ºC3-5. Time of blood sampling
and time of the last administration of the protease inhibitor was recorded in the case record form. The
concentrations of nelfinavir and indinavir plasma samples were analyzed by high performance liquid
chromatography21,22. Children were excluded when less than three samples were available. Plasma HIV-1
RNA quantitation was analyzed by a polymerase chain reaction assay (Roche Amplicor HIV-1 monitor test
version 1.5) at the same timepoints at which plasma drug concentrations were analyzed.
Medication and pharmacokinetics
Medication was administered in the following doses: indinavir 400 mg/m2 q8h or nelfinavir 30 mg/kg q8h,
zidovudine 120 mg/m2 q8h, lamivudine 4 mg/kg q12h. A day to day medication scheme including the
times with food restrictions was given.
At week 4, patients were admitted to the day-care unit to determine the steady state pharmacokinetics
of indinavir or nelfinavir. When a dosage adjustment of indinavir or nelfinavir was necessary to normalize
the area under the curve-concentration (AUC) curve to adult values (indinavir: 20 mg/L*hr, range 10-30
mg/L*hr, nelfinavir: 13-20 mg/L*hr), this procedure was repeated. For each child, potential drug interac-
tions were carefully evaluated.
Statistical Analyses
The percentage of samples fulfilling the criteria for non-adherence to antiretroviral therapy was assessed
for each child by three methods. Plasma concentrations of protease inhibitors in children were plotted in
a concentration-time curve, which was derived from steady state population pharmacokinetics in adults.
For each sample a concentration ratio was calculated by dividing the concentration in that sample by
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the time adjusted population value. According to method 1 concentration ratios below or above concen-
tration ratio limits (CORALs), consisting of the 5th and 95th percentile of population data obtained in
adults, were highly indicative of non-adherence. For indinavir 800 mg q8h, CORALs were <0.23 and >3.3.
For nelfinavir 750 mg q8h and 1250 mg q12h, CORALs were <0.36 and 2.117. Because many children have
high PI concentrations, method 2 evaluated plasma samples of PIs in which only the lower CORAL was
used. Method 3 was based on a more traditional approach in which only children with plasma samples
below the limit of quantification (0.04 mg/L) were considered non-adherent. Percentages were calcula-
ted by dividing the number of plasma concentrations within the limits defined by the 3 methods by the
number of visits. Virologic responders were defined as children who had an HIV-1 RNA value below the
limit of detection of 500 copies/ml at week 12 and during follow-up.
SPSS 9.0 (SPSS, Chicago, IL) was used for statistical analysis. Differences in the adherence rates between
virologic responders and virologic non-responders and between adherence rates and the two protease
inhibitors were analysed using the Mann Whitney U test (p-values are 2-tailed). The cumulative incidence
of HIV-1 RNA levels >500 (copies/ml) after week 12 (before week 12, HIV-1 RNA loads of children with
high baseline viral loads may be still decreasing) in children was calculated by means of Kaplan-Meier
analysis. The influence of an adherence rate <75% and ≥75% was determined with the logrank test. The
percentage of 75% was chosen, because Watson et al.12. observed a higher virologic failure rate in child-
ren who were non-adherent (defined as <75% of antiretroviral therapy prescriptions filled).
Definition of adherence
Patients were either 0% or 100% adherent at each assessment according to the methods that were used.
Overall adherence rates are given as the percent of the assessments for which the patient was 100%
adherent.
Results
Patient characteristics
Forty children with a median (range) age of 5.4 years (0.28-16.3) and a median (range) baseline plasma
HIV-1 RNA of 136,385 (2,680-2,480,000) were included. Thirty-one children started treatment with indi-
navir and nine children with nelfinavir.
The median number of samples per patient (range) was 6 (3-11) in the indinavir group and 4 (3-9) in the
nelfinavir group. Twenty-two children were classified as virologic responders and 18 as non-responders.
Adherence rates
Methods 1 (concentration ratios below or above CORALs), 2 (below lower CORAL) and 3 (below limit of
quantification) resulted in median adherence rates (IQR) for indinavir of 54 (25-69)%, 67 (50-92)% and
80 (63-100)% respectively. The median (IQR) adherence rates for nelfinavir were 60 (39-75)%, 100 (67-
100)% and 100 (100-100)%.
Relation between adherence and virologic response
In Figure 1A the adherence rates calculated by the three methods in virologic responders and non-respon-
ders are depicted. No difference between virologic responders and non-responders in adherence rate was
observed when analyzed with method 3 (p=0.6). However, adherence rates calculated with method 1
showed a trend to a higher adherence rate in virologic responders (p=0.07) and adherence rates calcula-
ted with method 2 were significantly higher in virologic responders. In virologic responders a median
(IQR) adherence rate of 85 (55-100)% was observed with method 2, whereas the median (IQR) adherence
rate in non-responders was 67 (25-75)% (p=0.04).
Figure 2 shows the cumulative incidences of patients with an HIV-1 RNA load > 500 (copies/ml) in child-
ren with an adherence rate of <75% and ≥75% as calculated with methods 1, 2 and 3. Children with a
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Figure 1A Compliance rates calculated with the three different methods in virological responders and 
non-responders. Error bars represent the interquartile ranges.
Figure 1B Compliance rates calculated with the three different methods in children using indinavir and in 
children using nelfinavir. Error bars represent the interquartile ranges.
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Figure 2 The cumulative incidence of patients with an HIV-1 RNA load > 500 (copies/ml) in children with a 
compliance rate <75% (filled line) and ≥75% (dotted line) as calculated with method 1 (Figure 2A),
method 2 (Figure 2B) and method 3 (Figure 2C).
Figure 2A
Figure 2B
Figure 2C
adherence rate of <75% more frequently (method 1, 2 and 3: p=0.06, p=0.01 and p=0.2 respectively)
had an HIV-1 RNA load >500 (copies/ml).
Adherence rate and influencing factors
Figure 1B presents the adherence rates calculated by the three methods in children using indinavir and
in those using nelfinavir. Adherence rates calculated with methods 2 and 3 were significantly lower in
children using indinavir than in those using nelfinavir (p=0.02 and p=0.02, respectively).
Age, ethnicity, prior treatment with antiretroviral medication and CDC classification stage were not
related with adherence rates.
Discussion
We studied the value of the measurement of the routinely determined plasma concentrations of indi-
navir and nelfinavir. The percentage of samples fulfilling the criteria for adherence was assessed for each
child using three different methods. For each sample a concentration ratio was calculated by dividing
the concentration in that sample by the time adjusted population value. According to method 1 concen-
tration ratios below or above concentration ratio limits (CORALs) were defined as non-compliant.
Because many children have high PI levels method 2 evaluated plasma samples of PIs using only the
lower CORAL. According to method 3 only children with plasma samples below the limit of quantification
were considered non-compliant.
The adherence rates calculated by the 3 methods were highly variable. When method 1 was used 22 of 31
(71%) and 7 of 9 (78%) of the children using indinavir and nelfinavir were indicated as non-compliant,
respectively. However, when method 2 was applied the numbers of non-adherent children were reduced
to 16 of 31 (52%) and 3 of 9 (33%). This reduction in the non-adherence rate may be explained by the
deletion of one limit and by the higher peak concentrations of protease inhibitors that are observed in
children18,19. Compliant children with higher plasma concentrations of the protease inhibitor due to
pharmacokinetic differences between children and adults are considered to be non-compliant in method
1 whereas according to method 2 these children would be considered compliant. Because administering
the medication too late can also cause higher plasma concentrations, in method 2 imperfect adherence
(administration of the drugs, but not in time) is considered as good adherence. Therefore this may result
in an underestimation of non-adherence. Method 3 also underestimates non-adherence, but a concentra-
tion below the limit of quantification of the protease inhibitor is highly indicative of non-adherence.
A relation between adherence rate and virologic response rate has been demonstrated in both HIV-1
infected adults and children treated with HAART11,12. In our study a difference between the adherence
rate to antiretroviral therapy in virologic responders and non-responders was observed with method 2
and a trend to a relation was observed with method 1. This indicates that the determination of plasma
concentrations of indinavir and nelfinavir followed by calculation as concentration ratio of the lower
CORALs (method 2) in children may be a useful measurement for the assessment of adherence in chil-
dren. The absence of a significant relation between virologic response and non-adherence according to
method 3 might be due to the small number of children and due to persisting detectable nelfinavir in
plasma after 2 missed doses17. Another explanation is the overestimation of adherence. Adherence may
be better at the day the hospital is visited. Whether the measurement of plasma concentrations below
the limit of quantification have additional value remains to be evaluated in a study with a larger number
of children.
Children treated with nelfinavir had significantly higher adherence rates than children treated with indi-
navir. This may be explained by the fact that it takes more missed doses (2.3) of nelfinavir than of indi-
navir (1.3) before the drug becomes undetectable in plasma17.
We conclude that the adherence rates as calculated as percentage of samples that fulfilled the criteria for
adherence using only the the lower CORALs (consisting of the 5th percentile of population data obtained
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in adults) of indinavir or nelfinavir in children and virological response are associated. This method may
therefore be a useful measurement for the assessment of non-adherence in children.
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Abstract
Objective:
To study changes in indinavir exposure over time in HIV-1 infected children.
Methods:
PI naive HIV-1 infected children were treated with indinavir, zidovudine and lamivudine. Steady
state plasma pharmacokinetic (PK) sampling was performed as standard of care. The AUC0-8 was
targeted between 15 and 30 mg/L*hr. PK sampling was repeated after dosage adjustment until
the AUC0-8 reached target values. Patients were included when the time interval between PK
samplings was ≥ 2 years and differences in dosage/m2 < 10% between PK samplings 1 and 2.
Corrections of dose for changes in body size were performed.
Results:
Six children were enrolled with a median age of 5.2 years (range 1.7-13.6 years). All had a viral
load below 500 copies/ml. The geometric mean (GM) of the AUC0-8h decreased from 25.3 mg/L*h
at the first PK-day to 19.1 mg/L*hr at the second PK-day (GMR (Geometric Mean Ratio): 0.76
(95%CI: 0.48-1.20)). The GM of Cmax decreased from 11.8 to 10.4 mg/L (GMR: 0.88 (95%CI: 0.59-
1.32). The GM of Cmin decreased from 0.08 to 0.07 mg/L (GMR: 0.86 (95%CI: 0.62-1.18).
All children had an AUC0-8 above 15 mg/L*hr on the first PK-day; three had an AUC0-8 below 
15 mg/L*hr on the second PK-day. In two of these three children the plasma viral load was 
> 500 copies/ml.
Conclusion:
Changes in indinavir exposure were observed in time. In two patients, decreased indinavir expo-
sure was associated with virological failure. Therapeutic drug monitoring should be performed
over time since this may prevent subtherapeutic dosing in children.
Introduction
Since the introduction of Highly Active Antiretroviral Therapy (HAART) the life expectancy of HIV-1
infected children has improved dramatically1. Still, institution of optimal treatment poses a major 
challenge. In children, large inter individual differences are observed in the pharmacokinetics of anti-
retroviral drugs, especially in protease inhibitors (PI). For example, Burger et al showed 18-fold variability
(2.8-51 mg/L*hr) in the AUC0-8 of indinavir in children treated with a dosage of 33 mg/kg metabolic
weight2. This is even more important when one considers that the level of viral suppression and the 
plasma concentration of indinavir are associated in adults and children3, 4. Therefore, we routinely per-
form pharmacokinetic analysis of plasma concentrations of PI in our hospital. Our approach resulted in
favourable results with 69% viral response after 2 years of treatment5. Yet, viral failure occurs in some of
the children. Data in animals and adults indicate that exposure to PI may gradually decrease over time6,7.
Currently there is no information on changes in the pharmacokinetic parameters after prolonged PI use
in children. However, changes over time can be expected in children, since the processes of growth and
development have a significant impact on drug absorption, distribution and clearance8. Decreased drug
exposure in time may lead to viral rebound, selection of resistant mutants and ultimately to treatment
failure. We here present a case study on the effects of time on indinavir exposure in six HIV-1 infected
children.
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Methods
Patients
PI naive HIV-1 infected children with a viral load above 5,000 copies/ml and/or a CD4+ cell count below
their age-specific reference value started HAART consisting of indinavir 400 mg/m2 q8h, zidovudine 120
mg/m2 q8h and lamivudine 4 mg/kg q12h. In all patients, steady state intensive plasma PK sampling of
indinavir was performed as standard of care. The AUC0-8 was targeted between 15 mg/L*h and 30
mg/L*hr2. PK sampling was repeated until the AUC0-8 reached target values. Hereafter, PK sampling was
not routinely repeated. However, in case of viral failure, single sample indinavir plasma levels were con-
sidered. Children were eligible for inclusion in this study, when data were available from both the first
intensive PK sampling with the dose resulting in an adequate AUC0-8 (=PK-day 1), and second intensive
pharmacokinetic sampling (=PK-day 2) on this (fixed) dose/m2, with a minimum interval of 2 years.
Dose adjustments < 10% of dosage in mg/m2 body surface area (BSA) were allowed between PK sam-
plings. Corrections of dose for changes in body size were performed for indinavir and for nucleoside
reverse transcriptase inhibitors (NRTI). Selected clinical data were obtained during regular visits to the
outpatient department. The study protocol was approved by the medical ethical committee of the
Erasmus MC. Written informed consent was obtained from parents and patients.
Pharmacokinetics
Patients took indinavir on an empty stomach and blood samples were collected at time points 0 (pre-dose)
and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7 and 8 hours post ingestion. Plasma was separated by centrifugation
(10 min at 3000 x g) and samples were stored at -20 °C until analysis. Indinavir concentrations were
determined in plasma by HPLC, as previously reported9. The assay has intra-assay and inter-assay varian-
ces below 7.48% and 3.46%, respectively10. Pharmacokinetic parameters were calculated in Microsoft
Excel© 97 by non-compartmental methods11.
For comparison of the various PK parameters the geometric mean (GM) of the ratio between PK-day 1
and 2 was calculated (GMR). For analysis of the pharmacokinetic data, SPSS© 10 and Microsoft Excel© 97
software were used.
Results
Between 1997 and 2001, 35 children started indinavir q8h in our hospital. The children had a median age
of 3.2 years range (0.2-13.6 year). Fifty-four percent of the patients was female. Sixty-three percent of
the children had a least one parent originating from a sub-Saharan country (n = 22). At the time of this
study (2000-2001), 8 children were still eligible for enrollment. Reasons not to include the remaining 27
patients in this case study were: loss to follow up (n = 5), a change in indinavir dosage per m2 > 10% 
(n = 1) and a medication change before this study was initiated (n = 21). Patients changed medication
before the study because of toxicity (n = 5), patient request (n = 1), failure to obtain acceptable PK 
values (n = 3), medication failure (n = 5) or medication was changed to a twice daily indinavir/ritonavir
containing regimen after less than 2 years of treatment with indinavir every 8h (n = 7). Of the 8
patients that could be enrolled in the study two were not. One due to suspected non-compliance on PK-
day 2 and the other because of difficulties with obtaining PK-data due to autism. The median age of the
6 included patients was 5.2 years (range 1.7-13.6) at the first PK-day and most (n=5) had at least one
patient originating from a sub-Saharan country. The time period to obtain the optimal dosage of indi-
navir was 1 to 9 months after start of IDV 400 mg/m2 (median 6 months). The median time between
the first and the second PK-day was 2.5 years (range 2.0-3.5 years). On the second PK-day the median
percentage of the original dosage per m2 was 98% (range 93%-109%). The absolute median dosage (mg)
of indinavir increased from 350 mg (range 300-800) to 450 mg (range 400-800). Three patients used
co-medication on the first PK-day (amphotericin B/co-trimoxazole, fluconazole/co-trimoxazole and co-tri-
moxazole). None of the patients used co-medication on the second PK-day.
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In four of the six children the AUC0-8 had decreased on the second PK-day. In two children the AUC0-8
had increased. For data of the individual patients see table 1. The GM of the AUC0-8, Cmax, Cmin and t1/2,
all decreased on the second PK-day compared to the first PK-day. The pharmacokinetic parameters for the
study group are summarized in table 2.
All children had an AUC0-8 above 15 mg/L*hr on the first PK-day. On the second PK-day the AUC0-8 had
decreased to below 15 mg/L*hr in three of the six children. These three children also had the lowest
AUC0-8 on the first PK-day. In two of these children virus could be detected on the second PK-day,
whereas all patients had a viral load below 500 copies/ml on the first PK-day. (See table 1) The median
CD4+ cell count as percentage of their age-specific reference value had increased from 66% (range 43-
131) to 106% (range: 51-165). No clinically relevant abnormalities were observed in blood chemistry
parameters for liver and kidney functions on PK-day1 and PK-day 2.
Discussion
Currently, no information is available on changes in PK parameters of PI after long-term PI use in chil-
dren. We therefore performed a case study in HIV-1 infected children using indinavir for a prolonged peri-
od and observed a decrease in the AUC0-8 between PK-day 1 and PK-day 2 in 4 out of 6 children.
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Table 1 The individual changes in AUC0-8 and HIV-1 RNA levels between PK day 1 and 2
1.A03 Black 4.4 2.8 37.7 < 500 17.5 < 500 46%
2.A05 Caucasian/ 1.7 2.7 27.7 < 500 30.7 < 500 111%
Black
3.A10 Caucasian 6.1 3.5 15.4 < 500 11.1 < 500 72%
4.A13 Black 13.6 2.6 20.6 < 500 10.2 5110 50%
5.A14   Black 10.9 2.6 20.4 < 500 14.8 3620 73%
6.A23 Black 3.1 2.0 38.7 < 500 54.3 < 500 140%
Time
between 
PK-day 1
and PK-
day 2
(years)
AUC0-8h
PK-day 1
(mg/L*h)
HIV-1 RNA
PK-day 1
(copies/
ml)
AUC0-8
PK-day 2
(mg/L*h)
HIV-1 RNA
PK-day 2
(copies/
ml)
Percentage
AUC-
II/AUC-I
Patient Race Age at 
PK-day 1
(years)
Table 2 Changes in pharmacokinetic parameters in time in HIV-1 infected children (n = 6). Values for the first
and second PK-day are presented as geometric mean (GM)
AUC0-8 25.3 (15.4-38.7) 19.1 (10.2-54.3) 0.76 (0.46-1.4) 0.48-1.2
Cmax 11.8 (8.8-17.0) 10.4 (6.5-21.0) 0.88 (0.5-1.6) 0.59-1.32
Cmin 0.08 (0.04-0.21) 0.07 (0.04-0.15) 0.86 (0.71-1.5) 0.62-1.18
t1/2 1.67 (0.8-2.4) 1.45 (0.9-2.0) 0.87 (0.5-1.9) 0.49-1.54
Cl/F 16.3 (7.4-38.8) 27.4 (7.4-78.3) 1.67 (1.0-2.7) 1.13-2.48
Cl/F*m2 20.6 (13.5-28.4) 30.9 (11-64) 1.5 (0.79-4.72) 0.75-2.98
Vd/F 39.3 (12.4-100) 62.5 (11.7-217.4) 1.59 (0.5-5.2) 0.66-3.84
Vd/F*m2 49.7 (15.9-97.5) 64.7 (17.4-142.4) 1.3 (0.45-8.98) 0.40-4.3 
Parameter First PK-day 
GM (range)
Second PK-day
GM (range)
GMR II/I (range) 95% C.I.
The differences found between the two PK curves cannot be explained by changes in the techniques,
since we used the same methodology for all PK curves. Inter-assay variability is not likely to be responsi-
ble for the observed changes in indinavir exposure, since the changes in AUC0-8 exceeded the inter-assay
variance by far10. We did not observe clinically relevant abnormalities in blood chemistry parameters.
Therefore, the changes in indinavir exposure were not the result of changes in organ function due to
indinavir usage. Also the co-medication used on the first PK-day was not expected to have caused a dif-
ference in PK parameters, because it does not interfere with the metabolism of indinavir12.
It is unlikely that growth influenced the results, since the medication dosage was based on square
meters of body surface and adjusted when length or weight had changed. Interestingly, in one child
(A13) the absolute dose was not increased, and still her clearance and volume of distribution had
markedly increased. Hypothetically, the decreased indinavir exposure may have been caused by a decre-
ment in indinavir exposure with age. However, this is not expected since younger children have an
increased hepatic enzymatic activity compared to older children and adults8. Duration of therapy per se
did not seem to influence the change in indinavir exposure, since both increased and decreased exposure
could be shown in four children who were on therapy for approximately the same time period (2.5
years). Still mechanisms such as the induction of P-glycoprotein and CYP 450 levels after prolonged PI
usage as also shown in vitro by Huang et al. may have resulted in the decreased indinavir exposure7.
Remarkably, the three children with AUC II below the 15 mg/L*hr threshold were the older ones, sugges-
ting that older children may be more prone to develop subtherapeutic indinavir levels in time.
An alternative explanation for the observed failure of therapy after prolonged use of indinavir, may be
non-compliance. Yet, in one of the children with a viral load > 500 copies/ml, the Cmin corresponded
with the C0, indicating that at least the preceding dose was taken in time. However, non-compliance
obviously influences the antiviral efficacy of indinavir and may thus have influenced our findings13.
Clearly, our study is limited by the small sample size of 6 children. Still, the included patients were repre-
sentative for age and race for the patient population using indinavir in our hospital. A difference existed
for sex, since all patients in the study population were female. In this study a confounding factor may 
be the selection of patients with decreasing exposure to indinavir, because children with increasing
exposure to indinavir are more likely to suffer from complications and to discontinue treatment before 
a second PK-sampling can be performed. As a result, these children would not have been included in this
type of study. However, we do not expect this phenomenon to be a major confounder, since only in a
small group medication change due to toxicity had happened.
At the time of this case study, random single indinavir plasma levels were not obtained in our hospital 
as part of the routine care for HIV-1 infected children. It was considered after viral failure occurred,
mostly to check for compliance. Currently, in out hospital both full PK samplings for PI levels and ran-
dom single sample plasma PI levels are part of the routine care for HIV-1 infected children, allowing for
optimal dosing and early detection of changed exposure of PI.
In conclusion, our data suggest an effect of time on indinavir exposure in HIV-1 infected children. Both
increased and decreased indinavir exposure was observed over time. Subtherapeutic plasma levels of indi-
navir were found, which in 2 of 3 cases were associated with viral failure. Regular monitoring of drug
levels may prevent subtherapeutic PI dosing in children receiving HAART.
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Introduction
This thesis aims to increase the knowledge on the clinical pharmacology of antiretroviral agents in HIV-1
infected children. Pharmacology has been defined as the study of substances that interact with living
systems through chemical processes1. Clinical pharmacology is the part of pharmacology uniquely con-
cerned with the pharmacology in humans2. Pharmacology is divided into the subdivisions of pharmacoki-
netics (concerned with the processes that determine the concentration of drugs in body fluids and tis-
sues over time) and pharmacodynamics (the study of the actions of drugs on target organs)3.
The thesis’ objective was driven by the finding that HIV-1 infected children tend to respond less well to
antiretroviral therapy. It was hypothesized that this weaker response may be due to a suboptimal use of
antiretroviral agents in children, which is related to the paucity of data on clinical pharmacology in HIV-
1 infected children.
The studies described in this thesis have explored four aspects of clinical pharmacology, which are often
insufficiently evaluated during drug development and licensing in children:
1. Pharmacokinetic-pharmacodynamic relationships
2. Drug-drug interactions
3. Dose finding and optimization
4. Therapeutic drug monitoring
Licensing of drugs for use in children
Historically, for at least 75% of marketed drugs, product labeling did not include directions for safe and
effective use in children, which was directly related to the fact that these drugs had not been tested in
children prior to licensing4;5. This has led to a situation in which in pediatrics, drugs were mostly used
off-label, a term which has been defined as “the use of an approved drug for either a non-approved indi-
cation or in a population of patients for whom the drug is not specifically approved”5. Off-label drug
doses used in children are mostly extrapolated from the approved adult dose per kg body weight.
However, since such calculations do not take into account differences in pharmacokinetics in children,
the derived pediatric dose may be either too low (subtherapeutic) or too high (toxic) in children.
Major underlying reasons for the lack of data in pediatric patients are the relatively small market of sick
children for commercial institutions, ethical limitations for the conduct of clinical trials in children and
difficulties related with trial design in children, e.g. a relatively high number of pediatric patients need-
ed due to higher variability in pharmacokinetics in children when compared to adults6.
However, during the past few years, several efforts have been made by the United States government
and drug registration authorities to encourage the conduct of pediatric trials during drug development
and after licensing7. These efforts have led to a considerable increase in pediatric clinical trial data and
labeling of medicines for children4;6. Meanwhile, it should be noted that until today, no action has been
undertaken by the European Community to stimulate pediatric drug research. Still, licensing of drugs in
children is often based on studies in limited numbers of children, of a selected age group, typically
excluding very young children. This is well illustrated by the fact that of 17 globally licensed antiretrovi-
ral agents, only 7 are licensed for use in children below 2 years old in Europe and 8 in the United States.
For example, in a 4 months old child with AIDS, a HAART regimen of appropriately licensed agents would
leave only one non-nucleoside reverse transcriptase inhibitor (nevirapine) and the class of nucleoside
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reverse transcriptase inhibitors as treatment options, excluding many other drugs, such as the whole
class of protease inhibitors and the non-nucleoside reverse transcriptase inhibitor efavirenz (Table 1,
Chapter 1). As mentioned before, these limited treatment possibilities in children often necessitate off-
label use in clinical practice. In children with a severe clinical presentation, a protease inhibitor based
regimen may be desirable as first choice, because of its documented efficacy in adults and children8;9.
Nelfinavir is a relatively well tolerated protease inhibitor of which a pediatric formulation is available.
However, the application of pediatric dose recommendations of nelfinavir in infants leads to a very low
drug exposure to nelfinavir, which is very likely to be insufficient (Chapter 2.1). This clearly illustrates a
risk associated with, often inevitable, off-label use of drugs in children.
Moreover, the dose selected for clinical trials in children is often derived from a body weight based dose
of which efficacy has been established in adults. However, using this approach, it is assumed that the
drug displays linear pharmacokinetics and similarity of pharmacokinetics and pharmacodynamics in
adults and children. This is not necessarily the case and may result in the choice of the wrong dose in
children.
Combination regimens in which desirable (for example pharmacokinetic boosting by ritonavir) or unde-
sirable pharmacokinetic interactions occur, have often not or very little been investigated in children.
Consequently, the prescription of such regimens in children is either omitted because of the fear of an
unacceptably high risk of inefficacy or toxicity due to the drug-drug interaction, or applied using the
“off-label principle”, under the assumption that a the pharmacokinetic interaction is acceptable and will
occur to the same extent as in adults. Especially with antiretroviral agents, the lack of knowledge of
pharmacokinetic interactions limits treatment options in children.
Finally, in general, very little efficacy trials, in particular comparative trials have been conducted in 
children.
Altogether, it can be questioned, if pediatric drug doses (in some cases even if licensed), including those
of antiretroviral drugs are appropriate, in particular in children of very young age.
Performing clinical trials in healthy children has been discussed as a possible equivalent of studies in
adult healthy volunteers6. An important argument for conducting clinical trials in healthy children is the
benefit which these trials could potentially bring to every child. Moreover, the enrollment of healthy
children could provide reliable additional pharmacokinetic data allowing for age specific dosing recom-
mendations in children. However, also several ethical questions emerge on this topic. Similar to trials in
pediatric patients, healthy children willing to participate in a trial and/or caregivers would have to be
adequately informed prior to enrollment and would have to be deemed reliable to give informed consent,
which may be difficult, especially in young children. A clear difference, however, between trials in
healthy children and pediatric patients is found in the benefit/risk ratio of these trials. It is generally
agreed that the inclusion of children in clinical trials is only justified if the benefit/risk ratio is in favor
of the participating child. Indeed, while pediatric patients are more likely to benefit from an experimental
treatment, trials in healthy children typically do not bring direct benefit to the individual participating
child, which is an argument not to perform clinical trials in healthy children. In addition, depending on
the trial design, a healthy participating child will be exposed to more or less personal discomfort, for
which it is difficult to determine a degree of acceptability6.
Clinical pharmacology in HIV-1 infected children
As mentioned earlier, the science of clinical pharmacology is divided into the subdivisions of pharmacoki-
netics and pharmacodynamics. Clearly, these two sciences are strongly related, since to exert their
action, drugs need to reach their active site. Thus, by influencing the pharmacokinetics of a drug, its
pharmacodynamics can be affected.
Pharmacokinetics consist of the processes of absorption, disposition, biotransformation and elimination3.
All of these processes are dependent of different factors. In children, developmental changes in pharma-
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cokinetics, i.e. changes occurring between birth and the end of adolescence play an important role10;11.
Consequently, depending on a drug’s physicochemical properties, its pharmacokinetics can differ with a
child’s age. Furthermore, the pharmacokinetics of a drug are related to the outcome of studies on drug-
drug interactions, dose finding and optimization and the usefulness of therapeutic drug monitoring.
This section will first concisely discuss the developmental aspects of pharmacokinetics in general
(described in more detail by Reed and Gal, Nelson Textbook of Pediatrics, 16th Edition, 2000 and Kearns,
2000) and discuss the findings described in this thesis. Subsequently, pharmacokinetic-pharmacodynamic
relationships, drug-drug interactions, dose finding and optimization and the usefulness of therapeutic
drug monitoring in HIV-1 infected children will be discussed, including own findings.
Developmental aspects of pharmacokinetics
Absorption
Several physiological processes are influencing drug absorption. Generally, these processes change most
dramatically during the first years of life.
Since most drugs are absorbed by passive diffusion rather than active/facilitated transport, gastric pH
may play an important role. In neonates, achlorhydria (increased gastric pH) is common, normalizing to
adult values at the age of 20-30 months. Compared to adults, gastric emptying time in neonates is
reduced due to a lower gastrointestinal motility, but, in contrast, infants and older children have shorter
gastric emptying time due to increased gastrointestinal motility. Of note, the presence of gastric con-
tents may influence drug absorption. The absorption of drugs may strongly differ between neonates and
infants and older children due to the different food patterns (hence gastrointestinal contents) between
these children.
Drug disposition
The relative amount of body fat and water are changing between birth and adolescence and may there-
fore influence the volume of distribution of drugs. While the percentage body water decreases strongly
within the first year of life, remaining relatively stable during the rest of life, the percentage of body fat
increases during the first year of life to a stable level during childhood and subsequently decreases to
adult values during adolescence.
Moreover, plasma protein binding may influence drug disposition. Decreased amounts of plasma proteins
are found in neonates and infants, which may lead to a decrease in the total (free + protein bound) plas-
ma level of highly protein-bound drugs. Thus, the total plasma concentration of a highly protein bound
drugs (such as most protease inhibitors) may not reflect the free fraction. Of note, acute infections may
also influence the circulating amount of plasma proteins.
Biotransformation
Biotransformation (or metabolism) alters or terminates the activity of drugs, in order to enable
excretion12. While many tissues, such as the gastrointestinal tract can be involved in metabolism, the
principal organ involved is the liver.
The metabolic pathways can be divided into Phase I (oxidative) and Phase II (mostly conjugative) reac-
tions. Major enzymes involved with Phase I reactions are cytochrome P450 (CYP) isoenzymes. Depending
on its isoform, CYP activity develops to adult values within the first months of life, subsequently tends
to exceed CYP activity in adults and then normalizes after adolescence. Glucuronidation is a major Phase
II metabolic pathway involved in drug metabolism. While its developmental aspects have been little elu-
cidated, it has been suggested that maturation of this metabolic pathway occurs during the first years of
life13;14.
Renal elimination
Excretion by the kidney is an important route of elimination for many drugs, including antiretroviral
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drugs and their metabolites. The development of renal function has been well evaluated and has shown
that activity increases strongly within the first 2 weeks of age and reaches adult values after approxi-
mately 6-10 months10.
Own observations
As described in the preceding section, major differences in pharmacokinetics can be encountered
between children and adults, the most dramatic changes occurring in neonates and infants. In this the-
sis, 4 studies included such young children (Chapters 2.1, 2.3, 3.2 and 4.1). However, typically, the num-
bers of these children were limited, which should be taken into account when interpreting results. For
nelfinavir, the difference between plasma levels in younger children (below 2 and 5 years old, respective-
ly) compared to older children was most evident and confirms other findings (Chapters 2.1 and 2.3)15-18.
This finding is likely to be related with developmental changes in the absorption and metabolism of nel-
finavir. Also, the absorption of nelfinavir is dependent of food, and gastrointestinal food contents in
neonates and infants may be inadequate for absorption of nelfinavir. Despite the advantage of a pedi-
atric formulation of nelfinavir, these pharmacokinetic properties may make nelfinavir less suitable for use
in very young children.
In the small number of children below 2 years old using indinavir with ritonavir, lower plasma levels of
indinavir were found. The decreased trough levels (Cmin) and AUC, but not peak levels (Cmax) suggest
increased hepatic metabolism in younger children. Apart from the absence of a licensed pediatric formu-
lation of indinavir, the risk of nephrotoxic side effects is an important disadvantage of the use of indi-
navir in children19;20.
The pharmacokinetics of nucleoside reverse transcriptase inhibitors importantly differ from protease
inhibitors and non-nucleoside reverse transcriptase inhibitors by the lack of CYP mediated metabolism.
Moreover, their absorption is not strictly food dependent, as with a number of protease inhibitors.
Significant age-related differences were found in the plasma pharmacokinetics of zidovudine and lamivu-
dine (Chapters 4.1 and 4.2). For both drugs, these age-related differences may have been related to a
higher volume of distribution of these drugs in younger children. For zidovudine, possibly, these findings
reflect a maturation of the metabolic pathway of glucuronidation. It is difficult to estimate the impact
of age related differences in plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in
children, since plasma levels do not necessarily reflect levels of their active, phosphorylated moieties.
Pharmacokinetic-pharmacodynamic relationships in HIV-1 infected children
Several studies have demonstrated that plasma levels of HIV-1 protease inhibitors are related to antiretro-
viral efficacy in HIV-1 infected adults21-25. Similarly, plasma levels of non-nucleoside reverse transcriptase
inhibitors have been shown to predict antiretroviral treatment outcome26-29. For nucleoside reverse tran-
scriptase inhibitors, pharmacokinetic-pharmacodynamic relationships are less clear, which is attributed to
the fact that antiretroviral activity is exerted by the intracellular phosphorylated moieties of these
drugs30-33.
While similar pharmacokinetic-pharmacodynamic relationships are very likely to exist in HIV-1 infected
children as in adults, little pediatric data have confirmed this hypothesis34. Clearly, the establishment of
a pharmacokinetic-pharmacodynamic relationship in antiretroviral therapy is difficult due to many other,
factors which influence therapy outcome, and these factors may be even more important in HIV-1 infec-
ted children than in adults. Examples of such confounders are compliance to medication (therapy may
fail despite adequate drug exposure), viral susceptibility to the investigated drug (less susceptible virus
will result in a higher inhibitory concentration of the drug), antiretroviral activity displayed by other
compounds of HAART (possibly masking, at least for a limited duration of time, the effect of suboptimal
plasma levels of the investigated drug) and intraindividual variability in plasma levels (a therapeutic
average plasma level, but suboptimal levels during part of the time may still lead to virologic failure).
Therefore, studies investigating pharmacokinetic-pharmacodynamics relationships of antiretroviral agents
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should evaluate a sufficient number of patients during a relatively long period of time.
In our heterogeneous patient population of HIV-1 infected children using nelfinavir, plasma levels of nel-
finavir after observed ingestion did not significantly correlate with antiretroviral efficacy (Chapter 2.1).
However, despite the heterogeneous patient population, this study found declining (although not signifi-
cantly) percentages of virological failure with escalating doses per kg body weight of nelfinavir.
In the second study of nelfinavir described in this thesis, a positive correlation was found between nelfi-
navir plasma levels after unobserved ingestion and virological response, confirming previous observations
in HIV-1 infected adults and children (Chapter 2.3)15;23;35.
While these data suggest a pharmacokinetic-pharmacodynamic relationship for nelfinavir and possibly
also other HIV protease inhibitors in children, more research should be performed, e.g. to determine
which pharmacokinetic parameter optimally predicts treatment response in HIV-1 infected children.
Moreover, little research has been performed to date to determine the pharmacokinetic-pharmaco-
dynamic relationships of non-nucleoside reverse transcriptase inhibitors in HIV-1 infected children.
Drug-drug interactions with antiretroviral agents
Both HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors are substrates of CYP.
Therefore, the pharmacokinetics of these agents are likely to interact with other medication sharing the
same metabolic pathway or modifying activity of CYP. In addition, protease inhibitors and non-nucleo-
side reverse transcriptase inhibitors are modifying the activity of several CYP isoenzymes, which leads to
an additional potential for pharmacokinetic interactions. Nucleoside reverse transcriptase inhibitors are
not metabolized by CYP, which makes these agents less susceptible to pharmacokinetic interactions.
Possible interactions with nucleoside reverse transcriptase inhibitors are most likely with drugs compe-
ting for the same enzymes for phosphorylation or sharing their (renal) elimination pathway36.
Since the past few years, the protease inhibitor ritonavir has been increasingly applied as a pharmaco-
kinetic enhancer of other protease inhibitors in the treatment of HIV-1 infected adults37. The principle of
such ritonavir-boosted regimens “simply” takes advantage of the strong inhibition of CYP3A4 by ritonavir,
the enzyme involved in metabolism of all protease inhibitors. Even at low (1/6 of normal) doses, rito-
navir is able to decrease clearance and prolong the plasma half-life of other protease inhibitors. The
advantages of ritonavir boosted protease inhibitor regimens include a reduced dosing frequency, more
convenient intake due to lower pill load and less food restrictions, the possibility to overcome other
pharmacokinetic interactions and to overcome decreased viral susceptibility. Its most common disadvan-
tages include gastrointestinal side effects and taste disturbances related with ritonavir use, which are
even seen with low-dose of the drug. With ritonavir-boosted regimens of indinavir, the risk of nephro-
toxic side effects of indinavir may be increased, which is related to the increased plasma levels of 
indinavir these regimens38;39. In children, the use of the very poorly tasting ritonavir liquid formulation
is a disadvantage of boosted protease inhibitor regimens.
To date, very little data on the use of ritonavir boosted protease inhibitors in HIV-1 infected children
have been published40-43. Two studies in this thesis have investigated the pharmacokinetics of ritonavir-
boosted protease inhibitors in children (Chapters 3.1 and 3.2). The investigated regimen of lopinavir with
efavirenz was explored as a new second line treatment option for heavily pretreated HIV-1 infected chil-
dren (Chapter 3.1). Lopinavir is currently the only licensed protease inhibitor combined with low-dose
ritonavir in the same formulation. An increased dose of lopinavir was applied to compensate for
increased elimination of lopinavir and ritonavir due to induction of CYP3A4 by efavirenz. This resulted in
pharmacokinetic parameters for both drugs similar to historical data in adults, suggesting that the evalu-
ated doses of lopinavir and efavirenz are generally correct in children.
An important reason for investigating the regimen of indinavir with low-dose ritonavir (Chapter 3.2) was
the finding that children show generally lower Cmin of unboosted indinavir than adults and may there-
fore be at a higher risk of virologic failure44;45. In HIV-1 infected children, ritonavir increases Cmin of
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indinavir, which enables twice daily dosing (Chapter 3.2). However, the data of 3 children younger than
2 years old suggest that this may not be the case for younger children. Additional dose modifications
would possibly be needed in this group of patients.
The case report described in this thesis shows how ritonavir was able to successfully counteract the
enzyme inducing properties of rifampicin in an HIV-1 infected infant (Chapter 2.2). The investigated anti-
retroviral regimen may constitute a treatment option for children who need concomitant treatment with
antiretrovirals and tuberculostatics containing rifampin.
These results illustrate how ritonavir can simultaneously boost protease inhibitors and counteract phar-
macokinetic interactions due to enzyme induction of CYP3A4 by concomitantly given drugs.
Dose finding and optimization in children
The establishment of correct doses and the subsequent further optimization of antiretroviral regimens is
of paramount importance in HIV-1 infected children. Incorrect dosing of antiretrovirals is bound to result
in reduced efficacy or toxicity. Moreover, optimization of dosing through a reduced dose frequency or
lower pill load may increase compliance to medication in HIV-1 infected children. Similarly, regimens with
less adverse events can improve quality of life and compliance to medication.
An evaluation of the dose range of 20-40 mg/kg q8h nelfinavir in HIV-1 infected children showed that
based on AUC, the lowest dose of 20 mg/kg q8h nelfinavir is insufficient in children, especially in child-
ren below 2 years old (Chapter 2.1). Since these data also suggest a possible saturation of nelfinavir
absorption process in children, it is unclear if dose increase will lead to therapeutic exposure to nelfi-
navir in all HIV-1 infected children. In addition, the study suggests that body surface area rather than
body weight should be considered as a dosing scale in HIV-1 infected children.
A reduced dose frequency offers additional convenience and may enhance compliance. For example, HIV-1
infected children of whom parents have not disclosed their child’s disease to their environment may
experience difficulties with medication intake during school time. From a pharmacokinetic point of view,
reduced dose frequencies from three times daily to twice daily are feasible for indinavir, if boosted with
low-dose ritonavir and for zidovudine, while lamivudine and abacavir may be given once instead of twice
daily (Chapters 3.2, 4.1 and 4.2).
While these data were favorable from a pharmacokinetic point of view, long-term safety and efficacy of
these regimens should be evaluated. For nucleoside reverse transcriptase inhibitors, data on intracellular
pharmacokinetics could provide additional information before evaluating efficacy. Since these regimens
were not or very little investigated in children below 2 years old, a pharmacokinetic evaluation is yet
needed in these patients.
Despite their high potency and the possibility of reduced dose frequency, protease inhibitor based regi-
mens may have disadvantages. Of these, poor palatability of medication plays an important role. Also,
long-term effect of lipid abnormalities, such as a possibly increased risk of coronary heart disease and
abnormal fat tissue distribution (lipodystrophy) due to the use of protease inhibitors are seen as disad-
vantages of these regimens. In children with virologic suppression, alternative regimens, in which pro-
tease inhibitors are replaced by other antiretroviral agents may be applied. The regimen of abacavir,
zidovudine and lamivudine exemplifies such a regimen. The combination showed good efficacy and
improvement of lipid abnormalities in HIV-1 infected children after protease inhibitor treatment (Chapter
4.3). While abacavir combined with zidovudine and lamivudine may be an easy-to-handle regimen for
maintenance therapy in HIV-1 infected children, further options should be explored.
Therapeutic drug monitoring in HIV-1 infected children
A currently posed definition of therapeutic drug monitoring (TDM) has been as follows: “TDM seeks to
individualize drug dose, guided by measurement of plasma drug concentrations. The aim is to bring (and
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keep) a patient’s plasma concentration within a target concentration (therapeutic) range”46. By main-
taining the plasma concentration of antiretroviral drugs within its therapeutic range, optimal viral 
suppression can be reached, and the chance of selection of viral mutants reduced. In the mean time, 
a therapeutic range can be applied to prevent adverse events due to high drug concentrations. In specific
cases, TDM possibly can help to overcome virus with decreased susceptibility to antiretroviral agents.
TDM may also be applied in the management of pharmacokinetic interactions. Finally, TDM of antiretro-
viral medication can be applied for the assessment of a patient’s adherence46.
However, to be useful, TDM should fulfill several general criteria. Plasma levels of the given drug should
be the best parameter a patient’s intermediate response. Also, pharmacokinetic parameters should be
characterized by a large interindividual variability. Moreover, plasma concentrations should correlate with
efficacy and/or toxicity of the drug within a narrow therapeutic range. Last but not least, an accurate
and precise assay with adequate specificity should be available for the drug46. In HIV-1 infected adults,
TDM of protease inhibitors and non-nucleoside reverse transcriptase inhibitors may be beneficial, since
these agents comply with the general criteria for TDM and because of based on the evidence from a
number of randomized clinical trials47-49.
HIV-1 infected children may benefit from TDM of antiretroviral agents, possibly even to a larger extent
than adults. Higher interindividual variability in plasma levels of especially protease inhibitors and deve-
lopmental changes in pharmacokinetics with time (Chapters 2.1 and 3.1) make HIV-1 infected children
very likely candidates for TDM. Also, the outcome of pharmacokinetic interactions may be less pre-
dictable in children than in adults. Moreover, especially young children may be more susceptible to 
toxicity of antiretroviral medication and may therefore benefit from TDM19.
A randomized controlled clinical trial to investigate the role of TDM in HIV-1 infected children (Penta-14)
is currently underway. Earlier, a comparison of pediatric studies investigating antiretroviral therapy,
reported that studies in which TDM of protease inhibitors was performed tended to have a better out-
come50. While it should be realized that it is difficult to compare outcome of different studies, this 
finding suggests a possible role for TDM in the treatment of HIV-1 infected children.
An additional question, which can be posed with regard to TDM in HIV-1 infected children is the frequen-
cy at which plasma sampling should be repeated. Adult data have suggested a decrease in plasma levels
of the protease inhibitor saquinavir over time51. In six HIV-1 infected children using indinavir, a tendency
to decreasing plasma levels of indinavir was observed, despite the fact that doses were unchanged except
for adjustments for growth. This may suggest, that TDM of indinavir, and possibly also other protease
inhibitors should be regularly repeated to prevent subtherapeutic dosing in HIV-1 infected children
(Chapter 5.2).
Compliance is a major problem in HIV-1 infected children and compliance rates tend to be lower in HIV-1
infected children than in adults52.
The lower plasma concentration ratio limit (CORAL) of the HIV-protease inhibitors, below which random
plasma concentrations reflect partial compliance or noncompliance, was able to predict virologic failure
in HIV-1 infected children using indinavir or nelfinavir (Chapter 5.1)53. The use of CORALs can possibly be
used to predict non-compliance to protease inhibitors in HIV-1 infected children, if low plasma levels due
to other reasons than non-compliance (e.g. pharmacokinetic interactions or increased elimination) have
been excluded by dose adjustments to target plasma levels to normal values (Chapter 5.1). The value of
CORALs in HIV-1 infected children should be further evaluated in an intervention study on compliance.
Future perspectives
Clearly, the unique aspects related with childhood make the treatment of HIV-1 infection in children
more complicated than in adults. A better understanding of the clinical pharmacology of antiretroviral
agents in HIV-1 infected children through the conduct of more pediatric trials in this area is yet needed.
Particularly in dose-finding studies, children of all age groups should be represented, since one pediatric
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dose may not necessarily fit children of all age groups. To obtain a sufficient sample size, efforts should
be made to conduct pediatric trials in HIV-1 infected childen using a multicentre approach. In view of
the challenges to obtain compliance in HIV-1 infected children, simplification of antiretroviral regimens
should be further explored.
Finally, the role of therapeutic drug monitoring in HIV-1 infected children needs investigation since it is
likely to improve therapeutic outcome.
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Despite the beneficial effect of HAART on both the prognosis and morbidity in HIV-1 infected patients,
antiretroviral therapies currently cannot fully eliminate HIV-infection. In addition, antiretroviral agents
often do not effectively suppress HIV-1, especially in infected children. Improvements in the treatment
outcome of HIV-1 infected children may be obtained through enhancing our understanding of the phar-
macokinetics of antiretroviral agents in children.
In chapter 2 we discuss the optimization of nelfinavir-containing highly-active antiretroviral therapy
(HAART). In chapters 2.1 and 2.3, the pharmacokinetics and pharmacokinetic-pharmacodynamic relation-
ship of the protease inhibitor nelfinavir are explored. Chapter 2.1 highlights the high interindividual vari-
ability in the pharmacokinetics of nelfinavir in HIV-1 infected children. In children younger than 2 years
of age and children using a dose of 20 mg/kg q8h, we observed a trend towards low exposure (AUC0-8 <
12.5 mg/L*h), which has previously been associated with virologic failure. Interestingly, dosing per body
surface area was a predictor of subtherapeutic plasma levels. In contrast, dosing on body weight was
not. This suggests that pediatric dosing of nelfinavir should be based on an estimation of body surface.
In chapter 2.3, we report the results of a study on the pharmacokinetic-pharmacodynamic relationship of
nelfinavir. In this context, we analyzed the association of plasma trough levels with treatment outcome.
Previously untreated children, who started combination therapy with nelfinavir and two nucleoside
reverse transcriptase inhibitors in whom a routinely measured morning nelfinavir plasma trough concen-
tration fell below 0.8 mg/L, had a significantly higher rate of virological failure. Similar to adults, subop-
timal pharmacokinetics of nelfinavir are related to virological failure and maintenance of the nelfinavir
trough concentration above 0.8 mg/L improves treatment outcome in HIV-1 infected children.
In chapter 2.2, we describe a case report of an HIV-1 infected infant with tuberculosis. The child was
safely and effectively treated with HAART containing nelfinavir and concomitant rifampin-based tubercu-
lostatic treatment. The follow-up of the patient showed that the addition of ritonavir can counteract the
undesirable pharmacokinetic interaction between protease inhibitors and rifampin, leading to lowered
plasma levels of the protease inhibitor. This was in particular achieved through a considerable increase in
plasma levels of the in vitro active metabolite of nelfinavir, M8.
In chapter 3, we discuss the dose finding of ritonavir boosted protease inhibitor based regimens.
The principle of pharmacokinetic boosting with ritonavir is based upon inhibition of the metabolic
enzyme CYP3A4 and results in the elevation of plasma levels, in particular the Cmin, of other protease
inhibitors, which are substrates of CYP3A4. Advantages of ritonavir-boosted protease inhibitor regimens
are less frequent dosing, the ability to overcome unfavorable drug-drug interactions (see chapter 2.2)
and the ability to maintain plasma levels above the inhibitory concentration (IC) of HIV with reduced
sensitivity for the protease inhibitor used.
The study described in Chapter 3.1 investigates the pharmacokinetic profiles of an increased dose of
lopinavir used with efavirenz as a nucleoside reverse transcriptase inhibitor sparing regimen in HIV-1
infected children. The non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz lower plas-
ma levels of protease inhibitors. A 30% increased lopinavir dose was applied, as is generally recommended
in patients using lopinavir with efavirenz. Plasma levels of lopinavir were highly variable between
patients, but the pharmacokinetics of both lopinavir and efavirenz were similar to historical controls.
This suggest correctness of the investigated doses. Therapeutic drug monitoring should be applied to
detect cases of abnormal plasma levels, especially of lopinavir, which displays the largest interindividual
variability in pharmacokinetics.
In chapter 3.2, we evaluate the pharmacokinetics of a ritonavir-boosted regimen of indinavir, in order to
define a pediatric dose. A significantly, approximately 2 times higher AUC0-24, a significantly, 5 to 8
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times higher Cmin, and a non-significantly increased Cmax of indinavir were found when compared to
children and adults using indinavir q8h. The AUC0-24 and Cmin of indinavir were similar to data of indi-
navir/ritonavir in adults, while Cmax was slightly decreased. The tolerability of the investigated doses
was generally good. Meanwhile, data on long-term safety and efficacy and additional investigation in
children below 2 years old this regimen are needed.
In Chapter 4, the pharmacokinetics and pharmacodynamics of nucleoside reverse transcriptase inhibitors
are reported.
Nucleoside reverse transcriptase inhibitors are commonly used as components of HAART. In addition,
these agents may be useful in therapy simplification because of a relatively low pill count, good tolera-
bility and the possibility of less frequent dosing. Moreover, NRTIs are applied to prevent or reverse
adverse events of other antiretroviral agents of other classes, e.g. dyslipidemia associated with the use
of protease inhibitors.
Nucleoside reverse transcriptase inhibitors are intracellularly converted into their phosphorylated, active
moieties. Analysis of the intracellular pharmacokinetics of these agents would possibly offer the most
reliable information. However, such quantification is still complicated. Plasma levels of nucleoside reverse
transcriptase inhibitors are currently used as an alternative for intracellular measurements, assuming an
(albeit weak) correlation between plasma- and intracellular levels, and therefore efficacy of nucleoside
reverse transcriptase inhibitors. The results found in chapters 4.1 and 4.2 should preferably be confirmed
in a comparative efficacy study including intracellular pharmacokinetics of the investigated regimens.
In chapter 4.1, we report a retrospective analysis of the plasma pharmacokinetics of zidovudine in HIV-1
infected children who switched zidovudine from q8h to q12h as part of a therapy simplification. The
pharmacokinetics of zidovudine q12h were not significantly different from q8h, suggesting bioequiva-
lence in terms of plasma pharmacokinetics.
In chapter 4.2, we describe a single-sequence, two-period, cross-over, open label pharmacokinetic study
in HIV-1 infected children who used lamivudine and/or abacavir q12h as part of HAART, were clinically
stable and willing to switch lamivudine and/or abacavir to q24h. The results indicated non-inferiority of
the plasma pharmacokinetics of the q24h regimens of lamivudine and abacavir to the corresponding q12h
regimens, both in children > 2 - 6 years and children >6 - <13 years old.
In chapter 4.3, the safety, efficacy and pharmacokinetics of abacavir are investigated in a prospective
open label study in which in HIV-1 infected children receiving 2 NRTIS and at least one protease inhibitor
with plasma HIV-1 RNA levels < 500 copies/mL, the protease inhibitor was replaced by abacavir. In an
intention-to-treat analysis, ten of the eleven enrolled patients had HIV-1 RNA levels < 50 copies/ml after
48 weeks of abacavir. The plasma pharmacokinetics of abacavir were similar to historical controls in HIV-1
infected children. The abacavir containing combination treatment was well tolerated and resulted in a
significant reduction of cholesterol plasma levels, but not of triglycerides. Replacement of PIs by abacavir
in HIV-1 infected children with HIV-1 RNA levels < 500 copies/ml provides continued viral suppression
and improvement of lipid abnormalities.
In chapter 5, we present the results of studies to evaluate therapeutic drug monitoring in HIV-1 infected
children.
Chapter 5.1 addresses the application of therapeutic drug monitoring for the detection of non-compli-
ance in HIV-1 infected children using HAART containing indinavir or nelfinavir. Plasma levels below a pre-
defined lower limit for the ratio of a patient’s plasma level to the corresponding population value in
adults, which has been found highly indicative for non-compliance in adults, predicted virologic failure
in HIV-1 infected children.
The case study described in chapter 5.2 observed a small but possibly clinically relevant decrease in time
of the plasma levels of indinavir in HIV-1 infected children despite regular dose adjustments for increase
in body size. Such changes in pharmacokinetics suggest that therapeutic drug monitoring should be 
regularly applied in HIV-1 infected children.
In chapter 6 (General discussion and future perspectives), we discuss four aspects which are often little
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investigated in drug development (pharmacokinetic-pharmacodynamic relationships, drug-drug interac-
tions, dose finding and optimization and therapeutic drug monitoring). These factors are likely to be
associated to the lower efficacy of antiretroviral treatment observed in HIV-1 infected children. The rele-
vance of own observations is discussed in view of the above mentioned. Finally, practical approaches for
the optimization of treatment in HIV-1 infected children are considered.
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Ondanks het gunstige effect van sterk werkende antiretrovirale therapie, ofwel “highly-active antiretrovi-
ral therapy” (HAART) op de prognose en morbiditeit van HIV-1 geïnfecteerden, zijn de huidige antiretro-
virale therapieën niet in staat om HIV-infectie te elimineren. Daarnaast is de suppressie van HIV-1 door
antiretrovirale middelen in het bijzonder bij geïnfecteerde kinderen niet optimaal. Een beter begrip van
de farmacokinetiek van deze middelen bij kinderen kan bijdragen aan een betere respons op behandeling
bij HIV-1 geïnfecteerde kinderen.
In hoofdstuk 2 wordt ingegaan op de optimalisatie van HAART regimes waarin de protease remmer (PI)
nelfinavir wordt gebruikt.
In de hoofdstukken 2.1 en 2.3, worden de farmacokinetiek en het farmacokinetisch-farmacodynamische
verband van nelfinavir onderzocht. Hoofdstuk 2.1 geeft de hoge interindividuele variabiliteit binnen de
farmacokinetiek van nelfinavir bij HIV-1 geïnfecteerde kinderen duidelijk weer. Een trend tot lagere bloot-
stelling (oppervlakte onder de plasmaconcentratie-tijd curve (AUC0-8) < 12.5 mg/L*h), die eerder werd
geassocieerd met virologisch falen was zichtbaar bij kinderen jonger dan 2 jaar en bij gebruik van de
dosering 3dd 20 mg/kg. Opmerkelijk genoeg had dosering op lichaamsoppervlak een voorspellende
waarde voor subtherapeutische plasma spiegels, in tegenstelling tot doseren op lichaamsgewicht;
mogelijk dient de dosering van nelfinavir bij HIV-1 geïnfecteerde kinderen gebaseerd te zijn op het
geschatte lichaamsoppervlak. Hoofdstuk 2.3 geeft de resultaten van een studie naar het farma-
cokinetisch-farmacodynamische verband van nelfinavir. Het verband tussen plasma dalspiegels en het
effect van de therapie werd onderzocht. HIV-1 geïnfecteerde kinderen die niet eerder waren voorbehan-
deld met antiretrovirale middelen startten HAART bestaande uit nelfinavir en twee nucleoside reverse
transcriptase remmers (NRTI). Kinderen, bij wie een in de ochtend afgenomen plasma dalspiegel van nel-
finavir beneden 0.8 mg/L werd gemeten vertoonden een vaker virologisch falen. Suboptimale farma-
cokinetiek van nelfinavir is niet alleen in volwassenen, maar tevens in HIV-1 geïnfecteerde kinderen gere-
lateerd aan virologisch falen. Het bewaken van een dalspiegel van nelfinavir boven 0.8 mg/L verhoogt de
effectiviteit van therapie bij deze laatste patiëntengroep. In hoofdstuk 2.2 wordt een casus beschreven
van een zuigeling met HIV-1 infectie en tuberculose. Het kind werd met succes tegelijkertijd behandeld
met HAART waarvan nelfinavir deel uit maakte en tuberculostatica, waaronder rifampicine. De follow-up
van de patiënt liet zien, dat toevoeging van ritonavir de ongewenste farmacokinetische interactie tussen
protease remmers en rifampicine kan tegenwerken, namelijk door een aanzienlijke verhoging van de plas-
ma spiegels van M8, de in vitro actieve metaboliet van nelfinavir.
Hoofdstuk 3 behandelt de vaststelling van doseringen van zogenaamde “ritonavir-boosted” regimes.
Farmacokinetische “boosting” is gebaseerd op inhibitie van het enzym CYP3A4. Dit resulteert in ver-
hoging van plasma spiegels, in het bijzonder van de dalspiegel (Cmin) van andere PIs, die substraten vor-
men van CYP3A4. De “ritonavir-boosted” regimes bieden voordelen, waaronder de mogelijkheid tot ver-
laagde doseerfrequentie, het tenietdoen van ongewenste geneesmiddel interacties (hoofdstuk 2.2) en de
mogelijkheid tot plasma spiegels van de gebruikte PI boven de benodigde remmende concentratie van
HIV-1, zelfs wanneer sprake is van een virus met verminderde gevoeligheid voor de gebruikte PI.
De studie beschreven in hoofdstuk 3.1 onderzocht de farmacokinetische profielen van een NRTI sparend
regime bestaande uit verhoogde dosering lopinavir in combinatie met efavirenz bij HIV-1 geïnfecteerde
kinderen. Aangezien non-nucleoside reverse transcriptase inhibitors (NNRTI) de plasma spiegels van PIs
verlagen werd, conform de aanbeveling bij gebruik van lopinavir met efavirenz, een 30% verhoogde
dosering van lopinavir toegepast. Hoewel plasma spiegels van lopinavir sterk varieerden tussen patiënten
waren de mediane farmacokinetische parameters van lopinavir en efavirenz gelijk aan historische con-
troles. Dit suggereert dat de onderzochte doseringen juist zijn gekozen. Therapeutic drug monitoring
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(TDM) dient te worden toegepast opdat abnormale plasma spiegels, voornamelijk van het in PK interindi-
vidueel sterk variabele lopinavir kunnen worden opgemerkt.
In hoofdstuk 3.2 werd de PK geëvalueerd van ritonavir-boosted indinavir, om pediatrische doseringen te
bepalen voor deze combinatie.
In vergelijking tot 3dd gebruik van indinavir bij kinderen en volwassenen werden een significante,
ongeveer twee maal hogere AUC0-24, een significant, vijf tot acht maal verhoogde Cmin en een niet sig-
nificant verhoogde topspiegel (Cmax) van indinavir gevonden. De AUC0-24 en Cmin waren gelijk aan data
van indinavir met ritonavir in volwassenen, terwijl sprake was van een licht verlaagde Cmax. Hoewel de
verdraagbaarheid van de onderzochte doseringen overwegend goed was, zijn veiligheids- en effec-
tiviteitsgegevens nodig over het langdurige gebruik van dit regime. In kinderen jonger dan twee jaar
dient het regime verder onderzocht te worden.
In hoofdstuk 4 worden de farmacokinetiek en farmacodynamiek van NRTIs beschreven. NRTIs worden
veelvuldig toegepast als onderdeel van HAART. Daarnaast vinden deze middelen door hun relatief klein
aantal tabletten per dosis, hun goede verdraagbaarheid en de mogelijkheid tot verlaagde doseerfrequen-
tie, toepassing bij vereenvoudiging van antiretrovirale therapie. Tevens worden NRTIs toegepast ter
voorkoming van, of ter vermindering van bijwerkingen als gevolg van het gebruik van andere klassen
antiretrovirale middelen, bijvoorbeeld afwijkingen aan het lipiden profiel geassocieerd met het gebruik
van PIs. NRTIs worden intracellulair omgezet tot de gefosforyleerde, actieve vorm. Hoewel de analyse van
intracellulaire farmacokinetiek van deze geneesmiddelen de meest betrouwbare informatie zou opleveren,
blijft deze intracellulaire kwantificering tot op heden gecompliceerd.
Plasma spiegels van NRTIs worden gebruikt als een alternatief voor intracellulaire metingen. Hierbij
wordt aangenomen, dat een (zwak) verband tussen bestaat tussen plasma- en intracellulaire spiegels en
de effectiviteit van NRTIs. De resultaten gepresenteerd in de hoofdstukken 4.1 en 4.2 dienen te worden
bevestigd in een vergelijkende effectiviteitstudie met onderzoek naar de intracellulaire farmacokinetiek
van de betreffende regimes.
Hoofdstuk 4.1 behandelt een retrospectieve analyse van de plasma farmacokinetiek van zidovudine bij
HIV-1 geïnfecteerde kinderen bij wie de doseerfrequentie van zidovudine in het kader van vereenvoudiging
van therapie werd verminderd van 3dd naar 2dd. De farmacokinetische profielen van 2dd zidovudine
waren niet significant verschillend van 3dd zidovudine, wat duidde op bioequivalentie wat betreft de
plasma farmacokinetiek.
De studie in hoofdstuk 4.2 betreft een single-sequence, two-period, cross-over, open label farma-
cokinetisch onderzoek bij klinisch stabiele HIV-1 geïnfecteerde kinderen, die 2dd lamivudine en/of aba-
cavir gebruikten als onderdeel van HAART en bereid waren tot omzetting naar 1dd gebruik van lamivu-
dine en/of abacavir.
Op basis van de resultaten werd, in kinderen uit de leeftijdsgroepen > 2 - 6 en >6 - <13 jaar oud, non-
inferioriteit van de plasma farmacokinetiek van 1dd lamivudine en abacavir geconcludeerd ten opzichte
van de overeenkomstige 2dd regimes.
In hoofdstuk 4.3 werden de veiligheid, effectiviteit en farmacokinetiek van abacavir onderzocht in een
prospectief, open label onderzoek. Bij HIV-1 geïnfecteerde kinderen die behandeld werden met twee
NRTIs en minstens één PI en een virale load in plasma van < 500 kopieën/ml, werd de PI vervangen door
abacavir. In een intention-to-treat analyse hadden na 48 weken gebruik van abacavir tien van de elf
patiënten een HIV-1 RNA load < 50 kopieën /ml. De plasma farmacokinetiek van abacavir was gelijk aan
historische controles bij HIV-1 geïnfecteerde kinderen. Het abacavir bevattende regime werd goed verdra-
gen en leidde tot een significante reductie van het plasma cholesterol, maar niet van triglyceriden. Na
vervanging van PIs door abacavir bij HIV-1 geïnfecteerde kinderen met een HIV-1 RNA load < 500 kopieën
/ml blijft virale suppressie bestaan en treedt een normalisering van lipidenafwijkingen op.
In hoofdstuk 5 worden resultaten gepresenteerd van evaluerende onderzoeken naar TDM in HIV-1 geïn-
fecteerde kinderen.
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Hoofdstuk 5.1 behandelt de toepassing van TDM bij het detecteren van therapieontrouw bij HIV-1 geïn-
fecteerde kinderen die indinavir of nelfinavir als onderdeel van HAART gebruikten. Plasma spiegels bene-
den een van tevoren vastgestelde ondergrens voor de ratio tussen de plasmaspiegel van de patiënt en de
overeenkomstige waarde uit een populatiecurve (die eerder bij volwassenen sterk indicatief bleek voor
therapieontrouw), voorspelde het optreden van virologisch falen bij HIV-1 geïnfecteerde kinderen.
In de case study die beschreven wordt in hoofdstuk 5.2 werd in HIV-1 geïnfecteerde kinderen een kleine,
maar mogelijk klinisch significante daling in de tijd opgemerkt van de plasma spiegels van indinavir,
ondanks aanpassingen in de dosering om te compenseren voor groei. Dergelijke veranderingen van de far-
macokinetiek suggereren dat TDM frequent dient te worden herhaald in HIV-1 geïnfecteerde kinderen.
In hoofdstuk 6 (algemene discussie en toekomstperspectieven) worden vier aspecten toegelicht, die in de
regel weinig onderzocht worden binnen het traject van geneesmiddelenontwikkeling, te weten farma-
cokinetisch-farmacodynamische relaties, geneesmiddeleninteracties, vaststellen en optimaliseren van de
dosering en TDM.
Deze factoren zijn mogelijk geassocieerd met een lagere effectiviteit van antiretrovirale behandeling bij
HIV-1 geïnfecteerde kinderen. Op de relevantie van de eigen bevindingen met betrekking tot het voor-
gaande wordt nader ingegaan.
Tenslotte wordt een beschouwing gegeven van praktische benaderingen ter optimalisatie van de behan-
deling van HIV-1 geïnfecteerde kinderen.
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